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A major area of interest is the identification of proteins that play a role in hormone 
dependent cancers and in collaboration with the MRC Centre for Reproductive 
Health we studied the gonadotropin releasing hormone receptor (GnRH-R). Other 
targets described in the thesis are the SH3 domain of PSD-95 and the protein BLyS.  
In order to identify potential inhibitory small molecules we have used a variety of 
computational data base mining approaches as well as using and developing 
experimental binding assays. It has become increasingly challenging to evaluate the 
most representative drug like small molecule compounds when using traditional high 
throughput screening methods. This thesis assesses the use of in silico tools to probe 
key protein-protein and protein-peptide interactions. These tools provide a means to 
identify enriched compound datasets which can be purchased and tested in vitro in a 
time and cost efficient way. 
The transmembrane protein GnRH-R provides an interesting opportunity to identify 
small molecules that could inhibit the binding of its peptide ligand GnRH.  This is a 
challenging project as there are few examples in the literature of drug-like molecules 
that bind to such protein-peptide interfaces.  The first step involved receptor 
modelling using solved crystal structures of homologous proteins. The model was 
then validated by developing structure activity relationships for established high 
affinity ligands. We also performed crystallographic and biophysical studies on the 
native GnRH decapeptide.  
Two other protein-protein systems were also examined using the same virtual 
screening and experimental ligand binding methodology. SH3 domains play an 
 iii 
important role in cell signalling and we used the PSD-95 protein as our target for 
study as a crystal structure has been published.  As well as identifying potential 
ligands we characterised structural properties of PSD-95 fusion proteins and also 
developed the basis for compound assay. The third system studied was B 
Lymphocyte Stimulator (BLyS) which is a target for treatment of a number of 
autoimmune diseases. This presented an interesting target for study as the protein 
binds to multiple receptors depending on its multimeric state. BLyS protein was 
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Chapter 1. Utilising virtual screening to aid the discovery of small 
molecule ligands to disrupt protein-protein and protein-peptide 
interactions 
1.1 Virtual screening 
The average cost of developing a new drug from the disease targeting stage through 
to becoming a marketable product is over $800m[1] and takes around 14 years[2]. A 
considerable focus of pharmaceutical companies is therefore to endeavour to reduce 
costs. One of the large costs associated with creating a new drug is in the number of 
failures which are encountered in the research workflow. Because of the demand to 
reduce the failure rate of a drug there is pressure to increase the potential success rate 
before the drug molecule itself is even synthesised. One method of doing this is by 
implementing a virtual screening strategy into the process. This has been quite 
successful and has led to the discovery of a number of chemically active molecules 
for key target proteins[3]. 
1.2 An overview of virtual screening strategies 
Whilst there is overlap in the overall result of virtual screening strategies the detailed 
methods of ligand selection and compound enrichment can be quite different. The 
different approaches may be tailored to suit the nature of the target protein depending 
on how well the protein has been documented. 
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1.2.1 Ligand based screening approaches 
In many cases the crystal structure of the target protein of interest may not be 
available.  This is particularly true for membrane proteins which make up a 
considerable proportion of drug targets[4], perhaps because purification as a 
recombinant protein is difficult or because the correct conditions have not yet been 
empirically derived. A ligand based screen is a useful approach for such proteins, 
however lack of receptor information is not the only reason to use this approach. If 
there are already well documented chemically active ligand molecules then the idea 
of similar molecule having similar chemical properties[5] to generate new novel 
compounds can be exploited. 
1.2.2 Identification of pharmacophores  
The idea of querying structure databases by pharmacophore, a particular arrangement 
of chemical groups (Figure 1-1), is not a new concept[6]. Since 1985 there have been 
publications which have described the use of computational methods to derive 
pharmacophores for serotonin inhibitors in the development of antidepressants[7] and 
beta blockers[8].  However it is becoming a more useful means of identifying 
potential compounds now that large chemical databases are easier to access. The 
recently published Pharmer program[9] which can search the Zinc database[10] of 2.7 
million commercially available compounds is a step in the right direction.  Typically 
at least one known active compound is needed in order to generate a pharmacophore 
fingerprint. However further success is likely if additional compounds are known so 





Figure 1-1. Pharmacaphore searching focuses on the positional space that particular chemical 
groups occupy in order to interact with the target molecule, disregarding the other properties of 
the molecule. In this example the chemical groups circled in blue and red are important for activity, 
their 3D positions are used as search parameters to find molecules with similar chemical groups that 
occupy these positions. 
 
1.2.3 Similarity searching 
In order to search for a molecule which is similar to a known active a way has to be 
found to describe the active compound in order to search the database. This can then 
be compared to another string using for example a Tanimoto Coefficient to 
determine similarity[11]. A common way of doing this is to use “fingerprints”, reading 
in a two dimensional structure and obtaining an output text string descriptor as 
described in Figure 1-2. The Daylight fingerprint algorithm is an example of this. 
However a number of fingerprinting algorithms exist which generate the text string 





Figure 1-2. Fingerprint generation in similarity searching is a method of describing atom types. 
The fingerprint generated is a textual interpretation of the molecule which can be compared against 
other compound fingerprint text strings to measure similarity. 
 
One of the disadvantages of this type of sorting was the time taken to generate 
fingerprints.  
1.2.4 Shape similarity 
More recently a new technique has been developed called Ultrafast Shape 
Recognition[13] which is a more rapid method of shape comparison because it does 
not rely on superposition of the starting ligand against the structures in a target 
database, a factor which not only reduces computational time but also removes the 
possibility for error in superposition[14]. Instead of considering the molecule as a 
solid 3D shape it breaks it down into a series of bound atoms (Figure 1-3). The main 
benefit of this technique is derived from the way that atom distances are measured 
between four key locations; the “molecular centroid (ctd), the closest atom to ctd 
(cst), the farthest atom to ctd (fct), and the farthest atom to fct (ftf)”[15]. This allows 
the maximum distances from the centre of the molecule to be calculated for rapid 
comparison.   
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This method has proven to be very successful in quickly analysing large datasets for 
similar structures in comparison to the traditional superposing approach[13].  
 
Figure 1-3. A simplified example of atom pairing for similarity searching. In a typical example all 
atom pair distances are calculated with respect to four reference locations: the molecular centroid 
(ctd), the closest atom to ctd (cst), the farthest atom to ctd (fct) and the farthest atom to fct (ftf ) thus 
eliminating the need for superposition regardless of ligand size[15]. 
 
1.2.5 Success of Ligand based screening 
Although as previously discussed the ligand based approach was slightly less 
favourable than being able to screen against an x-ray crystal structure of a receptor 
there have still been a number of reported active molecules found using this 
approach. Recent examples with possible therapeutic benefits include the discovery 
of novel IKK-β inhibitor which has been implicated in the management of 
inflammation and cancer through control of NF-κβ activation[16]. Another example of 
a cancer target derived from ligand based screening is that of inhibitors of human 
tyrosyl-DNA phospodiesterase (hTdp1)[17]. In this case pharmacophore filtering was 
used with fourteen known inhibitors to increase the likelihood that the compounds 
found would fit the binding profile for the active site.  
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1.3 Protein based screening approaches 
1.3.1 Docking experiments and docking optimisation 
If a crystal structure of the target protein is available then it is possible to go straight 
into docking optimisation and binding experiments. One interesting problem of 
molecular docking with respect to small ligands and their large protein targets is the 
number of different docking programs which exist (Table 1-1) to attempt to address 
the problem of predicting binding affinity. Reviews have drawn comparisons with 
regard to the efficiency and accuracy of a number of these programs[18, 19]. There 
have been noted difficulties in making a valid comparison[20], commonly the use of 
root mean square deviation between crystal structure ligand sites and the predicted 
pose from docking is used to assess docking success. However when dealing with 
small molecule ligands the changes in root mean square deviation can be small even 
if the ligand molecule is in a completely different orientation in the docked pose to 
the crystal structure.  
Table 1-1. A selection of commercial and academic docking software available for in silico 
screening.  
Program Affiliation Website 
Autodock The Scripps Institute http://autodock.scripps.edu/ 
DOCK UCSF http://dock.compbio.ucsf.edu/ 
FlexX BioSolveIT http://www.biosolveit.de/flexx/ 
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Fred OpenEye Scientific 
Software 
http://www.eyesopen.com/fred 






ICM MolSoft http://www.molsoft.com/docking.html 










1.3.2 Docking solutions are highly variable and should be interpreted 
with care 
One of the more frequently encountered difficulties when using molecular docking 
software is the lack of consistency of the results across a range of different programs. 
Because there is such a variety of ways to score molecular interactions the docking 
results are frequently open to interpretation. Should more emphasis be placed on the 
results obtained from commercial vendors rather than freely available software? 
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Comparison between the commercial FlexX against Glide and Dock, which are 
available as academic licenses, indicates this is not the case[21]  
This presents the problem of results being biased towards the scoring system being 
used[22]. One way of getting around this problem is by using multiple docking and 
scoring programs in the virtual screening stage. Whilst this is more computationally 
expensive it has the advantage of providing a more thorough validation of target 
docking results which should maximise the likelihood of poorly active compounds 
being removed in the “fail early” stage[3].   
1.3.3 Applying filters to compound databases is a useful method of 
enrichment 
A good docking score is not the only important factor in selecting compounds to take 
forward for testing. For example they may possess undesirable reactive chemical 
groups (such as an epoxide ring) or their molecular properties may pose difficulties 
in crossing the blood-brain barrier. It may also be advantageous to check for 
compounds which may interfere with assay results (for example they may possess 
delocalised ring structures which could affect a fluorescence assay). In order to 
reduce the unnecessary inclusion of these types of compounds, which can account for 
more than half of a commercial database[23],  it is often desirable to screen the 
database to remove any entries which do not meet the drug likeness criteria. 
A number of screens have been developed to make this process easier. The most 
widely known is the Lipinski rule of five which, since publication in 1997 has been 
cited over four thousand times[24]. The foundation of this rule is that drug like 
compounds are more likely if they have less than 5 H-bond donors, no more than 10 
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H-bond acceptors, molecular weight is below 500 daltons and the octanol-water 
partition coefficient (LogP) value should not exceed 5. However since these rules 
were published there have been a number of additional studies on the general 
properties of drug like compounds. Ghose et al[25] and Oprea [26] further tuned into 
the drug like space in chemical databases by extending the rules to include optimum 
values for rotatable bonds, molar refractivity and total atom number. Fortunately 
software such as Instant JChem (Chemaxon) or the FAF-Drugs2 server[27] exist 
which can do this process efficiently, being able to combine multiple drug likeness 
criteria as well as recognition of undesirable functional groups[28]. 
It should be noted however that overly stringent drug likeness filters will reduce the 
finding of more novel scaffolds which can be adapted at a later time to increase 
bioavailability. It can therefore be advantageous to examine compounds which 
border the boundaries of the database manually for their potential. Obviously this 
process is more suited to smaller databases where the number of compounds which 
may need to be manually examined are manageable. However this method also 
introduces a variable of human bias. A means of avoiding this is to employ a 
“machine learning” strategy where a software program is designed to look at a series 
of drug like and non-drug like compounds and create a set of rules to apply. While 
this method is still in relative infancy it is finding uses in drug discovery, most 
recently in work involving Hepatitis C[29].     
1.3.4 Filtering compounds by similarity in the post-docking stage is an 
efficient way of testing the most chemical space 
After a list of the top hits from docking studies is established it is common to assess 
how similar each compound is in respect to one another. Whilst it would be ideal to 
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test all top hits in an assay this is both financially and logistically challenging. 
Instead the compounds can be clustered based on similarity. If similar compounds 
share similar properties, testing all of the compounds from a highly similar cluster is 
unnecessary. In practice there are some exceptions to this paradigm, for example the 
addition of a methyl group to a compound may appear to be a small change but when 
added to fluorosulfonate to form methyl fluorosulfonate (magic methyl) the change 
in activity is huge. 
Figure 1-4 shows an example of clustering using fingerprinting and then organising 
by similarity using a Tanimoto coefficient.
 
Figure 1-4. A typical cluster dendrogram of a virtual screening docking experiment. This 
example shows the distribution of similarity by using the daylight fingerprint for each compound and 
then scoring similarity according to a tanimoto coefficient, therefore highly similar compounds score 




1.4 Compound solubility is a key factor in compound selection 
Whilst an assortment of tools are available which allow rapid elimination of 
undesirable compounds based on the likelihood of reacting to form covalent bonds 
and other errant behaviour, the accurate prediction of water solubility is still elusive. 
1.4.1 Difficulties in determining solubility. 
The most accurate way of determining solubility is by measuring it directly. This is 
difficult however when only a small quantity of (possibly expensive) sample may be 
available. The process itself is laborious and time consuming[30], particularly if the 
sample must be reclaimed from the solvent. 
If the general solubility equation (Equation 1) is used solubility can be estimated 
from the melting point and the LogP of the compound. This is quicker than direct 
measurement since the LogP is often given by the supplier and offers reasonable 
accuracy[31].  However the sample will likely be irreversibly altered during the 
melting process and this is not necessarily the most applicable equation for small 
molecule compounds[32].  
logSw=0.5−0.01(MP−25)−logKow       (Equation 1) 
Where Sw is the molar aqueous solubility, MP is the Melting Point (Celsius) and Kow 
is the octanol–water partition coefficient (LogP). 
1.4.2 Computational tools for estimating solubility 
The ability to accurately predict solubility from using structural information is 
important in the virtual screening process as poor solubility of samples is a major 
practical problem in screening for binding.  
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In the development of a predictive model a chemically diverse training set is required 
in order to gain the best structure activity hypothesis. Unfortunately the solubility 
information of compounds is often held confidentially by the supplier or the data just 
does not exist. Recently there have been joint ventures between companies such as 
Specs and Pharma Algorithms to launch a DMSO solubility predictor[33]. The 
manufacturer claims an overall prediction accuracy of 82% although the software is 
commercially licensed and has not yet been subject to review in the literature.  
1.4.3 Current software prediction models attempt to solve the solvation 
problem in a number of different ways 
A recent review of solubility prediction programs provides a survey showing how 
different groups have attempted to model the compound/solvent interaction[34]. Each 
group developed a prediction model using a large variation in training set size (the 
smallest training set size was 150 while the largest was 2874). After their model was 
generated it was used to predict the solubility of 21 compounds frequently used to 
test solubility models including sparingly soluble compounds such as benzocaine and 
DDT, fairly soluble compounds such as aspirin and highly soluble compounds such 
as antipyrine. This gave a solubility range of 2.45 mol/ L to 0.008 µM/ L. In each 
case the log units of molar solubility (logS) were calculated and compared to the 





Table 1-2. Summary of error values for a collection of solubility prediction methods. Figure 
modified from [34]. 
Lead author Descriptors used Training set size Test set size Standard error 
(log) 
Huuskonen 2D topological 884 413 0.6 
Hou Atomic 1290 120 0.79 
Jorgensen Whole molecule 150 149 0.72 
Yan 3D descriptors 797 496 0.59 
Wegner 2D topological 1016 253 0.54 
Delaney Whole molecule 2874 528 0.96 
Klopman 2D substructural 1168 120 0.79 
Liu 2D topological 1312 258 0.72 
Butina Whole molecule 2688 640 1.01 
Klamt Quantum 
mechanical 
150 107 0.61 
 
The range in standard error is 0.54-1.01 whilst the range in training set size varies 
from 150-2874. Given how small some of the training sets are this low error is fairly 
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encouraging, especially if we consider that experimentally derived solubility data can 
vary by as much as 1 log unit[35]. More interesting however is how the three lowest 
standard errors were seen in models which were all created using different 
approaches.  
1.5 Target selection for in silico screening  
The overall aim of this study is to identify small molecule inhibitors to three proteins. 
The first target is the Gonadotropin releasing hormone receptor which is a membrane 
bound protein controlled by a receptor-peptide binding event which regulates 
reproductive function[36] and has been implicated in the treatment of prostate 
cancer[37].  
The next target is postsynaptic density protein 95 (PSD-95). This is a commonly 
found scaffolding protein found near the membrane of postsynaptic neurons and has 
a novel SH3 domain which has been shown to mediate inflammatory pain via 
protein-protein interactions[38]. 
Finally the B-lymphocye stimulating factor (BLyS) which mediates the proliferation 
and differentiation of of B cells[39] is found to be upregulated in a number of 
autoimmune diseases including systemic lupus erythematosus[40].  
All three proteins are important medical targets with a need for development of small 
molecule inhibitors. They represent challenging interactions for disruption that 
virtual screening techniques can help to address. 
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1.5.1 GnRH-R as a target 
GnRH-R is a G-protein coupled receptor of the Class A (rhodopsin-like) family. The 
receptor has been shown to exist as three homologs in a number of species (GnRH-R 
I-III) and binds to the complimentary GnRH decapeptides (GnRH I-III). Only the 
type one receptor is active in humans[41]. Whilst the type two receptor is present in 
the human genome it contains a frame shift and premature stop codon which prevents 
transcription of a receptor which binds the GnRH-II peptide[42]. The GnRH-II peptide 
has however been shown to play a role in the control of inositol-1,4,5-trisphosphate 
by binding to the type one receptor[43]. The type three receptor is found exclusively in 
fish and amphibian species[44].  
GnRH-R I is a 328 amino acid protein (Figure 1-5) which unlike other members of 
the GPCR family does not possess a C-terminal tail. It does however possess an N-
terminal region which is thought to be largely disordered. The absence of a C-
terminal tail is important from a signalling perspective because this feature is often 
involved in the internalisation and subsequent desensitisation response. Subsequently 
the type I receptor displays delayed desensitisation when continually stimulated by 
an agonist molecule[45]. Studies have shown that the type II GnRH peptide and the 
cognate receptor show high conservation[46], so it can be considered that the loss of 
the C-terminal tail in the type I receptor was functionally important especially if it is 
noted that the point at which the C-terminus terminates, the YFSL motif, is known to 





Figure 1-5. The human type I GnRH Receptor. Ligand binding sites are indicated in red, 
structurally significant residues are highlighted green, GPCR conserved residues are shown in orange 
and signalling residues are shown in blue. Diagram taken from reference [48]. 
 
1.5.2 GnRHR binding the GnRH decapeptide controls reproductive 
function 
The 10-mer GnRH hormonal peptide is the key regulator of the reproductive system 
and stimulates the release of the Gonadotrophins; these are Luteinising Hormone 
(LH) and Follicle Stimulating Hormone (FSH)[49]. The hypophysiotropic peptide 
(GnRH I) has the amino acid sequence pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-
NH2 and is synthesised as a 92 amino acid pre-pro-hormone in the septal-preoptic-
hypothalamic regions[50]. It is secreted in a pulsitile fashion from the median 
eminence approximately every 30-120 minutes and travels via the hypophyseal 




Figure 1-6. Sex steroid production is controlled by GnRH binding the cognate receptor. The 
GnRH neurons from the hypothalamus project into the median eminence where the GnRH is released 
into the portal vein allowing travel to the anterior pituitary. GnRH binds the cognate receptor and 
LH/FSH are released. These hormones act at the ovaries and testis to produce testosterone/estradiol.  
 
The GnRH peptides typically bind their cognate receptor however substantial 
variation exists in GnRH peptide sequences (Figure 1-7). As the GnRH II cannot 
bind the human type two receptor it instead binds to the type one receptor. This is 
useful from a drug design perspective as it means more than one known active can be 




Figure 1-7. Sequence variation in GnRH decapeptides. The sequence variation amongst the types 
of GnRH is mainly in residues 5-8. These determine the specificity of the hormone. Blue shaded 
residues are highly conserved. Image modified from reference [46]. 
 
1.5.3 Therapeutic benefits of targeting the GnRH receptor 
It has been established that the GnRH receptor is critical in control of reproductive 
function and production of the sex steroids[51]. However it has been elucidated that 
GnRH-R upregulation and downregulation is found in a number of diseases. Perhaps 
most notable is the link between GnRH-R and hormone dependent cancers; there is 
evidence to suggest that treatment of prostate[37] and breast[52] cancer is possible 
through GnRH receptor antagonism. Other treatments are available which utilise 
GnRHR agonism including IVF treatment to aid conception[53] and endometriosis[54]. 
However to date there are still no clinically approved non-peptide drugs which target 
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the receptor either as agonist or antagonist. The need exists to develop a drug which 
is orally active and less inconvenient for patient use. 
The virtual screening process involving GnRH-R is discussed in chapters 2-4. 
1.6 Target selection for in silico screening - Post synaptic density 
protein 95 (PSD-95)  
1.6.1 PSD-95 is a scaffolding protein which belongs to the Membrane 
Associated Guanylate Kinase (MAGUK) family 
PSD-95 is a member of the Membrane Associated Guanylate Kinase (MAGUK) 
family of proteins and as such consists of three PDZ domains, an SH3 domain and a 
non-functional Guanylate Kinase (GK) domain[55]. Synapses are specialised 
structures which consist of an axon terminal and dendritic spine. These two regions 
are unconnected in the majority of mammals but nerve impulses must travel between 
them. As a result neurotransmitter is released from the axon terminal where they can 
then bind to the receptors on the dendritic spine and thus continue the signal by 
stimulating ion influx. As a result of this function the dendritic spine was found to 
have increased electron density in electron microscopy studies and therefore became 
known as the postsynaptic density (PSD)[56].  
The postsynaptic density has since been found to be a complex network of 525 
proteins with a combined weight of approximately 1 Million Daltons and a PSD-95 
occupancy of 18%[57], where it plays important scaffolding function between a 




Figure 1-8. MAGUK scaffolding within the postsynaptic density. The PSD-95 protein is anchored 
via interactions with occludin and claudin via the GK and PDZ domains respectively. From this 
position the SH3 and PDZ domains are able to bind their respective motifs and act as scaffolding 
molecules to other proteins. Diagram adapted from reference [58]. 
 
The function of PSD-95 has recently seen greater investigation leading to the 
identification of a number of interesting observations. Among these was the 
discovery that PSD-95 was involved in the behaviour of learning and memory using 
PSD-95 knockout mice whereby mice deficient in the protein displayed significantly 
slower progress in a water maze[59]. In addition changes in expression of the PSD-95 
protein is linked to a number of currently incurable neurological diseases including 
Parkinson’s and Alzheimer’s[60, 61]. 
1.6.2 MAGUK proteins contain novel SH3 domain structures  
In the MAGUK proteins it has been found that the SH3 domain is quite unique in 
comparison to the canonical SH3 domain found in other proteins. Rather than the 
usual five beta strands this domain contains six although two of these are not part of 
the SH3 domain. Strand E is attached to the “HOOK” domain which is an α-helix 
and loop region connecting the GK and SH3 domain and strand F is part of the GK 




Figure 1-9. Schematic diagram comparing the beta stand orientation in the canonical SH3 
domain (a) and in the MAGUK protein (b). The E and F strands in the MAGUK protein are 
contributed by the HOOK and GK domains respectively, the HOOK domain is shown in cyan.  
 
Figure 1-10. Intertwined structure of the SH3 domain in PSD-95. Spanning residues 428-709 of 
the protein the SH3 domain is coloured in orange and the beta strands have been numbered, the 
HOOK domain is coloured cyan and the GK domain in red. Note a portion of the HOOK domain is 
highly flexible and missing from the structure. 
 
Further discussion on the SH3 domain structure can be found in Chapter 7. 
1.6.2 PSD-95 binds to a number of therapeutically significant proteins 
The N terminus of the PSD-95 protein was shown to bind directly with the SH2 
domain of Src and the dopamine receptor D1 which is implicated in a number of 
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neurodegenerative disorders as well as the reward system of the brain[63]. It was also 
shown that overexpression caused an increase in the size and abundance of dendritic 
spines as well as enhancing the activity of glutamate receptors[64] due to interaction 
between PSD-95 and the glutamate receptor KA2[65] through the SH3 domain[66]. 
Perhaps the most interesting discovery was the association of PSD-95 with 
neuropathic pain in conjunction with NMDA. It was found that a shortened version 
of the PSD-95 protein prevented mice from exhibiting allodynia and hyperalgesia 
after sciatic nerve injury[67]. This makes it a very attractive target for further 
investigation as it may lead to the discovery of very potent new forms of pain relief.  
Through the PDZ domain the protein is also able to bind to and cluster GPCR 
proteins to the plasma membrane. As GnRH-R has the necessary YFSL motif 
necessary to associate with this domain there is scope for interaction between these 
proteins[68]. 
As well as virtual screening work involving assay development and compound 
testing of PSD-95 hits, biochemical characterisation of the protein was also 
performed and is discussed in Chapter 7. 
1.7 Target selection for in silico screening – B Lymphocyte 
Stimulator (BLyS)  
1.7.1 BLyS is a member of the Tumour Necrosis Factor (TNF) family 
BLyS (also known as BAFF, TNFSF13B or TALL1) is a cytokine involved in the 
maturation of B lymphocytes via interaction with the BAFF receptor (Figure 1-11) as 
well as TACI (transmembrane activator and calcium modulator ligand interactor) and 
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BCMA (B cell maturation antigen). The protein is expressed as a 285 amino acid 
membrane associated protein which is active in the membrane or in a cleaved soluble 
form after being released from the membrane via proteolytic cleavage[69]. The protein 
associates with TACI after it self-associates to form larger multimer complexes. 
Whilst it will usually form a trimer, these trimers can associate into a 60-mer virus 
like capsid[70] which is a requirement for signalling activity[71]. 
1.7.2 Maturation of B cells is an important part of immunity 
A mature B cell is generated through a four stage process beginning with the 
differentiation of hematopoietic stem cells into pro B cells and culminating in the 
maturation of immature B cells to mature B cells[72]. The maturation stages occur in 
special germinal centres in secondary lymphoid tissues providing humoral immunity 
and long-lived serological memory. This process is tightly controlled to prevent 
production of autoantibodies whilst maintaining the required level of humoral 
immunity. 
 
Figure 1-11. BLyS association with the cognate receptor and the TACI and BCMA receptors. 
Cleavage of BLyS from the membrane is possible via a furin protease, multimerisation is a 




1.7.2 Targetting BLyS for treatment of autoimmune disease  
It has been noted in the literature that elevated levels of BLyS can be found in the 
serum of patients suffering from a number of autoimmune diseases, including 
rheumatoid arthritis[73], Sjogren’s syndrome[74] and systemic lupus[75]. Recently there 
have been clinical trials to assess the efficacy of targeting BLyS with a monoclonal 
antibody, Belimumab, developed by Human Genome Sciences and GSK in the 
treatment of systemic lupus[76]. Trials for a BLyS selective peptibody antagonist 
called Blisibimod ( Anthera Pharmaceuticals) are also due to begin shortly, again for 
the treatment of lupus. Therefore there is a niche for the design of an orally active 
small molecule inhibitor which has the benefits of being more deliverable than the 
current treatments in clinical testing. 
Chapter 8 contains the details of the virtual screening workflow used with BLyS as 
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Chapter 2. Computational and biochemical protocols  
2.1 Computational tools and approaches 
The number of protein crystal structures covers approximately 10% of the known 
protein sequences[1, 2]. This discrepancy causes a continued need for the ability to 
generate protein structure using computational tools. Typically protein modelling is 
performed using known structures with high sequence identity to the protein of 
interest; however other structural information such as NMR data, image picking from 
electron microscopy or just using rudimentary rules of secondary structure 
organisation can theoretically be used to generate a model structure. 
In this chapter the computational tools that were used to generate homology models 
for the GnRH receptor using sequence homology to the rhodopsin and β2 adrenergic 
receptor are described. Docking programs and algorithms used to identify potential 
small molecule ligands are presented with the biochemical assays that were 
performed to test the inhibitors. 
2.2 MODELLER 
MODELLER[3] is a software suite designed to produce high quality three 
dimensional homology models using a template structure. Spatial constraints 
between Cα atoms, hydrogen bonds and dihedral angles which are calculated from 
the template structure are applied to the sequence to be modelled (Figure 2-1). The 





Figure 2-1. An overview of the model structure building process in the MODELLER program. 
 
2.2.1 Alignment of target and template sequences in MODELLER 
Sequence alignment in MODELLER can be executed by a Needleman-Wunsch[4] 
method which involves a global alignment of two sequences in an array where a 
numerical score is given to the similarity between two residues. The final alignment 
produced is the pathway through the array with the highest score. An alternative 
approach uses the Smith-Waterman algorithm[5] which is a local alignment method 
rather than a global one. This is slightly different from the Needleman-Wunsch 
algorithm in that when the array is created and the residue similarities are scored the 
score is based on sequences of any length, therefore gap penalties are introduced to 
prevent excessive insertions. Assuming two sequences are highly similar then both 
algorithms will give similar results, however when two sequences have low 
similarity the  Smith-Waterman algorithm is the preferred choice[6].  
33 
 
Initially alignments were produced using the Smith-Waterman algorithm in 
MODELLER, however these alignments did not correctly align conserved motifs 
between the G protein coupled receptor sequences. Alignments were instead 
generated using a pairwise alignment with the BLOSUM matrix in ClustalW[7] which 
is more robust when aligning sequences of low similarity. This is achieved by 
assigning higher scores to rarer amino acids that are found paired over more common 
ones. For example a Leu/Leu pair scores +4 whilst a Trp/Trp pair scores +11 because 
statistically Trp is a less common amino acid[8]. It is notable that matrices such as 
PHAT[9] have been designed specifically for membrane bound proteins, however it 
has been shown that ClustalW is equally applicable in membrane bound protein 
sequence alignment[10]. 
2.2.2 Calculating spacial restraints in the template structure 
After aligning the two sequences (or after two pre-aligned sequences are provided as 
in the above case) MODELLER calculates spatial restraints from the coordinate file 
(in the PDB file format) to apply to the model. 
The calculation of spatial constraints involves measuring a number of distances and 
bond angles. These include template Cα- Cα distances, backbone dihedrals (φ/ψ), 
sidechain dihedrals and van der Waals contacts. All of these constraints are 
automatically calculated by the software and stored for the next step. 
2.2.3 Generating the target model from spatial restraints of a 
homologous structure. 
Distance constraint rules used in MODELLER are derived using a structural database 
containing alignments of homologous proteins[11]. Model structures are generated by 
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using a Gaussian function (Equation 1) to calculate a probability density function for 
each of these spacial constraints based on the template structure and the similarity to 
the target structure. As an example the calculation of the probability density function 
for  Cα- Cα distance is shown in Equation 1. 
Equation 1 
Where d’ and d are the two equivalent Cα- Cα distances in the template and unknown 
structures respectively, σ is the standard deviation of the distribution of both 
distances. This is calculated from a polynomial which has three main dependencies; 
the similarity between the two proteins, the solvent exposure of the two residues 
spanning the distance and the proximity to the nearest gaps in sequence alignment 
between both proteins. A typical value is 1Å. Thereafter the spatial constraints and 
the CHARMM22 energy terms are combined into an objective function which is 
optimised in Cartesian space. The optimisation is performed using molecular 
dynamics with simulated annealing. 
MODELLER outputs a selection of structures which are scored by Discrete 
Optimized Protein Energy (DOPE) to suggest the best model which completes the 
modelling pipeline in MODELLER. 
The DOPE is an atomic distance-dependent statistical potential calculated from a 
sample of native protein structures. This uses probability theory to quantify if the 
differences between the template structure and the model are energetically 
favourable given the probability functions which were used to build the model.   
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Further refinement of the model is possible using other MODELLER functions 
including additional loop refinement which was required in the creation of GnRH-R 
structures. Because the sequence homology is lowest in loop regions between GPCR 
proteins the suggested loop regions are often incorrect. Sometimes this can be 
resolved by comparing the sequence to a protein database which may contain the 
required structural information for the required sequence which can then be 
optimised using an energy function. This type of approach is normally only useful 
for loop regions shorter than 6 residues, which is approximately half the size of a 
GPCR loop. Alternatively the loop can be refined ab initio using the loop.py module 
of MODELLER which runs the loop sequence through a number of relaxation steps; 
these allow for close atom contact before a molecular dynamics simulation which 
features rapid heating to 1000K and then a gentle cooling stage back to just above 
room temperature followed by a final relaxation gradient[12]. 
2.3 ProsaWeb 
A number of algorithms exist which are designed to generate 3D protein structure by 
homology modelling. Each modelling program typically has an inbuilt scoring 
system which assesses model quality by the minimum energy of the protein in the 
model conformation. Whilst this gives a general indication of the model quality it 
does not provide any insight into the quality of folding that is present in the model. In 
order to achieve this an independent method of testing was sought and in this case 
ProsaWeb[13, 14] was selected for this purpose. 
The ProsaWeb software was originally intended as a means of validating the 
accuracy of X-ray crystal structures; however, the method is also useful for 
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assessment of model structures. ProsaWeb runs on a webserver which is freely 
accessible and accepts model structures for error analysis in the standard PDB 
format. The program does not calculate model accuracy based on violation of steric 
principles such as atom close contact, its only function is to identify misfolded 
regions. These were developed using a “hide and seek” approach of picking out 
correctly folded regions from 50000 decoys[14]. Only the Cα atoms are used in the 
evaluation procedure; the energy of the structure as well as solvent exposure of each 
residue is calculated and used to derive a z score and residue energy. The z-score is a 
measure of the deviation of the total energy from the structure when compared to an 
energy distribution derived from the sampling random conformations. The z score 
alone is only meaningful when compared against the z score of proteins with similar 
size. The residue energies are calculated in linear fragments of 40 amino acids rather 
than as individual residues. This reduces large individual fluctuations in residue 
energy which the authors claim is not useful when investigating protein folds.   
2.4 LIDAEUS 
LIDAEUS (Ligand discovery at Edinburgh University)[15, 16] is a high throughput 
rigid body docking program which was written as a series of connected pipelines 
between 4 modular docking and scoring components (Figure 2-2). 
 
Figure 2-2. LIDAEUS docking pipeline. Preen adds atom type information and assigns partial 
charges. The Pose module is where the docking of the compound into the protein occurs, it will 
attempt to fit the molecule into the site points and outputs instances where atoms from site points and 
compounds match. Score assesses the potential energies of interactions between matched atoms and 




Before a protein can be submitted to LIDAEUS there must first be a set of energy 
maps defined for the target protein which are generated by using probe atoms around 
the space occupied by a ligand molecule docked into the target area. Three energy 
maps in total are required which contain information on hydrogen bonding, 
hydrophobic interactions and van der Waals attractions. The van der Waals 
attractions are defined using a Lennard Jones potential which describes the 
interaction between two uncharged molecules or atoms at a given distance. 
The map containing hydrogen bond donors and acceptors use complimentary probes 
to perform the respective calculations. These are weighted to favour specific 
hydrogen bond angles depending on the nature of atoms that are involved. 
LIDAEUS is able to use these three maps to approximate the energy of interaction of 
any ligand molecule that is docked within the ligand binding site specified earlier. 
Obviously large proteins may contain more than one binding site. Docking millions 
of small molecule fragments into a protein site which is not the target is wasteful in 
CPU time; therefore the maps also serve to direct LIDAEUS docking activity to 
defined regions of the target protein. The site points used in the rhodopsin based 




Figure 2-3. Site-points created for the rhodopsin based GnRH receptor model. White points 
represent hydrophobic contacts, red points indicated hydrogen bond acceptors and blue points are 
hydrogen bond donors. 
 
2.4.1 The preen stage 
Preen is the first stage in the LIDAEUS pipeline and is the module which reads in the 
small molecule from the users compound library formatted in an SDF file. During 
the molecule reading process preen adds additional atom type information, primarily 
this includes whether the atom is in a ring, the partial charges on the atom and also 
any missing hydrogens are added. 
 2.4.2 The pose stage 
In this step the small molecule which has been atom typed by preen is fitted into the 
target binding site of the protein as directed by the site points file. The program 
cycles through as many orientations as possible but without manipulating the 
rotational bonds within the small molecule. Because LIDAEUS is a rigid body 
docking program the ligand can only be manipulated by rotation and translation 
movements which are constrained by the site points provided. A successful pose is 
established by an atom position being docked within a certain tolerated distance of 
the site points; by default the first four atoms must be within 0.02 Å, 0.04 Å, 0.06 Å 
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and 0.08 Å. If the ligand matches these requirements then the ligand coordinates are 
saved into the ligand file and this is piped into the Score module. 
2.4.3 The score stage 
Ligands entering the scoring stage have their associated atom type values and the 
coordinates which were found to fit the defined fitting tolerance to the site points. 
The score module then takes the successful pose and uses the energy maps to 
calculate the energy contribution from each atom, giving a value in kcal /mol. The 
binding pose is then refined by applying energy minimisation before further rotation 
and translation is implemented to move the ligand into a more favourable position. 
During this ligand movement there is no site point involvement as the tolerance 
values associated with this are already considered to be met. In the most 
energetically favourable pose the binding energies contributed from van der Waals, 
hydrophobic and hydrogen bond interactions are used to make the score which will 
be used to rank the docked pose against the other molecules in the library. 
2.4.4 The Sort stage 
This is the simplest operation in the LIDAEUS workflow. Sort need only read the 
score information which is appended in the previous step and organise the top 1000 
compounds (or the user selected number) into numerical order. As the scores are 
displayed as values of kcal /mol the more negative the number the better the 
perceived pose interaction; in LIDAEUS docking a score which is less than -20 kcal 
/mol is considered to be a sensible cut off point. 
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2.5 AutoDock vina 
AutoDock vina[17] is a docking program which has the advantage of being able to 
treat both the ligand and protein as flexible structures. To start a docking run with 
AutoDock vina a little preparation is necessary; first the ligand and protein must be 
saved in the PDBQT file format and secondly the docking space must be defined. 
The PDBQT file format is unique to AutoDock and is generated using AutoDock 
Tools in the MGLTools package. The ligand and protein can be read from a PDB file 
after which the rotatable bonds which the program can identify automatically will be 
highlighted (Figure 2-4); these can be manually altered to make certain bonds more 
or less flexible depending on user preference. After rotatable bonds on the ligand and 
protein are suitable, both files are saved as the prerequisite PDBQT file. The next 
step is to define the search space which will be used in the docking procedure in the 
same way that the site points in LIDAEUS direct rigid body docking but without the 
associated interaction type information. 
 
Figure 2-4. Defining rotatable bonds of a sample ligand structure using AutoDockTools. Bonds 




The docking area sampling method is fairly simplistic, and involves manipulating a 
coloured box into the area that is to be included as a docking stage. The volume can 
be as large or as small as required (Figure 2-5); however there is an exponential 
increase in computation time as the volume of the box increases. Therefore a 
focussed search is preferable if the ligand binding site has already been biophysically 
established.  
 
Figure 2-5. Defining docking area of the target protein using AutoDockTools. The docking area is 
able to encompass an area as large as the user prefers; however, a search space greater than 27000Å3 
will prompt a warning from AutoDock vina. 
 
Once the docking area has been defined the coordinates of the grid box must be 
noted in order to be included in a configuration file which is required to supply to 
AutoDock vina via the command line. The configuration file also specifies the ligand 
molecule, the protein to dock into and the exhaustiveness of the search which can be 
set between 1 and 8, where 8 is the most exhaustive search.  
When AutoDock vina is performing a docking experiment it performs a number of 
runs consisting of sequential steps. Each step involves a random perturbation of the 
ligand-protein conformation followed by an optimisation step (using the Broyden-
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Fletcher-Goldfarb-Shanno algorithm); after optimisation the step is either accepted or 
rejected. Each optimisation consists of a number of evaluations with the scoring 
function as well as movement in the position-orientation-torsions coordinates. The 
number of evaluations that are performed are determined by convergence; whilst the 
number of steps in the run are determined heuristically depending on ligand size and 
flexibility. The number of runs are set by the exhaustiveness number that is selected 
in the configuration file.  
Increasing the exhaustiveness has a net increase on computational time; a setting of 6 
gives a reasonable trade off in computational time over increases in docking 
accuracy. 
2.6 EDULISS 
The Edinburgh University ligand selection system (EDULISS)[18] is a compound 
database which contains over 4 million unique compounds from the catalogues of 26 
chemical companies. EDULISS is more than a concatenated searchable compound 
collection. Each compound is associated with 1600 pre-calculated descriptors; these 
descriptors offer a wealth of biophysical information beyond the simplistic molecular 
weight and chemical formulae data that is often the limit of other databases.  
In this case EDULISS stores topological, geometrical, physicochemical and 
toxicological descriptors for each compound; this allows a more diverse selection of 
queries to be used to pre-select smaller families of molecules prior to screening. 
There are unique descriptors calculated for each compound which describe 
interatomic distances generally within the molecule as well as between hydrogen 
bond donors and acceptors, halogens, phosphorus and sulphurs. These allow 
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searching using ultrafast shape recognition which will be discussed in greater detail 
further in this chapter; but searching by pharmacophore is also possible using this 
method which is integrated into the EDULISS website (http:// 
eduliss.bch.ed.ac.uk/test/index.jsp) 
The statistics for the proportion of compounds which meet common drug likeness 
criteria are shown in Figure 2-6. 
 
Figure 2-6. Summary of the drug likeness criteria met by the compounds in the EDULISS 
database. Almost 75%  of the database pass both the Lipinski and Oprea criteria. Whilst the view 
could be taken that the whole database should pass as many drug likeness criteria as possible it should 
be considered that some diversity in the scaffolds are a useful method of finding novel ligands. 
  
2.7 Compound clustering by Tanimoto coefficient 
Molecular similarity is a key tool which has been used to cut the massive costs 
associated with developing new products within the pharmaceutical industry[19, 20]. A 
number of methods exist to derive similarity relationships between compounds in 
1D, 2D and 3D formats. 
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1D similarity could be considered a “low resolution” similarity matrix as it is 
typically based on simple information like atom count, molecular weight, logP and 
chemical formulae data.  
2D similarity is the most common form of similarity searching, it is relatively 
computationally inexpensive compared to 3D similarity searching but offers a far 
greater depth compared to 1D searches. A fingerprint for the 2D structure can be 
generated in seconds using the Daylight fingerprint software[21] although a number of 
other fingerprinting algorithms exist. 
3D similarity has the advantage of containing the most information for similarity 
searching; however, it has disadvantages that 2D methods do not. The most costly 
implementation of 3D similarity is the requirement for the generation of flexible 
conformers which allow alignment against query structures. Given that there has 
been no real advantage of using 3D similarity over 2D[22, 23] the use of 3D descriptors 
has generally fallen out of favour. 
After a method of similarity has been agreed the next choice is deciding which 
similarity scoring scheme should be used to compare structures. A number of 











In Table 2-1 the number of ON bits which are in structure A are substituted into term 
a, the ON bits in structure B are substituted into b and the ON bits common to both A 
and B are substituted into term c. Generally if an active and an unknown compound 
are found to share 0.85 similarity by a Tanimoto coefficient then there is an 80% 
chance that the unknown compound will also have activity[25]. 
Despite the choice in similarity coefficients the most widely recognised is the 
Tanimoto coefficient. Its widespread use may be a consequence of having a 
“molecular size normalisation in the denominator” [26] which allows it to still be 
effective in work with small molecules. Other methods can show bias to larger 
molecules because they have more ON bit strings to match to. In a recent review of 
similarity methods it was found when using one coefficient alone the Tanimoto 
method was the most favourable, although complimentary results were obtained 
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when using up to 6 different coefficients in a screen[27]. When using a Tanimoto 
coefficient compound similarity in relation to a query molecule is ranked between 0 
and 1. Scores closer to 0 indicated increasing dissimilarity between the query 
molecule and the compared structure; however this does not mean that scores of 1 
indicate that both structures are identical, only the fingerprints are.  It is also notable 
that the Tanimoto coefficient along with the Dice and Cosine measure the direct 
similarity between structures, the Euclidean and Manhattan/Euclidean coefficients 
measure the distance. The Tanitmoto coefficient value can however be converted to a 
distance measurement using the Soergel distance which simply subtracts the 
tanimoto value from 1 and is used in the clustering method described in this work. 
After the top 1000 compounds were output from LIDAEUS  a Lipinski ruleset was 
applied to further filter the set. The top 100 compounds were then clustered by 
similarity according to a Tanimoto coefficient before being converted to distance 
using the Soergel formula and plotted on a distance tree using an R script. A simple 
clustering example with the Soergel formula using a small dataset of 10 compounds 




Figure 2-7. A clustering of 10 compounds by Tanimoto coefficient. 
2.8 UFSRAT 
Ultrafast shape recognition (UFSR)[28] was briefly described in chapter 1, in this 
section the basic principles will be expanded upon with a worked example on how 
ultrafast shape recognition with atom types (UFSRAT) can be implemented in the 
search for GnRH-R inhibitors. 
Using UFSR as a similarity scoring system returns a value between 0 and 1; however 
unlike the Tanimoto coefficient, when a score of 1 is given it indicates a perfect 
match. The process follows two steps which simply calculate the molecular 
descriptors for the query structure and the unknown and then compares them. 
The descriptors used in UFSR can be grouped into four sets of three, so a single 
molecule has twelve descriptors in total. Calculation of the descriptors follows a 
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logical pattern that starts with selecting point A which is the centroid of the 
molecule. 
Next a list of Euclidean distances of all atoms to A is generated. This distribution of 
distances has mean, variance and skew values to A which are used to create the first 
three of the twelve descriptors. The atom which is closest to the centroid A is 
selected, let this be point B. The Euclidean distances of all atoms to B are compiled 
and the mean variance and skew are calculated; these account for descriptors 4 to 6. 
The furthest atom from B is then selected, let this be point C and again all Euclidean 
distances to this atom are calculated and used to generate the mean, variance and 
skew data that are used in descriptors 7 to 9. 
Finally, the atom which is furthest from atom C is selected, the Euclidean distances 
are calculated and the mean variance and skew data are used in descriptors 10 to 12. 
The scoring system is obtained using the equation shown below. 
 
In this example the score (S) from comparing the query (q) molecule against the ith 
structure (i) is given by substituting the descriptor numbers for the query and ith 
compound into the Mlq and Mli terms respectively. 
This technique is very powerful and delivered results which were not only closer in 
similarity to the query structure than EShape3D but was also 1546 times faster at 
returning the results[28].  
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This method was further developed by Steven Shave, a colleague in the group, by 
adding information on atom types into the descriptor terms which are expanded from 
12 terms to 48. This has the advantage of not only including information on all atoms 
but also being able to pick out hydrophobic atoms and hydrogen bond donor and 
acceptors. 
As an example a similarity search using the structure of the non-peptide antagonist 
Elagolix was performed. This compares EDULISS compounds from the 
Chembridge, Maybridge, Pubchem, Sigma and Specs catalogues against that of 
Elagolix. The results are shown in Figure 2-8. 
 
 
Figure 2-8. Similarity searching the EDULISS database using UFSRAT and the Elagolix 
structure. 
2.9 Surface Triplet Propensities (STP) 
Identifying ligand binding sites on proteins is a problem which has been addressed 
by a number of alternative methods. The most common approach relies on 
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identifying ligand binding sites by searching for surface cavities[29, 30]; this is fairly 
successful however difficulties occur when there are more than one cavity on the 
protein of similar depth. An alternative technique which uses the amino acid profile 
of a number of protein binding sites was developed using 804 ligand binding 
interactions[31]. This was used to create an algorithm which is not concerned with 
pocket depth but instead the residues which create the pocket. 
STP is a protein binding site prediction program developed by Wissam Mehio[32] 
which operates in a similar way. The surface of the protein is analysed with a probe 
that is the size of a water molecule and any group of 3 atoms that can be 
simultaneously touched by the probe are outputted as a triplet along with the atomic 
group information. 14 atomic groups exist to describe the properties of that group. 
An example of STP scoring the binding pocket of the rhodopsin derived model of 
GnRH-R is shown in Figure 2-9. 
 
Figure 2-9. Scoring of the surface of the binding pocket of GnRH-R with STP. STP was able to 
correctly score the pocket where the GnRH I hairpin associates. The program also scored a number of 





2.10 Biochemical assays techniques 
2.10.1 Culture of COS-7 cells 
COS-7 cells were cultured in 162cm2 cell culture flasks at 37 °C, 5% CO2 in 
complete medium (DMEM supplemented with 10% fetal calf serum). The cells were 
passaged once per week with cells being split approximately 1 in 20. 
2.10.2 Transfection of COS-7 cells with P41 plasmid 
10 µg of plasmid DNA was added to each 0.4 cm electroporation cuvette and kept on 
ice. Each 162cm2 flask of COS-7 cells was split between 2 cuvettes in the following 
way; each flask of cells was washed with 20mls of PBS (37oC, Ca2+, Mg2+ free) 
twice then the cells were detached by adding 2 ml of trypsin/EDTA and incubating 
for 5 minutes at 37 oC. 
8mls of complete medium was added to each flask and the cells were resuspended in 
the medium by pipetting. Resuspended cells were transferred into 50-ml sterile 
polypropylene centrifuge tubes and centrifuged at 2000 rpm for 3mins. The medium 
was aspirated and the cells in each 50 ml tube were then resuspended in 25 ml of 
prechilled electroporation DMEM (serum, glutamine and antibiotic free DMEM).  
The cells were pelleted again and the electroporation DMEM was aspirated. Cells 
were then resuspended in 3.5 ml of prechilled electroporation DMEM. 0.7 ml 
resuspended cells were added to each electroporation cuvette and mixed with the 
plasmid DNA by pipetting. Cells were pulsed at 960µF (capacitance) and 0.22kV in 
a Bio-Rad Gene Pulser MXCell then left at room temperature for 10 minutes before 
being mixed with 26 mls of complete media and seeded into 12 well plates. 
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2.10.3 Whole cell binding assay 
Transiently transfected COS-7 cells were incubated at 37 oC in complete medium for 
48 hours prior to assay. Cells were checked for confluence and then incubated with 
fresh complete medium for 30 minutes before any compounds were added. All 
compounds were diluted to their final concentration into ice cold DMEM 
supplemented with 0.1% BSA and radiolabelled 125I-[His5, D-Tyr6] –GnRH (100000 
counts /ml ) which has a very high affinity for the GnRH receptor[33]. Antagonist and 
peptide mixtures were incubated with the cells for 4 hours at 4 oC. 
Cells were finally washed twice with ice cold PBS and solublised by shaking with 
0.1M NaOH for 20 minutes at room temperature. Solubilised cells were then pipetted 
into 12 mm tubes and counted in a multigamma counter (Perkin Elmer Wallac).  
2.10.4 Inositol phosphate (IP3) assay 
24 hours after transfection the medium is replaced with 1ml inositol-free special 
DMEM (Gibco) containing 1% FCS, glutamine, antibiotics, and 1µl/ml 3H-myo-
inositol. Prior to incubation with compounds the special DMEM is aspirated and the 
cells are washed by incubating with HEPES-DMEM/0.1% BSA, 10mM LiCl for 30 
minutes at 37 oC. This is then aspirated and 500 µl HEPES-DMEM/0.1% BSA, 
10mM LiCl and 5% DMSO, with the appropriate final concentration of antagonist 
compound, is added to the cells and incubated for 30 minutes at 37 oC. 3nM of GnRH 
I is then added to each well, with the exception of the basal controls, and incubated 
for another 30 minutes. 
Cells are lysed using 10mM formic acid added to each well and incubated at 4 oC for 
30 minutes. Cell lysate is then added to AG 1-X8 resin in 12 mm plastic tubes and 
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briefly vortexed; once the resin settles the supernatant is aspirated and water is 
added, vortexed and aspirated. 60mM ammonium formate/5mM sodium tetraborate 
is then added, vortexed and then aspirated; thereafter 1M ammonium formate/0.1M 
formic acid is added then vortexed. The supernatant was then pipetted into 
scintillation vials where scintilint was added (Optiphase HiSafe 3) and counted using 
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Chapter 3. Building a model of the GPCR Gonadotrpin Releasing 
Hormone Receptor (GnRH-R). 
3.1 G-Protein Coupled Receptors as drug targets 
The GPCR proteins are a critical target for modern drug development. They are 
divided into five different families and account for around 2% of the total human 
genome[1]. Despite 50% of modern drugs being thought to act on GPCRs[2] they are 
still a relatively poorly understood receptor class due to the difficulties in obtaining 
high resolution crystal structure data [3]. To date there are still only six crystal 
structures of GPCRs reported in the literature. The first structure to be solved in 2000 
was Bovine Rhodopsin[4]. The publication of the solved structure was a result of the 
ability to obtain milligram quantities of purified protein relatively easily. This was a 
landmark paper in protein science and the seven transmembrane helix structure 
(Figure 2.1) became a foundation for GPCR modelling work for many years[5].    
 
Figure 3-1 Overall topology of the GPCR rhodopsin family. Members of the rhodopsin family 
possess a conserved structure consisting of 7 Transmembrane α helices (7-TM domain) connected by 
alternating hydrophilic intracellular and extracellular loops, an amino-terminus on the extracellular 





3.1.1 GPCR modelling using rhodopsin as a template structure 
As the first crystal structure of any GPCR, rhodopsin was the only template available 
to model the conformations of other GPCR proteins. Whilst this provided limited 
structural variation, it did provide modellers with a crucial starting point. 
A number of models were created using bovine rhodopsin as the template structure[6-
10]; whilst small molecule ligands were successfully found using this approach it does 
present limitations. Literature studies have evaluated the usefulness of using 
rhodopsin as a structural template in a variety of GPCR structures. These showed 
that whilst rhodopsin template modelling was useful in terms of generating a general 
placement of the 7 transmembrane helices, problems with active site residue 
placement caused incorrect natural ligand docking[11, 12]. This is a critical problem in 
ligand discovery[13]. 
A reason why this occurs is because as the sequence similarity between template and 
target sequence decreases below 30%, the model generated has a structure which is a 
reflection of the template more than the target primary sequence[14]. This idea is 
explored further in Chapter 5.7 where binding of template structure ligands to the 
target model structure is assessed. 
3.1.2 Subsequent crystallisation of rhodopsin-like GPCR proteins 
offered greater insight to GPCR structure 
It was not until seven years later that a new GPCR crystal structure was solved; the 
human β2-adrenergic receptor was the first ligand activated receptor structure[15, 16]. 
With this new structural insight into the mechanics of ligand induced movement the 
understanding of GPCR receptor signalling increased substantially. Over the course 
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of the next four years there was a relative explosion in the field due in part to 
production of lysozyme chimeric proteins and a further five structures were 
published: β1 adrenergic receptor[17, 18], A2A adenosine receptor[19, 20], CXCR4 
chemokine[21], dopamine D3[22]  and finally the histamine H1 receptor[23]. With six 
crystal structures now available (Table 3-1), significant GPCR insight can be gained. 
This is particularly true for GPCR activation. 
Table 3-1. Summary of current GPCR crystal structures published in the literature.  
Receptor PDB ID Function Therapeutic 
relevance 
A2A Adenosine 3EML Adenylate cyclase 
activation[24] Parkinson’s disease
[25] 
β1 Adrenergic 2VT4 Cardiac regulation[26] Angina, Glaucoma, 
Heart disease[27-29] 





CXCR4 Chemokine 3ODU Vascularisation 
factor[30] 
HIV treatment[31] 














3.1.3 GPCR activation is a multi-state structural event 
The current picture of GPCR activation depends on the structures movement between 
two key states, the inactive (R) state and the active (R*) state. In the R state the 
GPCR is still able to bind to and signal through G proteins, however this signalling 
activity is much lower than is induced upon agonist binding. In the R* state agonist 
binding causes conformational changes within the GPCR which increase signalling 
throughput significantly over basal activity.  However there is experimental evidence 
to show that intermediary states exist between these. Fluorescence work on the β2 
adrenergic receptor has shown that whilst the ligand free receptor has a preferred 
conformation, the structure is dynamic (Figure 3-2) and oscillates around this[35]. 
Agonist binding stabilises the active state but is not strictly required for the formation 
of R*. Whilst the majority of receptors will be in the R state spontaneous formation 
of R* is possible such that basal activity has been observed in the absence of agonist 
molecules[36]. 
The most significant structural change during activation is the 5-6Å migration of 
intracellular TM helices 5 and 6 away from the centre of the receptor[37], opening up 
the space for G protein association. Given the way G proteins are shared among 
receptors and the way in which one GPCR can signal through multiple pathways it 
has been revealed that the specificity of G protein association is actually a ligand 
specific rather than receptor event[38] given that the type of ligand that associates with 
the GPCR will affect the GPCR conformation in a specific way which will favour a 




Figure 3-2. Structural conformation changes in the activation of the β2 Adrenergic receptor. 
Binding of an inverse agonist rather than just an antagonist is the most effective way to prevent the 
activation of signalling through the G proteins as it prevents association with GS. Figure taken from 
reference [39]. 
3.2 Alignment of GPCR sequences shows low homology outwith 
key highly conserved domains 
Sequence alignments of the receptors (Figure 3-3 and Table 3-2) are surprising in 
that they have such low sequence identities. For the six proteins in Table 3-1 
sequence identities range from 15% to 59% even though they belong to the same 
class of receptor. The highly conserved glutamic acid/aspartic acid–arginine–tyrosine 
(E/DRY) domain (Figure 3-3) is a characteristic of the Class A GPCR family, 
however the significance is still somewhat ambiguous. Initially it was hypothesised 
by site directed mutagenesis that the motif was essential in maintaining the ground 
(ligand free) state conformation as a consequence of salt bridge formation between 
transmembrane (TM) helices 3 and 6. Later mutation experiments of the motif 
caused constitutive activation (CA) of the receptor[40].   By contrast however, the 
literature shows that this CA phenomenon is not observed in all members of the 
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family. A recent review summarised eight GPCRs which did not undergo CA as a 
result of similar mutations, GnRH-R is amongst those listed[41]. 
The NPxxY motif (Figure 3-3) is another conserved motif in the aligned sequences 






Figure 3-3. Sequence homology of the six GPCR crystal structures. The alignment shows that 
whilst there is reasonable identity between all GPCR structures the majority of the identity is 
restricted to the 7-TM helix regions (underscored in orange), most notably the Class A conserved 
E/DRY motif at the 150 residue region, CWxP around 450 residues in and the NPxxY motif in the 
490 residue region. 
 
Table 3-2. Pairwise alignment scores of GPCR crystal structures in a 7 x 7 matrix.  
PDB ID Length PDB ID Length Identity 
1F88 348 2R4R 365 15.0 
1F88 348 2VT4 307 17.0 
1F88 348 3EML 482 16.0 
1F88 348 3ODU 502 15.0 
1F88 348 3PBL 481 20.0 
1F88 348 3RZE 452 14.0 
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PDB ID Length PDB ID Length Identity 
2R4R 365 2VT4 307 59.0 
2R4R 365 3EML 482 24.0 
2R4R 365 3ODU 502 17.0 
2R4R 365 3PBL 481 28.0 
2R4R 365 3RZE 452 25.0 
2VT4 307 3EML 482 30.0 
2VT4 307 3ODU 502 21.0 
2VT4 307 3PBL 481 34.0 
2VT4 307 3RZE 452 30.0 
3EML 482 3ODU 502 45.0 
3EML 482 3PBL 481 53.0 
3EML 482 3RZE 452 54.0 
3ODU 502 3PBL 481 50.0 
3ODU 502 3RZE 452 49.0 
3PBL 481 3RZE 452 54.0 
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3.2.1 Microdomains and switch regions are conserved sequences which 
apply structural constraints to maintain inactive conformations 
As previously noted the E/DRY and NPxxY microdomains are observed to play roles 
as structural switches or so called “ionic locks” which are responsible for stabilising 
the R state structure. The Cys-Trp-Xaa-Pro (CWxP) motif is also involved in a 
similar role, a summary diagram is shown in Figure 3-4. 
The E/DRY domain on TM3 (Figure 3-4a) forms one of these ionic locks between a 
glutamate residue on TM6 and the Arg in the motif, but only when a pivotal 
asparagine in TM2 is in a protonated state[42]. 
The tryptophan in the CWxP motif undergoes a close packing interaction with 
Gly315 in the β2 adrenergic receptor (Figure 3-4c). When the glycine was mutated to 
an alanine the receptor exhibited constitutive activity demonstrating that the 
intermolecular force between them locks the receptor in the R state[43]. The R state is 
a structural conformation  
The highly conserved proline residue that is in the NPxxY motif causes a kink in the 
helix which forces the tyrosine into a pocket formed between TM2, 3, 6 and 7 
(Figure 3-4b). Water molecules in this region contribute hydrogen bonding stability 
to the receptor[44]. It is also a possibility that it may interact with an asparagine 





Figure 3-4. Analysis of ionic locks and microdomains in GPCR proteins. (a) The E/DRY motif 
interaction with E247 in rhodopsin. (b) The NPxxY motif interaction with N73 also in rhodopsin. (c) 
The CWxP motif interaction as observed in the β2-adrenergic receptor. (d) A cartoon schematic of the 
GPCR structure depicting where the DRY motif (Pink), CWxP motif (Green) and NPxxY (light blue) 
motifs are located. 
3.3 Alignment of GPCR crystal structures highlights favourable 
overlap of seven transmembrane helices. 
Alignment of the receptors by 3D structure rather than sequence is more illustrative 
of how the receptors share identity (Figure 3-5). Using rhodopsin as the fixed 
structure and aligning the other GPCRs against it, it can be seen that whilst sequence 
identity is low the structures themselves superpose well. Taking rhodopsin and 
dopamine D3 receptor as an example, even though sequence identity score is 
relatively low (20%) the structures themselves superpose better than might be 
expected (RMSD = 2.7Å). The pairwise alignment was performed using 197 Cα 




Figure 3-5. Structural alignment of GPCRs using rhodopsin (green) as the anchored protein. (a) 
Rhodopsin alignment with the β2 adrenergic receptor, Root Mean Square Distance (RMSD) = 4.1Å 
(b) Rhodopsin alignment with the β1 adrenergic receptor, RMSD = 3.3Å (c) Rhodopsin alignment 
with A2A adenosine receptor, RMSD = 3.0Å (d)  Rhodopsin alignment with CXCR4 chemokine 
receptor, RMSD = 4.6Å (e) Rhodopsin alignment with dopamine D3 receptor, RMSD = 2.7Å (f) 
Rhodopsin alignment with histamine H1 receptor, RMSD = 3.4Å. 
3.4 Discussion of sequence and structure alignments of the GPCR 
proteins 
Alignment results showed that there are only 13 residues which are fully conserved 
across all six of the GPCR sequences. Given that these proteins are 300-500 amino 
acids long this is a remarkably low conservation. This observation has been 
previously commented on in regard to evolutionarily “ancient” genes, where gene 
duplication and subsequent mutation allows a gene to change function whilst free of 
selection pressure[46].  
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The relatively low sequence identity between the GPCRs could be explained as a 
consequence of successful mutations after a gene duplication event from a common 
ancestor giving rise to the large number of GPCRs that have been found with a wide 
range of signalling roles[47]. 
3.5 Building a homology model of GnRH-R using a rhodopsin 
template 
As observed previously there is a low identity between residue type in GPCR 
proteins except in the case of structurally conserved microdomains. Therefore there 
is a difficulty in modelling an accurate receptor structure from one homology model. 
This is why in this work both rhodopsin and the β2-adrenergic receptor structures 
were used to create models. 
Three different model structures were made; the first two models were derived using 
homology modelling with the rhodopsin structure and were modified to reflect the 
expected positions of the receptor in the active and inactive states. The final model 
was created using the β2-adrenergic receptor structure and was made to reflect the 
inactive state. 
3.5.1 Rhodopsin and GnRH-R share low sequence homology 
Alignment of GnRH-R and rhodopsin showed an identity score of 15% (Figure 3-6); 
whilst it would have been preferable to have a larger identity to make our model 




Figure 3-6. Identity scoring of GnRH-R and rhodopsin residues. When aligning the two GPCRs 
the identity was only 12%. It is interesting that GnRH-R has substitutions in a number of the key ionic 
lock microdomains. The DRY motif is a DRS and the NPxxY motif is DPxxY. Transmembrane 
helices are underscored in orange. 
 
3.5.2 Homology modelling of the GnRH receptor based on rhodopsin 
In order to generate a homology model using MODELLER[49]  the input PDB file 
1U19 for the crystal structure of rhodopsin was used as it is currently the highest 
resolution structure in the PDB. After input of the GnRH-R I sequence into 
MODELLER five homology structures were generated and compared through 
superposition (Figure 3-7). The model quality was then assessed using ProSA-web[50] 
(Figure 3-8). This is a web server which evaluates distance pair potentials of the Cα 
backbone in the model as well as solvent exposure of each residue[51-53]. The z score 
generated for the structure indicates how the structure compares against protein 
scores computed for the entire PDB and calculates the model quality by measuring 
deviation of total energy in the structure against the energy distribution of the model 
in random conformations. This is then plotted alongside scores from proteins of 
similar size to allow comparison.  
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Alongside the GnRH-R model created from rhodopsin, the rhodopsin crystal 
structure was also evaluated with ProSA-web tool and a z score was obtained. This 
allows us to compare the z scores for the GnRH-R model and the rhodopsin crystal 
structure.  
 
Figure 3-7. Superposing the five GnRH-R model structures generated by MODELLER. 
Superposing the models showed how well the program was able to assess the positions of the flexible 
loop regions by fitting all structures to “best” model and looking at the variance in RMSD value. The 
RMSD value range was 0.23-0.38Å across the models and it can be seen that the TM regions are well 
defined whilst the IC and EC loops are not.  
 
In general the model scored fairly well. Figure 3-8 shows that the z score is in line 
with other proteins of similar size albeit in the outlying regions of the mean energy 
plot for x-ray structural data. Similarly the regions of high energy were localised to 
the portions of the helices which maintain high flexibility. Whilst the rhodopsin 
crystal structure produced a better z score, it too is placed near the edge of the x-ray 
results for similar size proteins. This suggests that the software may have greater 
difficulty analysing membrane bound proteins.   
71 
 
        
 
Figure 3-8. Using ProSA Web as a tool to check model quality. The best scoring GnRH-R model 
(Top) had a z score of -2.24. When this is plotted against proteins of a similar size the score is on the 
outlying regions of that obtained from X-ray crystallography but is still a reasonable fit (Top Left, 
black dot shows GnRH-R model score). Looking at energy potential of individual residues shows 22 
residues which have energy values out with the norm (Top Middle and Top Right). The crystal 
structure of rhodopsin was also evaluated (Bottom) and a z score of -4.11was calculated. 
 
3.5.3 Evaluation of GnRH-R rhodopsin-based homology models 
Next the differences between the models in terms of active site structural accuracy 
were examined according to the site-mutagenesis and peptide/non-peptide binding 
data[54-56] (Figure 3-9). The positions of the key GnRH peptide binding residues in the 
active and inactive state, as derived experimentally, were compared to the rhodopsin 
based GnRH-R model. Theoretically if the modelled positions of the key amino acids 
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are in close positions to those experimentally derived then there is higher confidence 
in the model quality. 
 
Figure 3-9. Evaluation of binding residue placement in MODELLER generated structure from 
rhodopsin. The five model structures are shown in white, residues in the experimentally determined 
ligand bound structure are shown in green, the ligand unbound state is in blue. 
 
Comparison between the active and inactive states shows that the model was able to 
predict Lys121, Asn212 and Asp302 positions fairly closely to the expected 
positions. The Asp98, Trp101 and Asn102 cluster along with Tyr290 are displaced 
from the expected position by the rotation on their respective helices. 
3.5.4 Flexible intracellular and extracellular loop regions present 
challenges in the model building process 
When docking experiments are carried out most of the extracellular loop regions will 
have to be removed as they will interfere with the docking into the active site. As 
loop refinement is a time consuming stage in model creation it may initially appear 
beneficial to remove them from the model entirely. However the positioning of the 
loops on both the intracellular and extracellular sides play a crucial role in defining 
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the rotation of the helices in the model, and are preserved and modelled as closely as 
possible given the information known. 
3.5.4.1 Loop optimisation  
Before adjusting the necessary active site residues manually the IC and EC loop 
regions were further optimised using the loop refinement module of MODELLER. 
The portions of the structure which had been highlighted by the ProSA Web energy 
scoring function were defined as the target regions for additional refinement. These 
regions were 96-110, 169-181, 211-223, 236-259 and 275-294 (Figure 3-7). After 
several cycles model ligand binding site positions were in close agreement with the 
experimental results and optimisation was deemed to be complete. This was 
particularly important because of the disulphide bonds between Cys14Cys200 and 
Cys114Cys195 on the ligand binding face[57]. 
3.5.5 Preserving ionic locks and microswitch domain interactions 
As discussed the GPCR ionic locks and microswitch domains are an important part 
of receptor function. Therefore in order to have the most representative receptor 
model it is useful to ensure that these are spatially accurate. There is however a 
degree of freedom with regards to how well the motifs fit into the model as they are 
are key players in structure activation and the method of activation between GnRH-R 




Figure 3-10. Comparison of microdomains between rhodopsin derived GnRH-R model (dark 
blue) and rhodopsin (cyan). The DRY ,CWxP and NPxxY motifs appear to align fairly well between 
both models, there are small deviations which are minor translation/rotational differences. Motifs 
which differ from the canonical residues are shown in parentheses. 
 
Our superposition of the three motifs (Figure 3-10) has shown that they align well; 
the CWxP motif in particular is very close (equivalent Cα- Cα distances are less than 
2Å). The DRS motif differs the most, a possible explanation for this may be due to 
DRY motif being a critical regulator of receptor ground state (Characterization of 
Intracellular Signaling Mediated by Human Somatostatin Receptor 5: Role of the 
DRY Motif and the Third Intracellular Loop) As rhodopsin is covalently bound to 





3.6 GnRH-R modelling using the β2-adrenergic receptor 
As previously discussed the β2-adrenergic receptor was the first ligand activated 
GPCR crystal structure, making it a more appropriate template structure for a GnRH-
R homology model though neither rhodopsin nor the β2-adrenergic receptor have 
sequence identities higher than 15% (Figure 3-6). The β2-adrenergic receptor does 
however have a higher sequence identity to GnRH-R than rhodopsin (Figure 3-11) 
3.6.1 Structure generation and loop optimisation of the GnRH-R model 
based on the β2-adrenergic receptor 
As in the previous GnRH-R modelling MODELLER was used to build the homology 
model. The PDB file 2R4R was used as the template structure file and the models 
produced were scored using ProSA Web (Figure 3-12). 
 
Figure  3-11. Alignment of GnRH-R and the β2-adrenergic receptor. The identity score for the 
alignment was 15% which is slightly higher than the 13% obtained from GnRH-R and rhodopsin. 
Since the β2-adrenergic receptor is also a ligand activated GPCR it is therefore a more suitable 




Additionally, the crystal structure of the β2-adrenergic receptor was also scored 
using ProSA-Web so that the z score could be compared between the two structures. 
The GnRH-R model created using the β2-adrenergic receptor structure had a 
calculated z score of -5.42. The β2-adrenergic receptor structure itself had a z score 
of -7.01 (Figure 3-12). 
 
 
Figure 3-12. ProSA-Web analysis of the GnRH-R β2-adrenergic receptor homology model (Top) 
and β2-adrenergic receptor structure (Bottom) . This model scored more favourably than the 
GnRH-R model from rhodopsin (z score -5.42). However the first flexible loop region is quite poorly 






As the first EC loop region was highly disordered after initial modelling an attempt 
was made to refine this region further using MODELLER. However the results were 
unnsatisfactory, and instead that part of the structure was rebuilt using the rhodopsin 
derived model part as the template and performing energy minimisation steps to 
tighten the structure.  
It is an interesting observation that the proposed model quality from the β2-
adrenergic receptor template scores better than that from rhodopsin. The z score is 
much closer to other proteins of its size than was seen with the rhodopsin derived 
model. Furthermore the β2-adrenergic receptor structure itself also scores more 
favourably; this indicates that the program does not have problems with the GPCR 
proteins as a whole, though rhodopsin may present a unique challenge.  
3.7 A comparison between models based on rhodopsin and the 
β2-adrenergic receptor 
3.7.1 Superposing the ligand free homology models of GnRH-R from 
rhodopsin and the β2-adrenergic receptor 
Now that a model has been created from a receptor with a constitutively bound 
ligand and one from a ligand activated receptor, it is interesting to look at the 
structural differences/similarities between them (Figure 3-13). 
The most obvious difference from the alignment is the position of TM6. Because the 
rhodopsin structure used as a template contained the ligand molecule this helix is in 
the active conformation which involves a 5-6Å movement of this helix in the distal 
plane. This can be checked through alignment of the ligand free opsin structure with 
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rhodopsin (RMSD = 1.6Å), which does indeed show that the opsin TM6 adopts a 
similar orientation to that of the β2-adrenergic receptor model. 
 
Figure 3-13. Structural alignment of GnRH-R models created using rhodopsin (magenta) and 
the β2-adrenergic receptor (orange). The two structures align with an RMSD value of 3.7Å which 
is a typical value for GPCR structure alignments and highlights a deviation in positioning of the TM6 
helix (highlighted by arrow). C14 and C200 disulphide bonding is shown in sticks in the extracellular 
loop. 
 
Relative positioning of the disulphide bonds between Cys14Cys200 is also slightly 
different. There is a distance of 6.1Å between the Cα of the Cys14 residues and 9.2Å 
between the Cα of the Cys200 residues. However disulphide bonds remain 
preserved. This should not be detrimental to small molecule docking as there is no 
known intramolecular interaction involving these residues and the target binding site 
is more deeply buried into the centre of the pocket. 
3.7.2 Examining differences in positioning of the conserved residues 
between model structures 
Examining the positions of the key conserved residues between both models and 
their respective templates, we observe variation in residue orientation and spacial 
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positioning (Figure 3-14). This is unexpected as the most heavily conserved residues 
are typically functionally important and should therefore occupy similar spaces. 
However it is possible that the difference is a result of conformational changes 
induced as a result of specific changes in structure to accommodate respective 
ligands. This highlights the difficulties of modelling protein structures with so few 
available crystal structures. As no consensus can be reached on how the helices will 
shift to accommodate ligand binding there is difficulty in determining which model 
is likely to be the most accurate. 
 
Figure 3-14. Comparison of key conserved residues positions between the rhodopsin (green) and 
the β2-adrenergic receptor (cyan) derived homology models. Positions of the same residues in the 
rhodopsin (transparent purple) and β2-adrenergic receptor (transparent dark blue) crystal structure are 
also shown. 
3.8 Understanding GPCR activation and signalling 
The signal transduction model of the receptor was first postulated in the Ternary 
Complex Model (TCM)[58]. This model proposed that GPCR activation occurred only 
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when agonist, receptor and G protein formed a complex in an agonist induced 
interaction. This was modified after it was found that ligand free GPCR proteins 
could change into an active state and bind to G-proteins[59]. As a result of the 
increase in available structural data, understanding of how the proteins are able to 
transmit signalling information across the plasma membrane has increased 
dramatically.  
 
3.8.1 Insights into GnRH-R signalling from the newly crystallised β2-
adrenergic receptor-Gs protein complex 
The first crystal structure of a GPCR-G protein complex has recently been published 
in the literature[60] by the same group who published the β2-adrenergic receptor 
structure. Again the receptor was stabilised using a T4 lysosyme chimera protein and 
bound to a high affinity agonist. The structure (PDB ID 3SN6) was aligned against 
our GnRH-R (β2-adrenergic receptor) homology model and we looked at the model-
G-protein complex interface to assess possible polar contacts within a 3.2Å distance 
between the GnRH receptor and the Gs protein. The interactions found were then 
compared with those of the β2-adrenergic receptor and the Gs protein. 
In the β2AR-Gs complex 20 β2AR residues are involved in creating 35 interactions 
to the Gs protein. Of the 20 unique residues 7 of them are also conserved within 
GnRH-R, these are residues R131, A134, I135, P138, S143 and L230. Of these 7 
residues only alanine is both conserved and potentially able to interact with the Gs 
protein. In the GnRH-R model there are 13 unique residues which can potentially 
form 19 interactions with Gs. These are shown in Table 3-3 and Figure 3-14. 
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Table 3-3. potential intermolecular interactions between GnRH-R and Gs. 
GnRH-R 
residue  
Gs residue  GnRH-R 
residue  
Gs residue  GnRH-R 
residue  
Gs residue  
Lys72  Tyr391  Gln244  Asp381 (2)  Asn257  Tyr358  
Ala142  His387  Glu248  Arg374  Ala261  Leu394 (2)  
Lys150  Lys34, Gln 35  Gln250  Arg342 (2), Asp323 
(2)  
Thr265  Leu393 (2)  
Asn152  Lys34  Gln253  Tyr350 (2), Gly353  Ser254  Arg385  
Thr237  Gln384  - - - - 
 
This new crystal structure gives an interesting insight into the possible binding 
mechanism between GnRH-R and the G protein coupling interactions. Whilst it is 
noted that Gs is not the natural G protein which couples with GnRH-R, there is a 
high identity between Gs and Gq/11 so it is likely that the two proteins have similar 
interaction mechanisms. This could give rise to the possibility of disrupting the 
GnRH-R signalling pathway through interruption of direct coupling between GnRH-




Figure 3-15. Comparison of Gs protein binding between β2-adrenergic receptor (left) and 
GnRH-R β2-adrenergic receptor homology model (right). Whilst the GnRH receptor is not known 
to bind to the Gs protein it does bind to Gq/11 which shares high identity (39%) with Gs. 
 
 
Investigating the potential interactions that could be targeted between GnRH-R and 
Gq/11 opens up the potential for new studies into GPCR drug design which can inhibit 
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basal activity whilst leaving the extracellular binding domain free for agonist 
binding. This G protein focussed approach may allow greater control of signalling 
from G protein coupled receptors which are able to bind to and signal via more than 
a single type of G protein receptor. 
This study will however focus on the targeting of the extracellular GnRH-R binding 
site for binding of small molecule inhibitors via modelling and validating the 
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Chapter 4. Theoretical and experimental studies on GnRH 
and agonist and antagonist peptide structures. 
4.1 Introduction 
The GnRH receptor is a clinical target for a number of therapies including prostate 
cancer and precocious puberty[1, 2]. However since there are currently no approved 
non-peptide drugs which are used to treat these conditions there is a need for rapid 
screening techniques in order to find possible small molecule GnRH-R 
pharmacophores. As the X-ray structure for GnRH-R is not currently available 
homology modelling must be used in combination with mutagenesis data to create a 
dockable receptor structure.  
In this study the models were created using two known GPCR crystal structures; the 
β2-adrenergic receptor and rhodopsin. When these models were created the high 
resolution β2-adrenergic receptor was the only ligand bound GPCR crystal 
structure[3]. As bovine rhodopsin has a constitutively bound ligand[4], ligands known 
to bind GnRH-R were compared between both models and the better docking 
structure used for futher in silico experiments.  
The traditional line between agonist and antagonist is slightly blurred when 
considering GPCRs. Traditionally an agonist initiates a specific response whilst an 
antagonist blocks this response, however continuous stimulation of GnRH-R by the 
GnRH-R peptide and the super-agonists causes desensitisation and internalisation of 
the receptor which causes cessation in signalling activity[5]. As noted in Chapter 1 the 
C-terminal tail which controls the rapid internalisation of the type II GnRH receptor 
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is missing from the type I structure. This causes a slower desensitisation response 
which is a poorer strategy to inhibit GnRH-R signlling; not just because of the 
increased time period to reach full efficacy but also because the initial surge or “flare 
effect”[6] in stimulation is detrimental to hormone dependent cancer treatment. Thus 
the GnRH-R antagonists were developed through residue substitution from the 
GnRH I peptide which had very high affinity for the receptor and demonstrated far 
quicker hypogonadism with no flare effect. 
4.2 Comparisons of GnRH receptor agonist and antagonist 
peptides  
In order to test the accuracy of the models an initial screen was performed which 
compared the docking response of four clinically approved antagonist peptides 
(Figure 4-1 and 4-2, Table 4-1). It was expected that these would score fairly well in 
docking simulations assuming our model was accurate. However a major difficulty 
in such an experiment is that small peptide structures are highly flexible and difficult 
to model which presents a challenge when carrying out docking work[7].  
















Abarelix 0.1 1416 Treatment of 
advanced 
prostate 




Antide <1 1591 Fertility 
treatment 
14 18 [9] 
Ganirelix 0.4 1570 Fertility 
treatment 
16 20 [10] 




17 18 [11] 
 
 
Figure 4-1. Comparison of 4 antagonist peptide structures with GnRH-I shows that a consensus 
of 3 key amino acids are required for binding to the receptor whilst avoiding activation of 
signalling. Non-natural amino acid substitutions are highlighted in black, terminology is as follows; 
D-Nal = D-Naptylalanine, D-Cpa = 4-chloro-phenylalanine, D-Pal = D-3-(3’-pyridyl)-alanine, D-Cit 
= D-Citruline, D-Ala = D-Alanine, D-hArg = dialkyl-D-homoarginine, N-Me Tyr = N-Methyl 







Figure 4-2. 2D structures of each antagonistic peptide. The structures show high similarity between 
all four peptide antagonists despite numerous residue substitutions. 
 
The four antagonist peptides all share the Ser4, Leu7 and Pro9 positions. However 
further substitution for non-natural amino acid groups is a key component of 
increasing binding affinity over the GnRH peptide. In contrast the agonist peptides 
that we examined (Table 4-2) have a much higher similarity to the GnRH-I sequence 
with minimal substitution in any of the four peptides. 
The most successful GnRH agonist and antagonist peptides were discovered from 
substituting the GnRH-I sequence with non-natural amino acids. The effect of a 
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single substitution is highly variable and may cause a change in interaction between 
the residue and the pocket or by altering the shape of the peptide in a specific way[12].  
Indeed it has been shown that from the entire ten residues of the decapeptide only a 
few key residues are required to preserve agonist activity (Figure 4-3 and 4-4). 
Table 4-2. Properties of the four selected high potency GnRH-R agonist peptides for docking 












Goserelin   1329.4 Treatment of 
breast cancer  
18  18  [13] 
Histerelin  <1  1323.5 Treatment of 
precocious 
puberty  
16  17  [14] 
Leuprolide  <1  1269.4 Treatment of 
prostate 
cancer  
16  16  [15] 
Nafarelin  <0.1  1322.4 Treatment of 
endometriosis  





Figure 4-3. Structural comparison of four high potency GnRH analogue agonist peptides. 
Minimal substituitions separate the agonist peptides. 
The almost exclusive substitution of residue Gly6 is a means to further “lock” the 
peptide in a hairpin turn configuration which makes it more suitable for receptor 
activation. This method of peptidometrics was so successful that it gave rise to the so 
called GnRH “Superagonists” with binding affinities many hundreds of times 




Figure 4-4. GnRH-I residue map and how residue substitution affects binding. Mutation of 
residues has shown that much of the decapeptide can be altered whilst still retaining functionality 
providing certain rules are followed to preserve specific interactions. Figure modified from [18]. 
4.3 Generating multi-conformers of peptide 
antagonist/agonists. 
4.3.1 Generation of Antagonist multi-conformer peptide structures 
As the docking procedure will incorporate a rigid body docking method, a series of 
50 energy minimised conformers were generated for each of the antagonist peptide 
structures to give more flexibility to the poses. The conformers were created from the 
energy minimised 2D SDF file of each peptide as found in the PubChem database[19]  
then converted to 3D and run through the conformer generating algorithm in the 




Figure 4-5. Superimposed conformer structures for each of the antagonist peptide. Abarelix 
Pubchem SID #17396902, Antide Pubchem SID #53788136, Cetrorelix Pubchem SID #11528755, 
Ganirelix  Pubchem SID#50064278  
4.3.2 Generation of agonist multi-conformer peptide structures. 
The 2D structures for the agonist molecules were obtained from the PubChem 




4.4 Comparing the agonist and antagonist multi-conformer 
peptide structures 
It can be noted that there seems to be a trend whereby the antagonist peptides form a 
hairpin which relaxes as further substitutions are made (Figure 4-7 dashed lines). 
However the agonist peptides seem far less prone to adopting this hairpin. This is 
particularly interesting given the structure of the GnRH peptide is believed to form 
the kind of hairpin bend shown by the antagonists from NMR data[21].  
 
Figure 4-6. Superimposed conformer structures for each of the agonist peptides. Goserelin 
Pubchem SID #49989249, Histrelin Pubchem SID #49989266, Leuprolide Pubchem SID #577770, 




Figure 4-7. Comparison of energy minimised conformation of four antagonist and four agonist 
peptides against GnRH. There appears to be a trend which shows that agonist peptides are naturally 
more linear than the superagonists. 
4.5 Docking agonist and antagonist peptide conformers 
using LIDAEUS and AutoDock vina 
After generating a model structure it is useful to conduct a positive control by 
docking ligands into the active site which have already been established to bind by 
biophysical techniques. 
In this section the docking of four commercial agonist and four commercial 
antagonist peptides into the rhodopsin and β2 adrenergic receptor models are 
discussed using rigid body and flexible docking programs. Furthermore, as a 
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negative control, beta blocker structures are docked into both receptor models and 
then assayed for activity. This is because beta blockers are a β2 Adrenergic receptor 
antagonist. 
4.5.1 LIDAEUS and AutoDock vina allow for rigid body and flexible 
docking environments  
LIDAEUS is a rigid body docking program which runs as a series of modules as 
described in Chapter 2.4. The modules create a docking and scoring pipeline which 
reads in a structure, docks it into the target protein and generates a score.  
The process requires generating a series of site points which tell LIDAEUS where 
the atoms reside. This involves specifying which atoms are involved in interactions 
within the active site and also creating energy maps which describe the hydrophobic, 
hydrogen bond acceptor, hydrogen bond donor and buriedness characteristics of the 
site points. 
AutoDock vina has a similar set up protocol (see Chapter 2.5 for full details), 
however rather than creating site points and energy maps a spacial grid is created 
which can accommodate the active site and ligand molecule. AutoDock vina has the 
advantage of being able to calculate potentials using flexible ligand and protein 
residues simultaneously. The force fields that it generates are similar to those in 
LIDAEUS, however it takes account of dispersion/repulsion, hydrogen bonding, 
electrostatics and desolvation. 
4.5.2 Preparing the model for docking  
To prepare the protein structure for molecular docking a modification was necessary. 
As previously observed the tertiary structure of the extracellular loop regions of the 
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GnRH-R model are likely to be highly variable and where they will be positioned 
cannot be determined with confidence. It would be undesirable for LIDAEUS to 
predict ligand interactions with the loop regions and so they were removed from the 
structure (Figure 4-8).  
 
 
Figure 4-8. GnRH-R model structure used for docking. The residues represented by sticks were 
removed from the final docking model to reduce the possibility of incorrect results as a consequence 
of the flexibility of the region. 
In addition, given that the key residues are all located on the helical regions the study 
would focus primarily on these. There are seven residues that are described as having 
a role in the binding of GnRH to its receptor from mutagenesis studies[22]: Asp98, 
Asn102, Asp302, Trp101, Lys121, Asn212 and Tyr290 therefore the docking 
experiment focussed around these regions. 
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4.5.3 Ligand site points specify binding regions on the receptor model 
Using the GnRH-R model with extracellular loop regions removed, a set of site-
points for LIDAEUS docking were created. Inspection of the binding pocket and 
knowledge of the key residues indicates that the pocket is relatively hydrophilic. 
However the Tyr290 and Trp101 residues will also confer some hydrophobic 
interactions. It was necessary to experiment with the site-point creation, as different 
parameters will produce a different balance of site-points types. It is desirable to 
create a set of site-points that reflect the nature of the binding pocket. The site-points 
are positioned around the binding pocket, close to the key residues as we might 
expect docked poses to form interactions with these residues (Figure 4-9).  
 
Figure 4-9. Site-points created for the GnRH receptor. The GnRH peptide is shown as yellow 
sticks. The site-points are displayed on the right. They are based on the physiochemical nature and 
structure of the binding pocket and use the GnRH peptide as a template to dictate where the site-points 





4.5.4 Agonist and antagonist docking results using flexible poses in 
AutoDock vina using the β2 adrenergic receptor homology model 
Docking results for the agonist peptides provided a maximum binding energy of  -8.8 
Kcal/ mol for the Goserelin and Histrelin peptides. The range of affinities was -7.7 to 
-8.8 Kcal/ mol (Figure 4.10) which fits quite well with the experimentally observed 
affinity range for the antagonist peptides. The affinity for the antagonists (Figure 4-
11) were slightly lower at -6.8 to -7.9 Kcal/ mol. This is slightly less than the agonist 
docking given that they have similar Kd values (Tables 4-1 and 4-2).  
 
Figure 4-10. Overlay of four agonist peptides in their respective docked conformations using 
AutoDock vina. All adopt a similar spacial orientation which involves the sixth residue of the 
modified peptide occupying the twelve o’clock position. Peptides shown are Goserelin(Cyan), 




Figure 4-11. Overlay of four antagonist peptides in their respective docked conformations using 
AutoDock vina. The peptides all adopt a similar special orientation which involves the sixth residue 
of the modified peptide occupying the twelve o’clock position. Peptides shown are Abarelix(Cyan), 
Antide(Magenta), Cetrorelix(Yellow) and Ganirelix(Pink). 
 
Examination of the hydrogen bonding interactions between the agonist peptides 
(Figure 4-10) indicates that there are numerous interactions for each docked peptide.  
Analysis of the residues within the GnRH receptor shows two residues in particular 
which are common features of the 4 peptide docking poses. Three of the four 
peptides interact with Tyr211 and all four interact with Asn305. Asn212 and Arg38 




Figure 4-12. Potential interactions between docked agonist peptides and the gonadotrophin 
releasing hormone receptor using a β2 adrenergic receptor derived model. (a) Leuprolide (b) 
Goserelin (c) Nafarelin (d) Histreline. 
 
If the antagonist docking interactions are examined it can be seen that in this case 
there is no one residue that all four peptides have a common interaction with. Instead 
three peptides interact with Asn212, thereafter interacting residues share between one 
and two peptides in common. The residues involved in the docking studies have been 




Figure 4-13. Potential interactions between docked antagonist peptides and the gonadotrophin 
releasing hormone receptor using a β2 adrenergic receptor derived model. (a) Abarelix (b) 
Ganirelix (c) Ceterorelix (d) Antide. 
 
Figure 4-14. Identifying hotspots in agonist and antagonist peptide binding to the GnRH-R β2 
adrenergic receptor homology model. The colour scale indicates the percentage of docked peptides 
which interact with the highlighted residue. 
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Comparison of the hotspots between agonists and antagonists highlights five residues 
which appear in both templates, Arg38, Trp101, Asn212, Ala209 and Asn305. These 
were compared to the GnRH binding residues which have been identified by site 
directed mutagenesis (Figure 4-9) and were found to have Trp101 and Asn212 in 
common. Whilst Asn305 has not been shown by mutagenesis to be involved in 
GnRH binding, there are no reports in the literature where it was tested. As Asn305 
is close to Asp302 which is part of the GnRH binding site, there is a possibility that it 
could perform an as yet undiscovered function. 
Therefore from the docking results using this model it could be advantageous to 
select small molecules which are able to bind to these residues in the development of 
future therapeutics. 
4.5.5 Agonist and antagonist docking results using flexible poses in 
AutoDock vina using the rhodopsin homology model 
The validation results from the β2 adrenergic receptor homology model showed good 
scoring for the clinically approved peptides. Therefore the same validation method 
was applied to the GnRH-R rhodopsin homology model for both the agonist (Figure 





Figure 4-15. Overlay of four agonist peptides in their respective docked conformations using 
AutoDock vina. All adopt a similar spacial orientation which involves the sixth residue of the 
modified peptide occupying the twelve o’clock position. Peptides shown are Goserelin(Cyan), 
Histerelin(Magenta), Leuprolide(Yellow) and Nafarelin(Pink).  
 
Figure 4-16. Overlay of four antagonist peptides in their respective docked conformations using 
AutoDock vina. The peptides all adopt a similar special orientation which involves the sixth residue 
of the modified peptide occupying the twelve o’clock position. Peptides shown are Abarelix(Cyan), 
Antide(Magenta), Cetrorelix(Yellow) and Ganirelix(Pink). 
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In this case the binding affinity range for the agonists was -7.3 to -8.6 Kcal/ mol 
whilst the range for the antagonists was similar at -7.2 to -8.0 Kcal/ mol. Whilst the 
increased consistency between both sets of results is more representative of the 
measured affinity of the peptides we should still consider that it is not necessarily an 
indication that the active site in the rhodopsin model is more or less accurate than 
that from the β2 adrenergic receptor model test. Conclusions on model accuracy can 
only be made from in vivo assay results. 
 
Figure 4-17. Potential interactions between docked agonist peptides and the gonadotrophin 
releasing hormone receptor using a rhodopsin derived model. (a) Leuprolide (b) Goserelin (c) 
Nafarelin (d) Histreline. 
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The possible interaction sites from the GnRH receptor to the modified peptides have 
been detailed in Figures 4-17 and 4-18. The agonist docking showed that both 
Asn305 and Ser118 were able to associate with three of the four peptides. If we 
compare that to the agonist results from the β2 adrenergic receptor model we note 
that Asn305 features in both sets of results. 
 
Figure 4-18. Potential interactions between docked antagonist peptides and the gonadotrophin 
releasing hormone receptor using a rhodopsin derived model. (a) Abarelix (b) Ganirelix (c) 
Ceterorelix (d) Antide. 
The antagonist peptides heavily favoured interaction with Ser118 in the receptor 
active site, however this residue was not a significant contributor in the β2 adrenergic 




Figure 4-19.  Identifying hotspots in agonist and antagonist peptide binding to the GnRH-R 
rhodopsin homology model. The colour scale indicates the percentage of docked peptides which 
interact with the highlighted residue. 
A comparison between the docking modes of both peptide types shows 8 residues 
which appear in both cases, Arg38, Trp101, Glu111, Ser118, Gln174, Asn212, 
Tyr290 and Asn305. Of these amino acids, Trp101 and Asn212 are residues which 
have been shown to be key components of the GnRH binding site from mutational 
study. 
The docking results from the β2 adrenergic receptor model and the rhodopsin model 
showed that the known peptide agonist and antagonists scored well in both models. 
Furthermore a number of residues were highlighted which participated in interactions 
between multiple peptides and were observed in both model structure docking 
experiments. 
The use of flexible docking peptide ligands into the GnRH-R receptor allowed the 
validation of the model structures as well as identifying potential residues for 
targeting with small molecules. 
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For further comparison both the β2 adrenergic receptor model and the rhodopsin 
model were docked with the antagonist peptide structures using the rigid body 
LIDAEUS software. 
4.5.6 Comparing Antagonist peptide rigid body docking results from 
LIDAEUS using rhodopsin and β2 adrenergic receptor homology 
models 
4.5.6.1 Antagonistic peptide docking into the Rhodopsin derived GnRH-
R model 
Taking the same 50 conformers that were described previously for Abarelix, Antide, 
Cetrorelix and Ganirelix the docked solutions within the GnRH-R active site were 
found using LIDAEUS (Table 4-3). 
The scores for the peptides were fairly similar between all four structures with the 
exception of Cetrorelix which scored far more favourably. However upon closer 
inspection of the docked poses it was evident that LIDAEUS had difficulty docking 
the peptide structures deeply into the binding site of the model. In all cases the best 
solution that LIDAEUS provided showed the peptides sitting further outside the 








Table 4-3. Scoring 50 peptide conformers for the Abarelix, Antide, Cetrorelix and Ganirelix 










-17.8 -16.6 -26.9 -18.0 
-17.5 -16.5 -19.1 -17.4 
-16.4 -15.1 -18.9 -16.0 
-16.0 -15.0 -18.6 -16.0 
-13.3 -14.4 -16.5 -14.7 
-13.1 -13.5 -16.2 -13.5 
-12.9 -13.1 -16.2 -13.2 
-12.8 -9.7 -15.5 -9.5 
 
4.5.6.2 Antagonistic peptide docking – β2 adrenergic receptor model 
The same antagonist conformers were then docked using the β2 adrenergic receptor 
model (Table 4-4). This time the peptide structures generally scored more favourably 
than in the rhodopsin model study, however there was still a notable difference in 
how deeply the peptide was buried in the pocket compared to the flexible docking 
approach. This suggests that in docking studies where highly flexible ligands are to 
be used there is an advantage in using an approach where the ligand and protein are 
allowed to be flexible. 
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Table 4-4. Scoring 50 peptide conformers for the Abarelix, Antide, Cetrorelix and Ganirelix 
antagonists using a structure modelled from the β2 adrenergic receptor, scores shown are the 









-25.5 -18.8 -23.0 -27.1 
21.2 -18.1 -22.2 -21.6 
-20.3 -17.6 -19.8 -19.5 
-15.7 -15.1 -19.7 -19.1 
-13.4 -15.1 -19.6 -17.2 
-13.1 -14.9 -19.3 -16.6 
-12.6 -13.9 -18.0 -15.6 
-12.3 -13.7 -16.5 -15.3 
-12.2 -13.4 -16.4 -15.0 







4.6 Crystallisation and characterisation of GnRH peptide 
A number of studies have examined the structure of the GnRH peptides using a 
number of characterisation techniques such as circular dichroism, NMR, 
fluorescence and a number of computational modelling methods[23-34]. A β-turn at 
position Gly6 was a common feature of all studies, however due to the highly 
flexible nature of the peptide no single consensus structure has been solved, if a 
single conformation in solution even exists. Hence there is considerable interest in 
obtaining a crystal structure of the GnRH peptide. 
4.6.1 GnRH I [D-Lys6,Trp7,Leu8] peptide crystallisation strategy 
After examining the conditions in which a number of short peptides were crystallised 
(Table 4-5) a hanging drop method was decided to be the most successful approach. 
Table 4-5. Crystallisation parameters for low molecular weight peptide fragments. 
Peptide Sequence Concentration 
(mg/ml) 
Method used Precipitant Reference 
NNQQNY  30  Hanging-Drop  100mM ZnSO4   [35] 
GNNQQNY  10  Hanging-Drop 100mM NaCl  [35] 
GNNQQNY  10  Bulk crystallization  N/A  [35] 
NNQQ (form 1)  30-50  Hanging-Drop 20% w/v PEG 
4000; 20% v/v 2-
propanol)  
[35]  





VEALYL  1.4  shaking at 37 °C for 1 
month  
150 mM NaCl  [35] 
LYQLEN  1.6  shaking at 37 °C for 1 
month  
150 mM NaCl  [35] 
VQIVYK  30  Hanging-Drop 45% v/v MPD  [35] 
MVGGVV (form 1)  30  Hanging-Drop 30% v/v MPD  [35]  
MVGGVV (form 2)  30  Hanging-Drop 20% v/v 2-
propanol  
[35] 
GGVVIA  15  Hanging-Drop 2.0 M ammonium 
sulfate  
[35] 
SSTSAA  30  Hanging-Drop 20% w/v PEG4000  [35] 
SNQNNF  10  Hanging-Drop 200 mM sodium 
acetate  
[35] 
ELLKKLLEELKG  10  Hanging-Drop 80% ammonium 
sulphate  
[36] 
AAAK  1  shaking at 37 °C for 1 
month  
PBS  [37] 
ECCNPACGRHYSC  45  Dialysis with PEG 20K PEG 20000  [38] 
 
The first hanging drop screen incorporated a simple ammonium sulphate screen to 
examine how easily the peptide could be precipitated from solution. A screen of 5-




Figure 4-20. Preliminary ammonium sulphate screen to determine precipitation point. 
From the ammonium sulphate screen it was found that at pH 5 the 5% drop remained 
clear however the other drops all showed a phased appearance which failed to 
develop into precipitate. In contrast at pH 7 the 5% and 10% drops both showed light 
precipitation whilst the 15%-30% drops showed heavy precipitation. A broad matrix 
screen was then used which consisted of the Crystal Screen 1 and 2 kits (Hampton 
Research) at temperatures of 4 °C and 17 °C using 10 mg/ ml peptide per drop. 
From these 196 conditions there were 3 which showed signs of crystal growth (Table 
4-6). 
Table 4-6. Conditions which show microcrystal formation of the GnRH peptide. 
Salt Buffer Precipitant Temperature (°C) 
0.2 M Zinc acetate 
dihydrate 







None None 2M ammonium 
sulfate 
4 and 17 
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None 0.1M sodium 
cacodylate trihydrate 
pH 6.5 




These conditions were interesting in the respect that a screening condition which was 
identical to the zinc conditions but replaced zinc with calcium produced no 
microcrystal growth. This suggests that the zinc itself has a specific stabilising effect 
on the peptide which can lock the peptide into a particular conformation, perhaps 
through GnRH-I chelating with the metal. This compliments the observation that 
incubating GnRH with zinc prior to competition binding with busarelin reduces 
GnRH effectiveness[39]. 
Taking the conditions from Table 4-6 and creating matrixes around these conditions 
to improve crystal size was unsuccessful in producing larger crystals, however the 
initial hit condition containing 0.2 M Zinc acetate dihydrate yielded needle crystals 
(Figure 4-21) which were large enough to obtain a dataset of 54 images at Δphi of 
7.5° (Table 4-7) using the IO3 beamline at the Diamond Light Source.  
 
Figure 4-21. Needle clusters of GnRH I [D-Lys6,Trp7,Leu8] peptide in 0.2 M Zinc acetate 




The data processing was performed using the program MOSFLM[40]. Owing to the 
weak nature of spots indexing was performed by manual selection of spots from 
multiple images throughout the dataset (Figure 4-22). 
 
Figure 4-22. Diffraction image of GnRH I [D-Lys6,Trp7,Leu8] peptide needles. Black arrows 
highlight the spots which are difficult to observe. 
Analysis using the program pointless[40] suggested the space group to be P212121 and 
the data processing statistics are shown below in Table 4-7.  
Table 4-7. Processing statistics for GnRH I [D-Lys6,Trp7,Leu8]  peptide. 
Space group P212121 
R sym 18.7% 
Resolution 3.0 Å 
Completeness 98% 
Cell dimension A 11.5 α 90° 
B 39.8 β 90° 




Calculating the cell volume gives a value of 19818Å3 and the molecular weight of 
the peptide is 1283Da. Using a Matthews coefficient[41] (Equation 1) this would give 
a solvent content as indicated below in Table 4-8. 




       (Equation 1) 
M     =   molecular weight of protein in daltons  
V     =   volume of unit cell. 
Z     =   number of molecules in unit cell = NA*NM 
NA  =   number of asymmetric units                  
NM  =   number of molecules in asymmetric unit. 
 
Table 4-8. Calculating solvent content of the asymmetric unit. 
Peptides in asymmetric unit Matthews coefficient % solvent 
1 3.86 68.15 
2 1.93 36.30 
  
Searching the Cambridge Structural Database (CSD)[42] for small peptides yielded 20 
structures with 12-17 residues. From this set of peptides, 2 structures (Figure 4-23 
and Table 4-9) also had a space group of P212121. Both of these structures adopted 
α-helical conformations however they both featured a number of α-aminoisobutyryl 






Figure 4-23. 2 peptide structures with space group P212121 were found in the CSD. Both 
structures adopt α-helical conformations due to α-aminoisobutyryl inclusion within the peptide 
sequence. 
Table 4-9. Cell dimension parameters for P212121 peptides from the CSD. 
 JEXSEK XEGCER 
Molecular weight 1155 1321 
Space group P212121 P212121 
Residue count 12 13 
a 10.33 9.96 
b 18.13 20.12 
c 35.0 39.31 
α 90 90 
β 90 90 
γ 90 90 
Peptides in asymmetric unit 1 1 
Matthews coefficient 1.42 1.49 
Solvent (%) 13.31 17.5 
 
From analysis of other peptide crystals of similar size this would suggest that there 
are 2 peptide molecules in the asymmetric unit. In addition a closer look at the unit 
cell dimensions indicate that the peptides are less likely to be helical and more likely 
to be strands. 
Attempts to solve the structure of the peptide using segments of β-strand have so far 
been unsuccessful. This is likely due to the weakly diffracting nature of the needle 
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crystals obtained. To date no better crystals have been obtained however further trials 
using the best condition found may yield better results in the future. 
4.6.2 Characterisation of GnRH peptide by circular dichroism 
Circular dichroism has been used before to establish structural information on the 
GnRH I peptide, however the GnRH I [D-Lys6,Trp7,Leu8] is thought to be a slightly 
more stable form of the peptide. Structural features were analysed using CD with 
increasing concentrations of 2,2,2-trifluoroethanol (TFE) (Figure 4-24). 
 
Figure 4-24. Circular dichroism spectra of GnRH I  [D-Lys6,Trp7,Leu8] in water and TFE 
solution. 
All spectra were recorded using a nitrogen flushed Jasco J-810 spectropolarimeter. In 
each case a final GnRH I [D-Lys6,Trp7,Leu8] concentration of 1mg/ ml was used 
which was prepared directly from lyophilised stock. Cell path length used was 0.02 
cm and data was recorded from 190 to 250 nm in 0.1 nm steps and was accumulated 
over 3 runs which were corrected for buffer. The CD spectra was deconvoluted  
using the DICHROWEB server[45]. 
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After analysis of the CD spectra it was found that in pure water the peptide was 
87.5% unordered with minor regions of strand, partial helix and turn. After addition 
of 40% TFE the unordered regions were 24%, strand was 50% and turn 22%. Helix 
contribution was a little over 4%. The large unordered regions of the peptide in water 
are an expected result, environment plays a large part in determining secondary 
structure[46]. Short peptide sequences are more flexible in water where stabilising 
interactions with larger molecules are not available[47]. Adding TFE to peptide 
solutions has been shown to cause a stabilising effect[48], a contributing factor as to 
why this is observed is thought to be TFE weakening the interactions between amide 
bonds and water which increases intramolecular hydrogen bonding[49, 50]. 
The native structure of the GnRH I peptide is thought to form a natural hairpin in 
physiological conditions[51]. Studies have shown that formation of a hairpin is a 
stabilising effect which is associated with proteins with structures composed of high 
proportions of strands and turns[52-54]. The CD data obtained in the 40% TFE study 
shows strand and turns to be the most common secondary structure elements within 
the peptide which could suggest that GnRH I  [D-Lys6,Trp7,Leu8] could also adopt 
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Chapter 5. Identification of small molecule inhibitors to 
GnRH-R using similarity searching.  
As previously discussed in chapter 1 there are currently no clinically approved small 
molecule antagonists of the GnRH receptor, meaning that all treatments are currently 
peptide based. Such therapy requires routine intramuscular injection or use of a slow 
release implant. These types of treatment are not only more inconvenient to the 
patient but they are also expensive to produce. There is therefore strong interest in 
developing small molecule antagonists; some progress has been made in this 
direction. 
5.1 Elagolix is a non-peptide orally active GnRH-R antagonist.  
During the course of this study the first orally active small molecule GnRH 
antagonist was found and entered into drug trials. Sodium R-(+)-4-{2-[5-(2-fluoro-3-
methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-
dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (branded Elagolix)[1] is a 
selective hGnRH receptor binding molecule with a dissociation constant of 54 pM[2]. 
The drug is expected to enter phase III clinical trials this year. 
5.1.1 Elagolix development through structure activity relationships. 
The synthesis of the Elagolix structure (Figure 5-1) was a result of chemical addition 
to a high affinity thienopyrimidinedione scaffold first identified in 1998[3]. 
Unfortunately this scaffold also had a high affinity for the CYP3A4 protein. The 
authors found that certain modifications not only increased the affinity for the GnRH 
receptor but also decreased the affinity to CYP3A4 to a far more tolerable level[1]. 
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Looking at Figure 5-2 the design decisions taken to produce the final molecular 
structure can be understood. 
 
Figure 5-1. 2D structure of the orally active non-peptide antagonist Elagolix (left) and the 
thienopyrimidinedione scaffold that it was built on (right). 
 
 
Figure 5-2. The uracil pharmacaphore used in Elagolix has been designed for high affinity. 
Modified from reference [1]. 
 
5.1.2 Docking the Elagolix molecule into the GnRH Receptor 
Whilst the binding interaction of thienopyrimidinedione antagonists has been studied 
previously this was expanded upon to focus specifically on the possible interactions 
between Elagolix with the receptor.  Of particular interest is how additions to the 
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scaffold change binding mechanics. Using AutoDock vina the possible alternative 
binding modes of Elagolix are explored and compared against results of docking the 
thienopyrimidinedione scaffold into the β2 adrenergic receptor model. Since the 
scoring system between docking software is so varied[4] the accuracy of the results is 
also an interesting point of discussion.  
5.1.3 Thienopyrimidinedione binding site analysis  
The interaction between the thienopyrimidinedione scaffold used in the Elagolix 
molecule and GnRH-R has been probed[5]. In a previous study it was proposed that 
the scaffold made 2 key hydrogen bonds with D302 and H306 (Figure 5-3). Only one 
of these hydrogen bonds extends to one of the key residues that bind GnRH 
described earlier in Figure 4-9. The same scaffold was docked using AutoDock vina 
into the β2AR receptor model created in this work and the binding modes compared 
in Figure 5-3 and Figure 5-5.  
 
Figure 5-3. Comparison of the suggested thienopyrimidinedione scaffold binding in the β2AR 
derived receptor model using AutoDock vina (left) against the literature docking study from 
Betz et al[5] (right). 
The docked scaffold resides in very different positions between both models, in the 
β2AR derived model the scaffold is positioned into the slightly deeper pocket closer 
to Q208 than was found in the literature study. There are also distinct differences 
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between model structures in the positioning of the highlighted amino acids in Figure 
5-3. The key difference is the lack of binding pocket formed by Y290, L300 and 
F309 shown in the literature docking, this cannot form in our β2AR model because 
the L300 residue is on the opposite side of the helix. 
5.1.4 Docking Elagolix using AutoDock vina 
The Elagolix structure itself was docked it into the β2AR receptor model using 
AutoDock vina and the most favourable pose is shown in Figure 5-4. We compared 
how the ligand would be posed in comparison to the more time consuming approach 
favoured by the authors, where they performed a series of molecular dynamics 
annealing experiments at various temperatures in a simulated solvated state before 
final energy minimisation was applied[5].  
 
Figure 5-4. Docking Elagolix into the β2 Adrenergic receptor derived model using AutoDock 
vina shows that as in the scaffold docking experiment the elagolix molecule is positioned into the 




5.1.5 Comparing docked poses of thienopyrimidinedione scaffold and 
Elagolix  
If the β2 AR and published models are compared there are key differences in each 
model with regards to where the highlighted residues are placed. Atomic coordinates 
for the published model are not available to align against our model. The published 
scaffold binding pose (Figure 5-4) shows a rather different binding pose to that 
obtained in our work (Figure 5-3), though both structures make reasonable hydrogen 
bonds with the receptor (Figure 5-5). The scaffold affinity for our receptor model 
was -9.4 kcal /mol which is higher than the score of -8.8kcal / mol obtained for 
elagolix.  This is interesting since the scaffold shows only two possible hydrogen 
bonds compared to the three bonds that Elagolix can form with Tyr284 and Asn212 
(Figure 5-5).  
 
Figure 5-5. Comparison of docked binding poses between thienopyrimidinedione scaffold  from 
this study (left) and the literature (middle) and Elagolix in the GnRH-R active site (right). 
 
5.1.6 Probing the antagonist activity of Elagolix 
It is not yet known if Elagolix acts allosterically and causes a structural change in 
GnRH-R which prevents GnRH association, or if Elagolix acts as a competitive 
inhibitor to prevent GnRH-I entry. To test the hypothesis that Elagolix acts as a 
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competitive inhibitor both the GnRH-I peptide and the Elagolix molecule were 
docked into the same receptor model to determine how closely the molecules would 
be if both occupied the active site simultaneously (Figure 5-6).  
From this docking data it can be observed that the Elagolix molecule occupies a 
significant area of the peptide binding site which would occlude the peptide from 
being able to gain entry, particularly given the far tighter binding affinity of the small 
molecule over the peptide sequence. 
 
Figure 5-6. Comparison of the docked poses of the GnRH-I peptide (a) and Elagolix (b) it can be 
seen that Elagolix occupies almost half of the space of the GnRH-I peptide. 
 
Closer inspection of the Elagolix docking suggests that it does not act as a GnRH-I 
peptide mimic; whilst the Elagolix molecule occupies similar space it does not make 
the same contacts as the peptide. Mimicry of the hairpin was a feature of the original 
scaffold. 
Whether active site occupation alone is the only factor affecting GnRH binding is not 




The Elagolix structure is a small molecule antagonist with a high affinity for the 
GnRH receptor. As a technique in developing further small molecule antagonists the 
Elagolix structure was used to search the EDULISS database for similar compounds. 
5.2 Using the EDinburgh University LIgand Selection System 
(EDULISS) as a search space for compound similarity. 
As described in Chapter 2.6 EDULISS is a database of chemical structures with 
associated descriptors. In this section the use of EDULISS as a search space for 
finding structures similar to Elagolix will be investigated. Similar compounds that 
are identified are then docked into the β2AR model using AutoDock vina and scored. 
Any compounds that are identified as suitable candidates from docking are then 
assayed for activity. 
5.3 Searching EDULISS for compounds similar to Elagolix 
using Ultra Fast Shape Recognition with Atom Type 
(UFSRAT) and docking with AutoDock vina 
Taking the structure of Elagolix (Neurocrine Biosciences) as a lead template a search 
of the EDULISS database was carried out using the software program UFSRAT as 
described in Chapter 2.8 to suggest compounds from the library which share similar 
structural characteristics (and therefore the possibility of similar interactions) with 
Elagolix.   
The top 100 compounds had a similarity range of between 0.95 and 0.92, six were 
selected for assay (Table 5-1). These compounds had a UFSRAT similarity from 
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0.95 to 0.93 and were docked and scored using Autodock vina as described in 
Chapter 2.5. The identity searched compounds had a predicted affinity range of -9.0 
to -8.1 kcal / mol; docking the Elagolix structure gives a score of -8.8 kcal / mol. The 
similar scoring to the Elagolix molecule is a good indicator that the compounds will 
have some form of activity. 
Table 5-1. The structure of Elagolix was run through UFSRAT and the top 10 similar 
compounds were scored in AutoDock vina for predicted affinity. 
 
The docked poses of the compounds were then compared to that of Elagolix (Figure 
5-7).  It was surprising to see compound 19 having a predicted affinity higher than 
Elagolix given that the Elagolix structure is so well engineered. However we can see 
from the docking results that this is due to the compounds ability to make four 
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hydrogen bonds to the receptor instead of the three hydrogen bonds of elagolix. All 
compounds were docked into the same pocket as Elagolix with 1-3 potential 
hydrogen bonds. Hydrogen bonding to Asn212 was common to all compounds 
except compound 16 which has a hydrogen bond to Ser118. 
 
 
Figure 5-7. Comparisons of binding locations between compounds found from EDULISS with 




5.4 Assaying compounds structurally similar to Elagolix with 
the GnRH receptor. 
Six compounds (compounds 14-19) which were readily available from Asinex were 
selected for assay. Initially a single point IP assay at 100 µM was performed to 
quickly assess if any of the compounds showed antagonist activity (Table 5-1). The 
assay mechanism relies on the activated signalling pathway of GnRH-R using IP3 as 
a second messenger. As tritiated inositol is added to the media prior to assay, the 
activation of GnRH-R can be followed by lysing the cells and measuring 
radioactivity of IP3 bound to resin. Compounds which are able to prevent GnRH-R 
activation by GnRH-I peptide will show lower radioactivity than the GnRH-I 
stimulated reference cells. The technical details are described in Chapter 2.10.4. The 
difference in inhibition between compounds 14 and 15 was particularly interesting 
given that they only differ by a single oxygen atom. Their binding poses were also 
very similar, however compound 14 made a hydrogen bond to Ala209 instead of 
Tyr283. From this screen compounds 14, 15, 17 and 19 were used in dose-response 
competitive binding assay. 
5.4.1 Whole cell binding assay 
The whole cell binding assay was performed as described in Chapter 2. Briefly this 
assay measures the decrease in radioactivity from competition binding. Competition 
arises between increasing concentrations of the test compound and an 125I-[His5, D-
Tyr6] –GnRH tracer peptide of high affinity. Therefore the lower the radioactivity 
reading, the better the compound is as a competitive inhibitor. 
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Results in Figure 5-8 suggest that all compounds were able to compete off the 
radiolabelled peptide to some degree. As such the compounds were then tested in a 
dose –response assay (details in Chapter 2) to measure inhibition of inositol 1,4,5,-
trisphosphate (IP3)  production (Figure 5-9). 
 
 
Figure 5-8. Results of whole cell binding assay of elagolix similar compounds at 0.01, 0.1, 1.0, 30 
and 250µM concentrations. (Top) Raw bound radioactivity reading. (Bottom) Radioactivity reading 




5.4.2 Inositol Phosphate inhibition (IP3) Assay 
 
Figure 5-9. Radioactivity from deuterated inositol produced by stimulation with GnRH peptide. 
Compounds are loaded onto cells prior to activation with agonist GnRH peptide and inhibition of IP3 
production is used to measure how well the test compound is able to occlude the peptide from GnRH-
R activation. 
In contrast to the whole cell binding results the IP3 assay showed that even at the 
highest compound concentration there was little receptor activation inhibition. 
5.4.3 Discussion of assay results for compounds selected by Elagolix 
similarity 
Figure 5-8 showed a fairly strong result for compound 15. 40% of the compound had 
bound to the receptor at the 30 µM point. However the same effect was not observed 
in the IP3 assay. One reason for this may be that the compound was displacing far 
more non-specifically bound radio labelled peptide than that bound to the active site. 
The results from the IP3 assay with compound 14 and 19 are also interesting to 
examine; after initially causing an inhibition response at 30 µM there was no further 
effect from increasing concentration despite showing increased radioligand 
displacement up to 250 µM in the binding assay. This is possibly due to the effect of 
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non-specific binding of the radioligand which is being displaced by the compound 
but which has no effect on IP3 production. 
5.5 Quinolone compounds as potential GnRH-R antagonists 
There have been a number of reports in the literature[6-9] which have identified 
quinolone (Table 5-2) based compounds as being antagonists to the GnRH receptor 
at high affinity. As a means to better understand the QSAR of these compounds and 
to further develop the scaffold, a select number of quinolone and quinolone-like 
compounds from a focussed inhouse compound library collection were tested to 
probe for antagonist activity. 




5.5.1 Selection of quinolone/quinolone-like compounds and AutoDock 
vina scoring 
In total 11 compounds from the inhouse quinolone-like library were docked and 
scored (Table 5-3), these were selected on the basis of the presence of the quinolone 
group or where the  group was absent sufficient quinolone likeness. Solubility data 
provided by the manufacturer was also a consideration.  
5.5.2 Assay of quinolone compounds  
Due to limited materials it was only possible to assay one concentration of each 
compound in a radioligand binding assay. All compounds were assayed at 33 µM 
except compound A10 which was 66 µM, the GnRH peptide control was 1 nM. 
 
Figure 5-10. Single point assay results for quinolone/quinolone like compounds. Results shown 
are for 33µM of the respective compound excluding A10 (66µM) and GnRH (1nM). All conditions 






































5.5.3 Discussion on the potential of quinolone compounds 
The assay results for quinolone and quinolone like compounds gave positive results. 
Of the eleven compounds assayed seven gave a decrease in bound radioligand 
readings. Interestingly the best scoring compounds did not show the largest binding 
activity. The largest change was 33% using compound G10 followed by 26% by 
compound D10. When docked into the receptor (Figure 5-11) these molecules do 
bind quite deeply into the active site. The position of D10 does not allow the 
formation of hydrogen bonds directly to any of the receptor residues however there 
may be a ring stacking interaction with Trp101. G10 is able to make two hydrogen 
bonds to residues Tyr211 and Asn212. 
 
Figure 5-11. Docked poses of compounds D10 (b) and G10 (a). The compound positions are 
located deeply into the pocket in the centre of the active site and represent a good target location for 




5.6 Docking beta blockers into the “β”2 adrenergic receptor 
derived GnRH receptor model demonstrates bias for β 
Adrenergic receptor ligands. 
As a control experiment, three common beta blockers were docked into the GnRH 
receptor model to assess how the use of the β2 Adrenergic receptor as a template 
structure affected the possibility of beta blocker structures scoring systematically 
high. There is no literature evidence indicating that beta blockers can bind to GnRH-
R therefore this experiment aims to determine two points; do beta blockers score 
highly in docking experiments with GnRH-R and secondly, does this translate to 
inhibition activity in an IP3 assay? 
5.6.1 Comparison of β adrenergic receptors. 
There are three known beta adrenergic receptors transcribed in the human genome. 
As previously described they are all members of the rhodopsin like GPCR family of 
which GnRH-R is also a member. Beta blockers have been developed to be selective 
for the receptor type that they target, β1, β2 and non-selective blockers are all 
available. As the GnRH-R model that we produced was based on the β2 adrenergic 
receptor, the structure of the model is heavily influenced by the helix conformations 
of β2AR. This would make testing a β2 selective drug a logical decision.  However if 
the other β adrenergic receptors share high identity to the β2AR then the drugs which 
target those receptors may also be useful. An alignment of the β adrenergic receptors 





Table 5-4. Identity comparisons between the Beta Adrenergic receptor sequences. 





Beta 1 Receptor  477 Beta 2 Receptor  413 48.0 
Beta 1 Receptor  477 Beta 3 Receptor  408 50.0 
Beta 2 Receptor  413 Beta 3 Receptor  408 39.0 
 
 
Figure 5-12. Sequence alignment of beta adrenergic receptors 1-3 indicates most homology is 
found in the membrane-bound regions of the receptor structures. The type 1 receptor shares 50% 




The three beta adrenergic receptors share between 39-50% identity. This is a fairly 
high score given that these are GPCR proteins. As observed previously the 
membrane bound regions of the proteins are the regions which share the most 
identity. As the identity scores were fairly high it is useful to dock ligand molecules 
for all receptor types against the GnRH receptor model that has been derived. After 
the model and subsequent docking experiments in this study were concluded using 
the β2 receptor as a template, there was a subsequent publication of the β1 adrenergic 
receptor. There is scope for the creation of a GnRH-R model using this structure. 
However given the high identity of the buried residues between types β1 and β2 the 
usefulness was questionable, especially when we consider the transmembrane 
regions of each protein can be superimposed with an RMSD of 0.809Å (Figure 5-
13). 
 
Figure 5-13. Superimposing the Turkey β1 adrenergic receptor (PDB code 2VT4) and the 
Human β2 adrenergic receptor shows an RMSD value of 0.809Å. Alignment of the protein 
sequences between the Turkey and Human β1 adrenergic receptor shows 284 identical residues and 90 




In the docking experiment we used three beta blocker structures; Bisoprolol (B1 
selective), Butaxamine (B2 selective) and Propranolol (non-selective) to cover the 
full spectrum of drug selectivity for the adrenergic receptor (Table 5-5). The 3D 
structure generation and docking procedures were the same as described in Chapter 
2.  
























5.6.2 Docking the B1 Selective beta blocker Bisoprolol into the GnRH 
receptor. 
The first docking result from the beta blocker family gave a consistently lower score 
for the GnRH receptor than both the peptide and non-peptide antagonists that have 
been docked thus far. The shape of the Bisoprolol molecule did however allow the 
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molecule to dock into the receptor in an elegant manner despite the lower affinity, 
creating potential hydrogen bonding to Asn305 (Figure 5-14). 
 
Figure 5-14. Docking the Bisoprolol molecule into the GnRH receptor indicated that one 
hydrogen bond could be formed between the ligand and receptor. 
 
5.6.3 Docking the B2 Selective beta blocker Butaxamine into the GnRH 
receptor model. 
The docked butaxamine molecule may form two hydrogen bonds with the receptor 
(Figure 5-15), this would involve residue Asn212. Interestingly although this 
interaction contains an extra hydrogen bond, the predicted affinity is the same as 
bisoprolol. 
 
Figure 5-15. Docking the blocker Butaxamine into the GnRH receptor suggests hydrogen 




5.6.4 Docking the non-Selective beta blocker Propranolol into the GnRH 
receptor model. 
The final beta blocker docking experiment produced the highest affinity of all 
molecules tested (Figure 5-16). This may be a result of the unselective properties of 
the ligand for a specific beta adrenergic receptor. In this case only potential hydrogen 
bonding to Leu286 seemed likely. The reason for increased affinity is unclear; 
initially as the ligand has an extra ring in the structure it was thought this might be 
able to form a ring stacking interaction but close scrutiny of the docked model 
indicates this not to be the case. It is noteworthy that the hydrogen bond location is 
however closer than in the other docking experiments. 
 
Figure 5-16. Docking the unselective beta blocker Propranolol into the GnRH receptor suggests 




5.6.5 Inositol phosphate production assay indicates no GnRH receptor 
agonist or antagonist activity from Propranolol. 
As the Propranolol molecule was the highest scoring compound from the virtual 
screening study the compound was assayed by measuring the effect that it had on 
inositol phosphate production at a concentration of 250 µM. 
Reviewing the results of the inositol phosphate assay (Figure 5-17) indicates that no 
definitive increase or decrease in inositol phosphate was recorded. This indicates that 
250 µM Propanolol has no binding interaction with the GnRH receptor regardless of 
how well it performed in the docking experiments. 
 
Figure 5-17. Comparison of Inositol phosphate production between the basal state and the 
250µM Propranolol incubated cells shows that IP production is not significantly affected. 
 
5.6.6 Homology models have a degree of bias for the template structure 
ligands 
The first aim of this study was to establish if beta blockers scored highly in docking 
experiments using a model derived from a beta adrenergic receptor. It was found that 
all beta blockers docked with poorer scores than GnRH-R specific ligands. To further 
explore this idea the same three beta blockers were docked into the inactive 
rhodopsin derived GnRH-R model. All three beta blockers scored an affinity 
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approximately 1 kcal/ mol less than was observed for the beta adrenergic derived 
GnRH-R model (Figure 5-18). 
 
Figure 5-18. Comparison of docked beta blocker positions and scores between GnRH-R models 
derived from the β2-adrenergic receptor and rhodopsin shows higher scoring in the β2-
adrenergic receptor model. 
 
It is interesting that the non-selective beta blocker scored the most favourably in both 
models, this may be because the fused ring structure allows the molecule to make 
more favourable contacts than the selective beta blockers. 
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Assay results showed that despite the docking results being favourable there was no 
measurable interaction between the beta blocker and receptor. Therefore when doing 
virtual screening using a model structure it is useful to examine top hits for 
similarities to ligands for the template structure so that they can be assessed more 
rigorously prior to purchasing for assaying. 
5.7 Conclusions and future work 
The main goal of this chapter was to address how similarity to a known small 
molecule inhibitor of GnRH-R could be exploited to data mine similar structures 
from a large structure database. Using the Elagolix structure as a template, six similar 
compounds were identified from EDULISS using UFSRAT and assayed for activity. 
From these six compounds, four were then used in a dose response curve to measure 
competitive binding to the GnRH receptor and were found to compete off 30-55% of 
the tracer peptide at 250 μM. Furthermore compound 15 was able to compete off 
45% of the tracer at 50 μM. These compounds also demonstrated antagonist activity 
in a GPCR activation assay. This is a really encouraging result for our β2 adrenergic 
based GnRH-R model structure, as stated; the only way to test model accuracy is by 
performing assays using suggested ligands.  
Since we were able to identify four compounds all of which showed binding and 
antagonist activity then we are able to validate the model accuracy as well as the 
approach of using homology modelling for GPCR proteins. 
Additionally quinolone compounds provided another compound similarity search 
approach. Again the compounds which were docked went on to show competitive 
activity when tested by assay. Of these compounds G10 was particularly notable, 
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with 34% of the tracer peptide displaced at a concentration of 33 μM.  Ideally these 
compounds would then be tested using a dose response IP3 assay to assess the actual 
receptor activity inhibition. 
However the latter part of this chapter does demonstrate one of the issues that can 
occur when using low sequence similarity structures as a modelling template. 
Namely that the template structure can introduce ligand bias. It was found that 
ligands to the β-adrenergic receptors scored more favourably in models created using 
the β2-adrenergic receptor as a template than a model created from rhodopsin. The 
scoring was also lower than the GnRH receptor specific ligands which acted as a 
positive control. 
All compounds identified could have their chemistry further optimised to increase 
binding activity as part of a QSAR analysis. From this novel scaffolds may be found 
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Chapter 6. Identifying small molecule inhibitors using a 
LIDAEUS database mining approach  
In Chapter 5 the use of similarity searching as a means of discovering novel 
compounds with affinity for the GnRH receptor was investigated and compounds 
were identified with antagonist activity. Whilst this has the advantage of similar 
compounds having similar chemical properties, the potential of finding new scaffolds 
for future drug development is reduced[1]. In this chapter an alternative approach of 
database mining was focussed on; a high throughput screening study was employed 
to dock and score over five million compounds against the GnRH receptor which 
generated compounds to assay for activity. 
In this section of virtual screening three models of GnRH-R were used; two models 
were based on rhodopsin in the active and inactive states (as described in Chapter 
3.5) and the last model was based on the β2-adrenergic receptor in the inactive state 
(as described in Chapter 3.6). The changes in the active site conformation between 
all three models are highlighted in Figure 6-1. The site points in all models 
incorporated these residues into the docking area. 
 
Figure 6-1. Positions of the key GnRH binding residues in each of the three model structures. (a) 
Rhodopsin derived GnRH-R in the active conformation. (b) Rhodopsin derived GnRH-R in the 
inactive conformation. (c) β2-adrenergic receptor derived model in the inactive conformation. 
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6.1.1 Docking the GnRH-R model derived from rhodopsin in the active 
conformation with EDULISS compounds using LIDAEUS 
In the active conformation GnRH-R is in the ligand bound state. This docking 
experiment allowed an attempt to dock small molecules into the receptor as a means 
of selecting for antagonists that have high affinity for the ligand bound conformation. 
This allows ligand selection based on displacement of the GnRH-I peptide. 
Figure 6-2 shows the structure of the model which was used in these docking 
experiments as well as the positioning of the site points (site point generation is 
described in Chapter 2.4) which were used to guide the ligand positions to the 
GnRH-I active site. 
The top 100 compounds from the virtual screening study were retained for further 
filtering. 
 
Figure 6-2. Structure of the active conformation rhodopsin derived GnRH receptor model used 
in this part of the docking study. Image shows side and top down views of protein chains with 





6.1.2 Compound selection for assay 
As the compounds from this screen were selected based on docking score rather than 
similarity to a reference structure compound selection was slightly different to the 
method used in Chapter 5. As discussed in Chapter 1.3.4, when a large chemical 
space is being investigated it is more efficient to cluster compounds by similarity, 
then to pick a compound to be a representative of each cluster rather than testing all 
members of the cluster. The method used to do this was to firstly increase the drug 
likeness of the candidate molecules by applying the Lipinksi rule of five to the top 
100 compounds; this reduced the compound number from 100 to 63. The remaining 
63 compounds were then clustered (as described in Chapter 2) according to Soergel 
distance which is the compliment of the Tanimoto co-efficient[2] (most similar 
compounds score closest to 0) using Daylight fingerprints (Figure 6-3). 
 
Figure 6-3. Clustering of active state GnRH-R from homology modelling with rhodopsin. 
Picking compounds from a clade as a representative of biological activity from within the group is an 





Upon completion of the clustering stage three compounds (Table 6-1) were selected 
from the remaining selection to test. The compounds were selected based on criteria 
such as predicted solubility, availability and LIDAEUS score. 
Table 6-1. Compounds selected for assay from the active state structure search for antagonist 
ligands. 
 
6.1.3 Assay of potential antagonist compounds from active state 
rhodopsin homology model 
The assays of the compounds from the screening described in this chapter are the 
same as those used previously. Compounds were assayed at a concentration of 
100µM in a single point inositol (1,4,5) trisphosphate (IP3) assay as described in 
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Chapter 2.10.4 and Chapter 5.5. The assay is performed in the presence of 5% 
DMSO with a GnRH-I stimulated negative control included to allow visualisation of 
antagonist/agonist activity, the results are displayed in Figure 6-4. 
 
Figure 6-4. Results of IP assay for 100 µM antagonist compounds from rhodopsin active state 
model. Each condition was set up in duplicate and the average radioactivity reading was calculated. 
GnRH I was used as a positive control. 
 
Of the three compounds tested only compound A showed no significant IP inhibition, 
however this compound did appear to have small agonistic properties. Compounds B 
and C both showed an inhibition of IP production that was greater than 50% at the 
100 µM concentration. These compounds were tested in a radioligand binding assay 
to assess how well they could compete GnRH-I from the active site (Figure 6-5).  



























Figure 6-5. Radioligand binding assay of compounds produced from EDULISS screening of the 
GnRH-R rhodopsin model. 
 
The binding assay results showed that compound B was able to successfully compete 
with the radiolabelled peptide with increasing concentration. Compound C was less 
active, 25% of the radiolabelled peptide was competed off at 50 µM, however with 
increasing concentration beyond this point no further effect was observed. This 
coincides with the observation that the compound became more insoluble as final 
compound concentration increased. Compounds which form aggregates are an 
established source of false positives in small molecule screening[3, 4], therefore care 
must be taken when such behaviour is observed. The non-specific inhibition which 
can occur as a result of aggregate formation is thought to occur by sequestering 
enzyme molecules within the aggregation which reduces the ability to bind the 
activating factor[5, 6]. This cannot take place in this assay because the receptor is 






















Virtual screening using the rhodopsin derived active state model allowed the 
discovery of two compounds which were able to demonstrate inhibition of IP3 
production and thus receptor inhibition as well as competitive inhibition with a high 
affinity tracer peptide. A weak agonist was also found which suggests that structures 
which are far smaller than the native peptide are still able to form key interactions 
capable of activating the receptor. 
6.2 Docking the GnRH-R model derived from rhodopsin in the 
inactive conformation with EDULISS compounds using 
LIDAEUS 
The conformation of the rhodopsin derived inactive state GnRH-R model (Figure 6-
6)  was designed to mimic the active site when in a ligand-free state, this 
theoretically allows small molecules to be found which can bind to this state and 
prevent GnRH-I peptide binding. As the ligand molecules in EDULISS are too small 
to bind to all of the residues involved in agonist binding, activation of receptor 
signalling should be avoided whilst still restricting GnRH I access to the binding site. 





Figure 6-6. Model structure used in this docking experiment which represents GnRH-R in the 
inactive state based on the rhodopsin structure. This model differs from the active site rhodopsin 
derived model by 1.7Å in a RMSD fit of 97 Cα atoms. Rotation of residues 290 and 302 are a feature 
of this model. 
 
The docking process that was followed is the same as that used for the active state 
model, however the site points differed slightly in this case. As the target is the 
peptide free structure the site points do not need to be clustered so heavily towards 
the active site residues; providing the small molecule can make a strong interaction 
with any residue located close to the active site then it should be sufficient to block 
entry of the peptide and prevent receptor activation. After docking was complete the 
top 100 hits were retained for further filtering. 
6.2.1 Compound selection for assay 
Of the top 100 compounds, 43 passed the Lipinksi rule of five. These were clustered 
using the same method that was applied to the hits obtained for the active state 




Figure 6-7. Clustering of inactive state GnRH-R from homology modelling with rhodopsin. 
Picking compounds from a clade as a representative of biological activity from within the group is an 
efficient way of rapidly screening potential inhibitors. Black arrows indicate the position of the 
compounds selected. 
 
From the 43 compounds which passed the Lipinski criteria three compounds were 
selected to assay. The structures of these compounds are shown in Table 6-2 
overleaf. LIDAEUS scores from this selection are lower than those obtained for the 
active state model, however this was because the highest scoring compounds were 
not in stock with the suppliers. 
6.2.2 Assay of potential antagonist compounds from inactive rhodopsin 
homology model 
The assay method for the three chosen compounds for the inactive state rhodopsin 
derived model was the same as that used for the active state model; compounds were 
tested using IP3 inhibition and competition binding against a radiolabelled peptide. A 
single concentration IP3 assay was used first to quickly determine the potency of 
antagonism of the selected compounds (Figure 6-8). 
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412.350 7961791 -42.541 
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425.431 STOCK4S-46535 -42.162 
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Figure 6-8. IP inhibition results for antagonist compounds derived from the inactive GnRH-R 
rhodopsin homology model. 
 
The one point assay results (Figure 6-8) showed that all of the selected compounds 
had antagonist properties. Compound E reduced IP production the least with a 
reduction of 20% at 100 µM concentration, compounds D and F were slightly more 
potent causing a decrease of 53% and 65% respectively. 
As compounds D and F showed antagonist activity in the single concentration IP 
assay they were then tested in a dose-response binding assay with a compound 
















Figure 6-9. Binding assay of compounds derived from rhodopsin homology model.  
 
The binding assay indicates that both compounds D and F are able to compete the 
tracer peptide from the receptor binding site. This supports the view that the 
antagonist effects which were observed in the IP3 assay occur because of specific 
binding to the receptor rather than a non-specific decrease in IP3 production which 
could have been attributed to cell toxicity[7]. 
No agonists were found from this round of screening. Whilst it would be attractive to 
attribute this as a factor of the difference between the active and inactive models it is 
also possible that the 41 compounds which were not assayed could have agonist 




6.3 Docking the GnRH-R model derived from the β2 
adrenergic receptor in the inactive conformation with 
EDULISS compounds using LIDAEUS 
This model structure (Figure 6-10) is similar to the model that was discussed in 
section 6.2 as it is also an inactive state model, however it differs in the template 
model which was used. Using the β2 adrenergic receptor as the template structure 
allows the transmembrane helixes to be modelled in a way which accommodates the 
association and dissociation of a diffusible ligand[8]. This should create a model 
which is more representative of the GnRH-R structure although it does share the 
same limitations as previous crystal structures; the crystal structure can only capture 
a single “moment” of the receptor structure oscillation[9] which was discussed in 
Chapter 1.  
 
Figure 6-10. Structure of the inactive GnRH receptor model derived from β2AR. This model has 





The creation of site points and the subsequent LIDAEUS screening were performed 
as described for the previous two models, in this model the site points tended to 
cluster in a more centralised location over the previous models. The top 100 
compounds were selected for further filtering. 
6.3.1 Compound selection for assay 
The top 100 compounds were filtered by the rule of five which left 74 compounds 
remaining to be clustered according to Soergel distance (Figure 6-11). 
 
Figure 6-11. Clustering of inactive state GnRH-R from homology modelling with β2AR. Picking 
compounds from a clade as a representative of biological activity from within the group is an efficient 
way of rapidly screening potential inhibitors. Black arrows indicate compounds selected. 
 
From the 74 compounds which passed the Lipinski criteria thirteen compounds were 
selected to assay, these are shown in Table 6-3. The LIDAEUS scores from this 
selection were more favourable than those obtained for the compounds from the 




Table 6-3. Compounds selected for assay from LIDAEUS β2AR GnRH-R model 
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404.366 NP-007310 -47.1548 
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406.426 NP-002445 -42.9256 
13 
 
428.43 NP-015267 -56.132 
 
The compounds contained a number of hydroxyl groups as well as one compound 
with an epoxide ring. Toxicophore screens would usually remove epoxide ring 
containing compounds due to their high reactivity with proteins[10], although a 
number of very successful drugs such as Clopidogrel (for treatment of cardiovascular 
conditions) and Omeprazole (for treatment of gastric disorders) contain 
toxicophores[11]. 
6.3.2 Assay of potential antagonist compounds from β2 adrenergic 
receptor homology model 
As in the previous assays the compound concentration of the single point IP assay 
was increased to 100 µM for testing. Of the 13 compounds from the β2AR model 
there were three compounds which demonstrated antagonist behaviour in the IP 
assay. These were compounds 5, 8 and 12 (Figure 6-12). 
Ideally these compounds would have been tested in a dose-response assay as 
previously used for the rhodopsin derived models, however this was not possible in 




Figure 6-12. One point assay results of compounds selected using the β2AR model structure. 
6.4 Comparison of results from each model structure 
Taking the most active compound from each of the three model structures and using 
AutoDock the possible interactions for each compound were mapped within their 
respective model structure (Figure 6-13). 
The affinity of the best poses of each compound and their interactions with the 
receptor model are shown in Table 6-4 and highlights a few points for discussion. 
Whilst compound D was the lowest affinity ligand by AutoDock score, it performed 
the most favourably at lower compound concentration in the assays. The compound 
has the possibility of forming twice the number of hydrogen bonds of the other two 






















Figure 6-13. Comparison of docked positions of the most active compounds. (a) Rhodopsin 
model: active conformation with compound B.  (b) Rhodopsin model: inactive conformation with 
compound D. (c) β2AR model: inactive conformation with compound 5. 
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Table 6-4. Affinity scoring for each model compound which produced the most inhibition. 
Compound Docking affinity 
(kcal/mol) Hydrogen bonds 
B -8.3  2 
D -7.5  4  
5 -8.1 2 
 
An interesting outcome of this study is the discovery of eight compound structures 
which showed inhibition of IP3 response from the GnRH receptor which were found 
using three different model structures. From these eight compounds two showed 
antagonist activity in two different assays which quantifies them as not being false 
positives resulting from an artifact in the assay. 
The variation in model structure and the relative indifference in small molecule 
affinities is perhaps a reflection on the current state of the majority of GPCR 
structural information. A fuzzy picture with defined boundaries, just enough to 
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Chapter 7. Biochemical analysis and structural 
characterisation of Post Synaptic Density protein 95 (PSD95) 
7.1 Introduction 
As described in Chapter 1 the goal of targeting the SH3 domain of PSD95 is to 
inhibit the scaffold activity that is linked to the transmission of neuropathic pain after 
sciatic nerve injury[1, 2]. This is a significant area of research as current analgesic 
treatment of sciatica often involves the use of strong opiates which are habit forming 
after extended use[3]. 
The pathway involving PSD95 controlled inflammatory response involves the 
recruitment of phosphatidylinositol-3-kinase-C2α (PI(3)K-C2α) which is a signalling 
molecule belonging to the PI(3)K  family[2]. This signalling molecule contains a 
proline rich sequence FPLWKLPGFPNRMVLG at residues 1477-1492, which can 
associate with PSD95 (Figure 7-1) in the spinal cord increasing inflammatory 
sensitisation[2]. The aim of the work described in this chapter is to identify small 
molecules capable of inhibiting the interaction of PSD95 and PI(3)K-C2α to act as 





Figure 7-1. A proline rich region of PI(3)KC2α is able to associate to the SH3 domain of PSD95 
and control inflammatory response. 
 
7.1.1 Canonical SH3 domains 
Src-homology 3 (SH3) domains are found in a number of signalling pathways and 
aid signal transduction through protein-protein interactions[4].  SH3 domains are 
found in a number of eukaryotes, it has been found that in the human genome there 
are over 500 SH3 domains[5];  this makes it an attractive target for development of 
ligand molecules using virtual screening. 
 The SH3 domain is comprised of around 60 residues and can be split into two 
classes, the first class binds proline rich motifs of sequence pΦPxΦP while the 
second class binds the motif ψPpΦPΦ where P represents a proline residue, p 
represents a proline residue which is not highly conserved, Φ represents a 
hydrophobic residue and ψ represents an aliphatic residue[6].  
The binding pocket of the SH3 domain consists of a small area (~400Å2) between the 
n-Src and RT loops (Figure 7-2), peptide association is weak (generally not more 
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than 50 µM[7]) and type I or II peptide specificity is determined by the positioning of 
a well conserved tryptophan in the specificity pocket[8].  
 
Figure 7-2. SH3 domain from ABL tyrosine kinase (PDB ID 1ABO). The proline rich peptide 
binds in a class I conformation in a shallow pocket that is created between the n-Src loop and the RT-
loop. The specificity pocket contains an integral tryptophan which determines peptide class binding.  
 
Binding of proline rich sequences to the SH3 domain causes discrete conformational 
change within the protein. This was observed in NMR analysis of the SH3 domain of 
SEM5 where chemical shifts were observed for residues localised in the RT and n-
Src loops. These residues were F163, D164, F165, N166, Q168, E169, E172, N190, 
W191, P204, N206, Y207, S170, G171, L173, F175, W192 and S205 which are 




Figure 7-3. Surface view of SEM5 protein with residues which undergo chemical shift on ligand 
binding shown as sticks.  
 
The ligand binding is coupled to reduced flexibility within the RT-loop in a 
cooperative mechanism; in the unbound state there is greater flexibility in the RT 
loop than any other region in the SH3 domain. Once the proline rich peptide begins 
to associate, the flexibility of the RT loop is greatly reduced and the ligand affinity 
increases. 
Use of peptide sequences to disrupt SH3 domain interactions in treatment of 
conditions such as prostate cancer have been reported[10], however peptides are less 
attractive than small molecules as potential drugs. Small molecule inhibitors of SH3 
domains have also been reported in the literature[11, 12], the small molecule reported 
(Figure 7-4) acted as a broad range SH3 interaction disruptor against a number of 




Figure 7-4. Structure of  the SH3 domain small molecule inhibitor UCS15A[12].  
 
Widespread disruption of SH3 domain interactions is undesirable, however the 
UCS15A molecule is a useful proof of concept that the SH3 domain is druggable and 
further modification of the scaffold may be a means of increasing specificity. 
7.2 Identifying a druggable construct of PSD95   
As discussed in Chapter 1, the SH3 domain of PSD95 has a unique intertwined 
structure involving the SH3 domain and from the Guanylate Kinase (GK) domain. A 
ligand bound crystal of the PSD95 SH3 has not yet been obtained, so initial 
computational study was performed to assess which areas of the structure would be 
most favourable to bind to. 
Using the program STP (as described in Chapter 2) a map of ligand binding 
propensity was generated for the SH3-Hook-GK fragment of PSD95 as shown in 
Figure 7-5. The program highlights the trench that forms between the SH3 and GK 
domains as a likely binding area. The area that scores most favourably (red) is the 
area which incorporates a highly conserved ASP residue which when mutated in 
other SH3 domains eliminates PxxP binding[13].  
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Despite the apparent similarities between the SH3 domain of PSD95 and the 
canonical SH3 domain there are subtle differences between the structures as shown 
in Figure 7-6. 
 
Figure 7-5 Binding propensity of the SH3-Hook-GK region of PSD95 as coloured by STP. The 
program colours areas which are most likely to act as a binding site as red whilst the areas least likely 
to act as a binding site as blue. (a) Ribbon diagram illustrates the structural arrangement of the protein 
fragment (b) Surface area view coloured to indicate possible binding regions. The black line indicates 
the typical PxxP motif binding orientation to traditional SH3 proteins. 
 
 
Figure 7-6. Comparison of binding orientations of class I and II SH3 domains to PSD-95. In both 
illustrations PSD-95 is shown as a translucent grey structure aligned with the SH3 domain it rests on 
and the canonical SH3 domain is shown in orange. RMSD values for structure alignments are 0.7Å 





A comparison of the canonical class I and class II peptide binding SH3 domains with 
the PSD95 SH3 domain shows a non-canonical peptide binding interface (Figure 7-
6). Overlay of the PSD95 SH3 with the SH3 domain of 1ABO (Figure 7-6a) shows 
occlution of the peptide binding interface by an alpha helix. This is also evident 
when PSD95 is overlaid with the class II 1SEM domain (Figure 7-6b). 
This highlights a fundamental difference in binding orientation given the way that 
the PSD-95 molecule clashes with the ligand structure of both the class I and II 
domains. This suggests that whatever molecules were found to bind to PSD-95 may 
have some inherent specificity to MAGUKs, depending on the region targeted, which 
is very beneficial from a drug design aspect. 
7.2.1 Alignment of the PSD95 SH3 domain with canonical SH3 
domains  
A pairwise alignment created using ClustalW of the PSD95 SH3 domain against 8 
other class 1 and class 2 SH3 domains indicates higher than expected conservation 
between the sequences (Figure 7-7). 
The percentage identity between the sequences in comparison to PSD95 SH3 ranges 
from 14% to 29% (Table 7-1). This range in identity score is surprising for such a 
highly conserved domain particularly given the low RMSD values for the 3D 
structural alignments. The highest RMSD value was 1.52Å against 2J7I which is an 






Figure 7-7. Sequence alignment of canonical SH3 domains (both Class I and II) and PSD-95 
SH3 domain.  The sequence corresponding to PSD95 SH3 is labelled as “SH3”. Residues that are 
fully conserved across all sequences are highlighted by an asterisk. 
Table 7-1. Identity scores between PSD95 SH3 and 7 other class 1 and class 2 SH3 domain 
proteins. 
 
These proteins recognised specific proline/arginine sequences of PXXXPR[14], 2BZ8 
also binds similar proline/arginine sequences[15]. The RMSD value of 1.08 for 2OJ2 
is also a point of interest as this protein is able to bind to a non-typical proline rich 
sequence of xxxPpxP[16]. This highlights the diverse roles that the SH3 domain plays 
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in protein interactions; where a number of subtle changes from a core motif allow it 
to play an integral part in a number of scaffold functions. 
To further investigate the diversity within the ligands of SH3 domains, 6 peptide 
structures which bind to SH3 domains from Table 7-1 were overlaid (Figure 7-8). 
 
Figure 7-8. Overlay of peptides structures which bind to SH3 domains aligned in Figure 7-7.  
1ABO (green), 1CKA (cyan), 1SEM (magenta), 2BZ8 (yellow), 2JZI (pink), 2OJ2 (white). 
 
To further investigate the peptide sequences which have been shown experimentally 
to bind to SH3 domains an extensive literature survey was performed to identify 
peptide sequences which are able to bind SH3 domains[16-31]. From this survey a 
database of 214 SH3 peptides was compiled. The frequency of each of the amino 
acids (where possible three residues before and after the PxxP motif) was established 
(Figure 7-9). The nomenclature used is as follows; residues found N-terminal to the 
PxxP motif are denoted as -3, -2 and -1 whilst residues C-terminal to the PxxP motif 
are denoted as +1, +2 and +3. 
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The analysis was extended to include only the two “x” residues located between the 
prolines within the PxxP motif. The nomenclature used is as follows Px1x2P which is 
shown if Figure 7-10. 
 




Figure 7-10. Amino acid distribution within the PxxP motif. 
 
The analysis of the peptide sequences gives a general peptide consensus sequence of 
RPLPPLPPPP. This is an interesting observation as a large number of proline 
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residues are not typically found physiologically. This is likely because long 
polyproline peptides will typically form helical structures which would have 
difficulty associating with the SH3 domain. 
7.3 Expression, purification and characterisation of a drug 
target region of PSD95 
Construct design 
A total of three constructs were produced, all of which were truncated forms of the 
full PSD95 sequence. The features of each construct are shown in Figure 7-11 
overleaf. 
7.4 Cloning, expression and purification of constructs A, B 
and C 
7.4.1 Construct A of PSD95 
The cDNA fragment corresponding to bases 417-724 of the Rattus norvegicus PSD-
95 protein was amplified by polymerase chain reaction (PCR) from the full length 
sequence, using the following primers which were optimised for the Gateway® 
recombination cloning system (Invitrogen) ; forward primer 
(CCGAAAACCTGTATTTTCAGGGCTCAGGGACTGCATCCTTG) and reverse 
primer (GGGGACCACTTTGTACAAGAAAGCTGGGTCCTATCAGAGTCTC 
TCTCGGGCTG). The resulting PCR product (Figure 7-12a) was purified and then 
further amplified using the previous reverse primer with the following forward 





Figure 7-11. Construct design of druggable PSD95 recombinant protein. All constructs had the 3 
PDZ domains at the N-terminus removed as these are unnecessary for testing of ligand binding. A 
TEV cleavage site was introduced to remove tags which were added for affinity purification. 
Alignment of all three sequences shows the larger N-terminal region prior to the SH3 domain in 
construct C contributed by GST. Construct A has a larger C-terminal region due to the presence of the 
Hook and GK domains. 
 
TACATATGTCGTACTACCATCACCATCACCATCACGATTACGATATCCCA
ATGACCGAAAACCTGTATTTTCAGGG). This PCR product (Figure 7-12b) was 
then cloned into the PDONR221 vector and subsequently shuttled into pDEST14. 
This correct sequence was verified by DNA sequencing (DNA Sequencing & 




Figure 7-12 Cloning of SH3-Hook-GK construct. (a)PCR generation of fragment corresponding to 
residues 417-724 (lane 1). (b) PCR generation of TEV cleavable 6 His Tagged fragment ready for 
pDONR221 cloning.  
 
Recombinant protein was expressed in E. Coli BL21(DE3) cells in LB media 
containing 50µg/ml carbenicillin. Cells were grown with shaking (250 RPM) at 37°C 
until the A600 reading was approximately 0.6 and expression induced by addition of 
0.5mM IPTG. Growth was continued for 4 hours before cells were harvested by 
centrifugation at 12000 x g for 30 minutes. Cells were resuspended at 10% 
weight/volume in ice cold Lysis buffer (50mM sodium phosphate, 300mM NaCl, 
10% glycerol) with excess protease inhibitor cocktail (Roche) and then lysed using a 
cell disruptor (Constant Systems) at 25KPSI. Cell lysate was centrifuged at 50,000xg 
for 1 hour and supernatant containing protein was passed through a 0.22 µm filter 
before being loaded onto a 5ml HiTrap IMAC FF column (GE Healthcare) which 
had been charged with Nickel and pre-equilibrated with Buffer A (Lysis buffer with 
20mM Imidazole). A gradient of 0-100% Buffer B (Lysis buffer with 200mM 




Construct A protein was successfully expressed and purified to >95% purity from 
estimation of relative band intensity from coomassie stained SDS-PAGE gels (Figure 
7-13).  The final protein yield was approximately 20 mg per litre of culture. 
Figure 7-13. Purification of SH3-Hook-GK fragment of PSD95. The HiTrap IMAC FF column 
loaded with cell extract begins to elute PSD95 at approximately 10% 0.25mM Imidazole. Gel analysis 
of lettered fractions shows the recombinant protein purity is >95%.  
 
7.4.2 Construct B of PSD95 
The SH3-HOOK-GK DNA fragment was amplified using the same forward primer 
as described in 7.3.1 and a modified reverse primer (5'-GGG GAC CAC TTT GTA 
CAA GAA AGC TGG GTC CTA TGA CCA CTC TCG TCG CTC GAC-3') which 
creates a DNA strand of 249 bases. This PCR product (Figure 7-14) was then cloned 
into the pDONR221 vector and subsequently shuttled into pDEST14. This correct 
sequence was verified by DNA sequencing (DNA Sequencing & Services, 





Figure 7-14. PCR product of SH3 domain alone was approximately 250bp in length. 
 
Initial expression in BL21(DE3) showed the protein to be expressed in inclusion 
bodies. A number of different cell lines and expression times and temperatures were 
used to increase soluble protein however these were not successful. The C41(DE3) 
cell line at 37°C for 4 hours expressed the best insoluble yield (Figure 7-15), this 
insoluble protein was used in refolding experiments. 
 
Figure 7-15. Expression trials with construct B showed highest expressions from C41(DE3) cells 
induced for 4 hours at 37°C. 
 
Cell pellets were resuspended to 10% wt/vol in 25 mM NaH2PO4, pH 8.0 and 
passed once through a Constant Systems Cell Disruptor set to 22 kPSI, at 4˚C. 
Following this the lysate was centrifuged at 15,000 xg for 10 min at 4°C and the 
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pellet resuspended in 15 ml 25 mM NaH2PO4, 0.5 M NaCl, 0.5 % Triton X-100, pH 
8.0 at 4˚C, and subjected to sonication (4 x 10 sec bursts). The sample was then 
centrifuged at 15,000 xg 10 min at 4 °C. The above was repeated twice and the 
resulting pellet resuspended in ~ 40 ml of 6 M guanidine hydrochloride, 25 mM 
NaH2PO4, 0.5 M NaCl, 5 mM imidazole, 1 mM 2-mercaptoethanol, pH 8.0, 
homogenized in a dounce homogeniser, and left gently stirring for 2 hrs at 4˚C. The 
sample was then centrifuged at 15,000 xg for 15 min at 4 °C and passed sequentially 
through 0.45 μm and 0.22 µm filters. The filtered solution was then loaded onto a 5 
ml nickel charged IMAC FF (GE Healthcare) column pre equilibrated in 6 M 
guanidine hydrochloride, 25 mM NaH2PO4, 0.5 M NaCl, 5 mM imidazole, 1 mM 2-
mercaptoethanol, pH 8.0, at 1 ml.min-1. The column was washed for 10 column 
volumes of the same buffer followed by 10 col. vols. of 6 M guanidine 
hydrochloride, 25 mM NaH2PO4, 0.5 M NaCl, 20 mM imidazole, 1 mM 2-
mercaptoethanol, pH 8.0 at 1 ml.min-1. A reverse gradient, over 50 column volumes, 
was then run with 25 mM NaH2PO4, 0.5 M NaCl, 20 mM imidazole, 5 mM 2-
mercaptoethanol; 0.1% TX-100; 10% Glycerol, pH 8.0, followed by a further 5 
column volumes of the same buffer at 1 ml.min-1. The column was then washed with 
10 column volumes of 25 mM NaH2PO4, 0.5 M NaCl, 20 mM imidazole, 5 mM 2-
mercaptoethanol: 10% Glycerol, pH 8.0 at 1 ml.min-1 and bound protein eluted with 
a gradient of imidazole from 20 mM to 500 mM over 20 column volumes at 1 





Figure 7-16. Refolding and purification profile of SH3 domain construct B. 
 
The SH3 protein that was recovered from column refolding was >95% purity by 
coomassie gel analysis, however the protein precipitated shortly after elution. A 
number of methods were employed to keep the protein soluble including elution by 
pH instead of imidazole, refolding by dilution instead of on the IMAC column and 
use of additives. None of these were successful and further characterisation of the 
SH3 domain was not possible. To attempt to resolve this insolubility, construct C 
was created which is an SH3 domain with an N-terminal GST tag. 
7.4.3 Construct C of PSD95 
To create this construct the  pDONR221 vector incorporating the SH3 domain 
sequence was used in the Gateway LR reaction with the pDEST15 vector. This 
correct sequence was verified by DNA sequencing (DNA Sequencing & Services, 
University of Dundee). 
This construct was identical to construct B with the addition of an N-terminal GST 
tag. The tag was incorporated by Gateway recombinase reaction of the construct B 
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sequence into pDEST15 which has an N-terminal GST as part of the vector 
sequence. 
Expression trials were conducted using three cell lines: Bl21(DE3), Rosetta Origami 
2 and Origami 2 (DE3). 10ml cultures were setup for each cell line and cell samples 
were taken before induction, 4 hours after induction and then after overnight 
induction. Cultures were grown at 37 °C with shaking at 250RPM and 50µg/ml 
carbenecillin. 
Expression trials showed that Rosetta Origami 2 and Origami 2 (DE3) cells had 
much slower growth rate than the BL21 (DE3) cells. However after overnight 
induction production of SH3-GST was considerably higher in the Origami 2 (DE3) 
cells. Protein production in the most favourable conditions is shown if Figure 7-17. 
 
Figure 7-17. Whole cell pellet SDS PAGE gel of construct C overexpression trials. Gel shows 
uninduced (U), Induced for 3 hours (I3) and induced for 18 hours (I18) results. 
 
Culture volumes were scaled up to 1L and cells were grown until an O.D of 0.6 was 
reached then induced with 0.5mM IPTG for 4 hours. Cells were harvested by 
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centrifugation at 12000 x g for 30 minutes. Cells were resuspended at 10% 
weight/volume in ice cold Lysis buffer (50mM sodium phosphate, 300mM NaCl, 
10% glycerol) with excess protease inhibitor cocktail (Roche) and then lysed using a 
cell disruptor (Constant Systems) at 25KPSI. Cell lysate was centrifuged at 50,000xg 
for 1 hour and supernatant containing protein was passed through a 0.22 µm filter 
before being loaded onto a GSTrap column and eluted using a gradient of 0-10mM 
reduced glutathione 50mM Tris HCl, pH 8. 
The addition of the GST tag did increase the solubility of the protein, however there 
was a large number of other contaminating proteins which co-purified with construct 
C (see Figure 7-18).  
 
Figure 7-18. Purification trace of SH3-GST and SDS-PAGE analysis. Elution of the protein was 
rapid following low concentration of reduced glutathione. This low binding to the GSTrap column 
caused high contamination of the sample. 
 
A number of methods were used to try to reduce the contamination; the elution 
gradient was made shallower, eluted fractions were desalted into PBS and then re-run 
over the GSTrap column and ion exchange was also attempted. None of the methods 
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tested were able to significantly decrease the contamination and further 
characterisation with the construct was not possible. 
7.4.4 Discussion of PSD95 constructs and purification methods 
Construct A was designed to remove the three N-terminal PDZ domains as they were 
not required for binding assay. Construct B was designed to probe the stability of the 
SH3 domain without the strands which are contributed by the Hook and GK 
domains. This deletion significantly compromised the stability of the domain and 
caused the protein to be expressed within inclusion bodies, attempts to refold the 
protein into a soluble form were unsuccessful. Construct C was designed to increase 
the solubility of the truncated SH3 domain by addition of the large GST tag[32] which 
was successful; however difficulty was encountered in achieving separation from 
contaminating proteins. Therefore construct A was the only protein used in further 
characterisation studies. 
7.5 Characterisation of PSD95 construct A 
7.5.1 Gel filtration analysis of construct A 
Gel filtration studies were carried out using a Superdex 75 10/300 GL column at a 
flow rate of 0.5ml/min. The column was equilibrated with 50mM sodium phosphate 
(pH 8), 300mM NaCl, 10% Glycerol at 4°C. Molecular weight calibration was 
performed using the following standards: Aprotinin (6500Da), Ribonuclease A 




Concentrated SH3-HOOK-GK protein was applied to a Superdex 75 10/300 GL 
column and eluted with sodium phosphate buffer (Figure 7-19). The results showed 
that the majority of the protein was a monomer in solution with a small percentage 
existing as a dimer. This is in agreement with the idea that the SH3-HOOK-GK 
modules found in MAGUK proteins can dimerise to form higher order structures[33]. 
 
Figure 7-19. Gel filtration analysis of construct A protein reveals the protein is primarily in a 
monomeric state. 
 
7.5.2 Thermal denaturation of construct A 
In a thermal denaturation experiment the target protein is heated over a temperature 
range which completely unfolds the protein. A compound which binds to the protein 
and emits a fluorescent signal as the unfolding continues is included in the assay and 
allows measurement of the change in fluorescence (and therefore melting 
temperature). This provides a rapid method to assess how well folded the protein is. 
Furthermore thermal denaturation assay is recognised to be a useful technique in 
high throughput testing of potential drug compounds[34]. In addition there is 
experimental evidence to suggest that the data obtained from such studies is 
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comparable in quality to that obtained from Isothermal Calorimetry (ITC) even at 
low (<50) µM Kd[35] . The assay is performed in the same way as a standard thermal 
denaturation experiment but with ligand molecules added, thereafter shifts in 
unfolding temperatures are monitored. The advantages of this technique over more 
traditional methods is that it is easily adaptable to high throughput screening since 
the assays can be set-up in 96 well plates and no information is required on the target 
protein’s binding site. 
When screening compounds the expected result for a positive hit is an increase in 
melting temperature as a result of compound binding contributing stabilising effects 
to the protein. However this is not always the case, there are occasions where a 
decrease in melting temperature in response to ligand binding can occur. This has 
been attributed to the ligand binding to an unfolded state of the protein[36]. 
Protein concentration screening 
A protein concentration range of 0.5-8 µM with 10X Sypro orange (Invitrogen) was 
used to assess the optimum concentration to obtain a low signal to noise ratio. 
Sample volume was 25 µl protein and 25 µl 20X Sypro orange in buffer (50 mM 
NaPO4 pH 8, 300 mM NaCl and 10% glycerol). All experiments were carried out in 
a thin walled 96 well plate (Bio-rad) closed with sealing tape and measurements were 
made using a Cycler iQ Real Time PCR Detection System (Bio-Rad). Each sample 
was measured in triplicate and the averages were calculated. 
The wavelengths for excitation and emission were 490 nm and 575 nm respectively. 
Fluorescent readings were taken between 20 °C and 80 °C in 1 °C increments after 
each temperature had been held for 90 seconds.  
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The protein melt concentration results showed that the protein had unfolded 
completely by 61 °C (Figures 7-20). From these tests it was decided that 4 µM 
protein was an optimal concentration given the signal strength and low error. 
 
 
Figure 7-20. Protein concentration effects on thermal melting.  
 
DMSO concentration screening 
In the majority of cases small molecule stock solutions are made using DMSO as the 
solvent. To understand what effects DMSO concentration can have on the protein 






























































maximum concentration of DMSO in our experiments to limit the effect that DMSO 
had on our results. 
 
Figure 7-21. Effects of increasing DMSO concentration on protein stability in thermal 
denaturation studies. In low DMSO concentration there is an observed increase in the protein 
melting temperature  
 
From Figure 7-21 it can be seen that as DMSO concentration increases the melting 
point of the protein decreases. The exception to this is in the 0.5-2% region where 
there is an observed increase in melting temperature with a maximal increase over 
the mean melting temperature by 1 °C. It may be the case that DMSO is able to bind 
to parts of the protein structure non-specifically which causes slight increases in 
protein stability. Eventually a tipping point is reached where non-specific DMSO 
binding induced stability is offset by the increasing disruption of secondary structure 
which is caused by higher DMSO concentration[37]. A decrease in melting 



























found up to a concentration of 21 %. From these results it was decided that a final 
DMSO concentration of no more than 5% would be used in compound assay. This is 
a useful concentration as it doesn’t cause a large increase or decrease in protein 
melting temperature whilst still allowing compounds to retain solubility in solution.  
7.5.3 Circular dichroism analysis of construct A 
All spectra were recorded on a nitrogen flushed Jasco J-810 spectropolarimeter. 
Protein was dialysed into 50 mM NaPO4 (pH 8) and 50 mM KF at a concentration of 
2.4 µM and used with a cell of 0.02 cm pathlength. Data was recorded from 250 to 
190 nm with a 1m bandwidth and 10 nm min-1 scan speed. Secondary structure was 
deconvoluted using the SELCON3 method on the DICHROWEB server[38].  
To confirm that the protein was well folded 2.4 µM protein was used in circular 
dichroism analysis (Figure 7-22). The results showed that the protein was folded 
correctly and the approximate alpha helix content (39%) was close to that of the 
reported crystal structure (31%).   
 




















7.5.4 Discussion on the characterisation of construct A 
From the characterisation studies it can be concluded that the protein is well folded 
with structure which is in close agreement with the literature. This study highlights 
that though the protein can exist as a dimer this does not affect the thermal stability 
of the protein, a single melt peak is consistently observed irrespective of increasing 
protein concentration in the range 0.5-8 µM. 
The melting profile can be influenced by the presence of DMSO solvent, literature 
studies show that DMSO causes instability in proteins[39]. Whilst this was also 
observed in this study, at concentrations below 5% there was an increase in stability. 
This was a useful observation as this construct was then utilised for high throughput 
small molecule virtual screening, given the heavy use of DMSO as an organic 
solvent for small molecule libraries. 
7.6 LIDAEUS docking into the PSD95 SH3 domain 
7.6.1 Defining the site points of PSD95 SH3-HOOK-GK 
The area targeted for LIDAEUS docking was defined in a similar way to GnRH-R as 
described in Chapter 2. Briefly, a peptide molecule was used to define the area on the 
protein surface that was used to generate an energy map which could then be 
submitted to LIDAEUS. The site points that were used in the docking study are 





Figure 7-23. Determination of site points for LIDAEUS docking experiments. (Left) A peptide 
molecule is orientated along the expected binding region of the SH3 domain to define the spacial area 
used to generate an energy map. (Right) The site points which were used in LIDAEUS docking. Cyan 
spheres represent hydrophobic sites, blue represents hydrogen bond donors and red represents 
hydrogen bond acceptors. 
 
7.6.2   LIDAEUS results using multiple conformers and flexible docking 
In this docking experiment the workflow was changed to accommodate an AutoDock 
step after a multi-conformer version of the EDULISS database was docked into the 
protein by LIDAEUS. Previously the EDULISS database in use was a single 
conformer version. The top 5000 compounds from the LIDAEUS docking were re-
docked and re-ranked by AutoDock (using the same method as for GnRH-R in 
Chapter 2) of which the top 100 were used in clustering (Figure 7-24). 
From the clustered compounds, 6 were chosen for assay. These were supplied by 
ChemBridge and were easily available. However they still represented a high scoring 
section with 4 of the compounds chosen residing in the top 20. The structure, 
LIDAEUS ID, Chembridge ID and Autodock scores of the selected compounds are 




Figure 7-24. Compound clustering results for PSD-95 from LIDAEUS. Position of compounds 
selected for assay are indicated by black arrows. 
 
The suggested potential interaction sites between each compound and the PSD95 
SH3 sites are shown in Figure 7-25.  Examination of the docked structures shows 
three compounds which avoid binding through the conserved SH3 ASP residue and 
three structures which dock at least part of the molecule into the ASP conserved 
region. Ligand association to more than one part of the PxxP binding region is useful 
because it allows greater flexibility when selecting for binding, specifically for 
PSD95 as well as opening up a broader selection of scaffolds which can be modified 
for better affinity if they are found to be active compounds. 
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Figure 7-25. Potential binding interactions of 6 LIDAEUS conformers docked into the SH3 




7.7 Assay development for the in vitro testing of small molecule 
compounds from virtual screening 
A key component of the drug development workflow is the ability to test the 
compounds that are selected from virtual screening. In this part of the study the use 
of two assay techniques are assessed; the first is a fluorescence based assay which 
utilises intrinsic tryptophan fluorescence, the second is a competition binding assay 
which uses a fragment of a protein which has been shown to bind to the SH3 domain. 
7.7.1 Using intrinsic tryptophan fluorescence as an assay technique for 
LIDAEUS compounds 
Construct A contains four tryptophan residues, the W470 residue which is well 
conserved among SH3 domains is a requirement of binding in the specificity 
pocket[40]. As this tryptophan is located directly in the targeted binding site for the 
small molecule ligands (See figure 7-26), then changes in fluorescence intensity can 
indicate interactions between small molecules in environments close to the 
tryptophan residues. 
 
Figure 7-26. The SH3 domain of PSD95 contains a tryptophan residue (magenta) in the 
specificity pocket which is exposed to the surface. An example peptide typical of an SH3 binding 




Fluorescence measurements were taken using a Fluoromax-3 spectrofluorometer 
(Horiba Jobin Yvon) with a 3.5nm slit width. Total sample volume was 600 µl in a   
1 cm path length quartz cuvette at 4 °C. The excitation wavelength was 295 nm and 
the emission range was from 320-450 nm in 0.5 nm increments. Readings were taken 
in triplicate and then averaged. All readings were corrected for using buffer blanks. 
All compounds were dissolved in 100% DMSO, however compound #6786900 was 
insoluble in 100% DMSO and was not used in further assays. The compounds 
themselves were tested first to establish their native fluorescence by excitation at 
295nm and scanning for emission from 320 to 450 nm with a slit width of 5nm 
(Figure 7-27). 
 
Figure 7-27. Intrinsic fluorescence from LIDAEUS compounds selected for assay. 20% DMSO 
was used as the blank. 
 
All compounds exhibited some fluorescence, however compound # 7643136 was so 





























accurately read; therefore this compound was removed from further assay study. The 
remaining four compounds were tested with 0.5 µM of construct A protein at a 
concentration of 125 µM (Figure 7-28). The changes in fluorescence as a result of 
compound incubation were quite dramatic. Compound #5676364 caused a large red 
shift of the peak by approximately 60 nm. None of the other compounds caused such 
a large change, however they did cause the peak to change shape and sharpen with a 
blue shift by approximately 10 nm indicating an increased non-polar environment.  
Figure 7-28. Effects of compound incubation on tryptophan fluorescence. 
Large red shifts in tryptophan fluorescence spectra are typically observed in 
experiments involving protein interactions with chaotropic agents, high 
concentrations of urea or GnHCl unfold proteins causing increased solvent exposure 
to the tryptophan residues[41].  However these wavelength changes are usually less 
than 20 nm. The change in protein structure which has resulted in this large red shift 
caused by compound #5676364 is an area that would be interesting for further study. 
The remaining compounds caused a similar change in peak shape however they 
differed in respect to how they affected the fluorescence intensity. Compounds 
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#5732082 and #7202320 both acted as fluorescence quenchers, the observed 
quenching may be attributed to a dynamic or static effect. Which effect is causing the 
reduction in signal intensity is unclear; as the tryptophan is surface exposed the 
formation of a complex (static) or just small molecule/tryptophan collision (dynamic) 
are possible. 
The increase in fluorescence that was observed from #7940094 is in contrast with the 
expected result, namely a quenching effect as a result of direct ligand/small molecule 
association as was observed for compounds #5732082 and #7202320. However the 
increase in fluorescence suggests that there is an increase in hydrophobic 
environment directly surrounding a tryptophan residue[42], possibly caused by 
conformational changes induced by small molecule association elsewhere on the 
molecule.  
7.7.2 Using competition binding for LIDAEUS compound testing 
The peptide sequence of the PI(3)K-C2α fragment which was shown to bind to the 
SH3 domain of PSD95 had not been published prior to the beginning of assay 
development with the truncated PSD95 protein. At this point in assay development 
there were four known proteins which could associate with PSD95 SH3 domain. 
These were KA2[43], Pyk2[44], Huntingtin[45] and the GK domain of PSD95[46]. The 
aim was to obtain a peptide sequence which could bind to the SH3 domain and use it 
in a competitive assay. Two peptide sequences were tested; 
MLKRLVPPPPKRMIYand FITC – LLDDPGPPGGP RPQAPTP. The 
MLKRLVPPPPKRMIY sequence was obtained as a result of private communication 
with S Grant at the Sanger Institute. This was tested by thermal denaturation assay, 
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however no significant change in melting point was observed even at a 50:1 peptide : 
protein ratio. 
The FITC – LLDDPGPPGGPRPQAPTP sequence was obtained from part of the 
kainite 2 subunit which was found to bind to the SH3 domain via a proline rich 
sequence near the C-terminus[47]. The FITC chromophore was added to try to 
establish binding activity via fluorescence polarisation. This also yielded a negative 
result. 
Rather than continue with peptide sequences the C-terminal fragment of the Kainate 
2 receptor was ordered from Genscript and subsequently cloned into the pDEST14 
vector for expression and purification. 
7.7.2.1 Cloning KA2 C-terminal construct 
The cDNA sequence corresponding to residues 861-979 of the Glutamate receptor, 
ionotropic kainate 5 from Rattus norvegicus was purchased (Genscript) and cloned 
into the pDEST14 gateway expression vector using the forward primer 
(CCGAAAACCTGTATTTTCAGGGCATGGAAAACATTGGCG GTATCTT) and 
reverse primer (GGGGACCACTTTGTACAAGAAAGCTGGGTCCTATTATTCAT 
GTTCGGTC AGTTC).  
The cDNA sequence corresponding to residues 861-979 of the KA2 receptor was 
amplified by PCR with primers incorporating the Gateway recombinase sites (Figure 
7-29a) and then finally re-amplified using primers containing the gateway 




Figure 7-29 Cloning of SH3/GST domain construct. (a)PCR generation of fragment corresponding 
to residues 861-979 (lane 1). (b) PCR generation of TEV cleavable 6 His Tagged fragment ready for 
pDONR221 cloning. 
 
7.7.2.3 Overexpression and purification of the KA2 C-terminal construct 
To optimise the protein yield expression trials were performed using two cell lines 
with three different growth media and two concentrations of IPTG as shown in 
Figure 7-30.  
 
Figure 7-30. Optimising expression of KA2 N-terminal fragment. Recombinant protein expression 
was tested in 36 conditions by varying cell line, growth media, IPTG concentration and temperature. 
 
Cell pellets were resuspended to 10% wt/vol in 25 mM NaH2PO4, pH 8.0 and 
passed once through a Constant Systems Cell Disruptor set to 22 kPSI, at 4˚C. The 
cell lysate was centrifuged at 15,000 xg for 10 min at 4°C. The pellet was 
resuspended in 8M urea and applied to a nickel charged IMAC column at a flow rate 
of 1ml/min.  A gradient was applied of 6M-1M urea in 50mM Sodium phosphate 
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(pH 7.5) 10mM Tris-(pH 7.5), 20% glycerol followed by a 5 column volume wash 
with 50mM Imidazole in PBS. A gradient from 20mM to 500mM imidazole in PBS 
then followed to elute the target protein.  
Expression was optimised using the BL21Star and Rosetta Gami 2 cell lines in 
addition to varying IPTG concentration, temperature and media type. As the 
overexpressed protein was contained within insoluble inclusion bodies the insoluble 
fraction was resuspended in urea prior to loading onto the column. After the 
refolding step a standard imidazole gradient in PBS was suitable for the elution of 
the protein (Figure 7-31). The refolded KA2 fragment was stable in the PBS buffer 
and no precipitation was observed. 
 
Figure 7-31. Purification of KA2 N-terminal fragment. Purification required an initial urea gradient 
to refold the protein followed by an imidazole gradient to elute. Very little protein was lost during the 






7.7.2.4 Assessing interaction of the KA2 fragment and construct A by 
native gel 
To test if the fragment was able to bind to construct A containing the SH3-HOOK-
GK domains a native gel was run (Figure 7-32) 
 
Figure 7-32. Assessment of Construct A binding to KA2 subunit using a native gel. (a) Construct 
A. (b) refolded KA2 subunit. (C) Construct A and refolded KA2 subunit.  
 
The results of the native gel suggested that there is very little interaction between the 
KA2 fragment and construct A. Possible reasons for this include the KA2 fragment 
being folded incorrectly during the on-column refolding step. Due to time constraints 
further investigation and development of this assay method were not possible. 
7.8 Conclusions and future work 
 The crystal structure of the SH3-HOOK-GK domains of PSD95 was available for 
the virtual screening work for this protein which contained a non-canonical SH3 
domain. While the SH3 domain is non-canonical, literature evidence shows that the 
domain is still able to facilitate traditional proline rich sequence association. 
Structural study using STP indicated that this was still likely to be via the selectivity 
pocket and surrounding area despite the presence of an alpha helix in the binding 
region. Following protein purification, thermal denaturation studies showed that the 
protein melted at 61°C. This melting temperature was sensitive to increasing DMSO 
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concentration which after initially causing an increase in melting point caused a 
gradual decrease.  
Small molecule ligands were identified using a database mining approach and the 
development of an assay was attempted. The use of tryptophan fluorescence was 
particularly suited to this study given the location of a highly conserved tryptophan 
in the specificity pocket which was a target for ligand docking. All molecules tested 
affected the tryptophan fluorescence profile; the most interesting change was from 
compound 5676364 which caused a large red shift of the peak. This suggested that 
the compound may have chaotropic properties, however a literature search of 
molecules of similar structure did not confirm this. 
In future work it would be useful to incubate the PSD95 construct A protein with 
compound 5676364 and then measure the circular dichroism spectra to look for 
unfolding activity caused by the small molecule. 
The activity of the other compounds in the study was varied in that there were 
increases and decreases observed which were compound dependent. It is not possible 
to confirm if these changes are caused as a result of binding to the PxxP binding site 
however competition assay with a peptide sequence FPLWKLPGFPNRMVLG from 
the PI(3)K-C2α signalling molecule could give more insight. Furthermore if the 
peptide sequence was tagged with a fluorophore like fluorescein or FITC then 
fluorescence polarisation could be used as a possible rapid assay method, this could 
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Chapter 8. Biochemical and structural characterisation of B 
Lymphocyte Stimulating Factor (BLyS) 
8.1 Introduction 
BLyS (also known as BAFF, THANK, TALL-1,zTNF4 and TNF13B) is a protein 
ligand that belongs to the tumour necrosis family (TNF) which plays a functional 
role in B cell immunity and has recently come under study as a target for treatment 
of autoimmune disease, most notably systemic lupus[1, 2].  
Action of BLyS is mediated through binding to the relevant TNF receptor. BLyS is 
known to bind to 3 receptors; BAFF-R, TACI (transmembrane activator and calcium 
modulator ligand interactor) and BCMA (B cell maturation antigen), however 
binding to TACI and BCMA requires multimerisation of the BLyS trimer. 
As a consequence of BAFF receptor activation through BLyS, B cells receive a 
primary survival signal. Mice which overexpress BLyS have increased numbers of B 
cells produced in many tissues[3]. Consequently, if the regulation of BLyS production 
becomes compromised and upregulation of BLyS takes place, the survival signals 
triggered by BLyS can override death signals to autoreactive B cells giving rise to 
autoimmune disease[4]. 
Therefore, if the binding interface between BLyS and BAFF-R is targeted for 
disruption by small molecules, there is potential for the development of orally active 
drugs for treatment of autoimmune disease that would be more cost efficient and 




8.2 Druggability of the BLyS/BAFF-R complex 
 The crystal structure of BLyS in complex with BAFF receptor fragments has been 
solved (PDB ID 1POT)[5]. From the crystal structure it is known that BLyS and the 
BAFF receptor bind in a 1:1 stoichiometry, furthermore the interaction between both 
proteins is not affected by multimerisation. This is an important feature as BLyS can 
exist in monomeric, trimeric and 60-mer states[6]. Interaction between BLyS and the 
BAFF receptor is mediated through conserved cysteine rich domains (CRDs) from 
the receptor with the TNF homology domain (THD) from BLyS[7]. The CRDs 
usually contain in the region of six cysteine residues which form three disulphide 
bonds and elongate the shape of the receptor, the positions of the cysteines are not 
conserved. In the BAFF receptor four cysteines are found in the CRD which form 
two disulphide bonds (Figure 8-1). 
 
Figure 8-1. The cysteine rich domain (CRD) of the BAFF receptor. This creates a hairpin structure 
containing the DxL motif which is an essential feature of BLyS/BAFF-R binding[8]. 
 
The TNF homology domain of BLyS (Figure 8-2) is composed of ten β-strands 
which are arranged as two antiparallel β-sheets with a greek key topology[9]. Strands 
A, A′, H, C and F form the innermost sheet which plays a role in establishing trimer 
222 
 
contacts, while strands B, B′, D, E and G are surface exposed and make up the outer 
layer of the sheet. The DE-loop of BLyS is more extended than in other THDs, this 
allows the protein to form multimers composed of many trimers.  
 
Figure 8-2. The TNF homology domain of the BLyS monomer (left). The extended DE loop 
allows interactions between two BLyS trimers in a “handshaking” fashion.  
 
If the BLyS trimer structure is examined (Figure 8-3) it can be noted that the BAFF 
receptor binds to each monomer via a series of hydrogen bonds which are mediated 
by Asp26 and Leu28 of BAFF-R and Arg231, Arg265 and Tyr206 of BLyS. 
 
Figure 8-3. Structure of BLyS trimer complexed with BAFF-R fragments. The BLyS (coloured 
green) binds to the BAFF-R fragment (coloured cyan) through a network of hydrogen bonds that 




8.3 Expression, purification and characterisation of BLyS 
8.3.1. Expression 
BL21 (DE3), BL21 Star and Rosetta Gami B cells were transformed with plasmid 
encoding the full length BLyS protein with an N-terminal histidine tag. Transformed 
colonies were selected for using 50µg/ml kanamycin. Overexpression optimisation 
was performed using three cell lines, four types of growth media, two IPTG 
concentrations and three temperatures as shown in Figure 8-4. Cells were grown until 
OD600 reached approximately 0.8, and then expressed for 17 hours. 
 
Figure 8-4. Overexpression trials of BLyS protein. In total 63 conditions for overexpression were 
evaluated in this trial. Growth media used included standard LB, 2XTY, Autoinduction media 
(Novagen) and Terrific Broth (TB). Autoinduction media does not require IPTG to induce protein 
expression and therefore only one culture was set up for each cell line in this media. 
 
The soluble BLyS fraction was still very low yield (< 0.3 mg/ L), however the 
difference in insoluble protein between the lowest and highest yield was threefold. 





Figure 8-5. Overexpression trials for BLyS protein showed protein is still insoluble. The gel 
shows the Soluble (S) and Insoluble (I) fraction for each of the expression conditions listed. After 
evaluating 64 conditions there was minimal increase in soluble BLyS protein. 
 
8.3.2  Refolding and purification 
The majority of the BLyS protein was insoluble so refolding the protein was 
required. Insoluble cell pellets were prepared as follows: Whole cell pellets were 
resuspended in 50mM NaPO4 pH 7.4 and lysed by cell disruption at 22KPSI. Lysate 
was centrifuged at 30,000 xg for 20 minutes and the insoluble pellet retained and 
solubilised in either 8M urea or 6M GnHCl depending on method used. Three 
refolding protocols were tested to compare their effectiveness; the first was an 
approach based on folding by dilution whilst the second and third used on-column 
refolding.  
Protein refolding by dilution 
Insoluble BLyS inclusion bodies were resuspended in 8M urea at 4 °C with stirring 
for 1 hour. The resuspended pellet was then filtered sequentially through 0.45 µm 
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and 0.22 µm filters and then loaded dropwise into refolding buffer (50 mM HEPES, 
10% glycerol, 500mM NaCl, 0.25mM NDSB, pH 8) at a 1:10 dilution. 
On column refolding 
Two types of on column refolding were compared. In the first instance insoluble 
BLyS was resolubilised in 8M urea, filtered through 0.45 µm and 0.22 µm filters 
before loading on an IMAC HiTrap FF column charged with nickel sulphate. BLyS 
protein was refolded using a gradient of 6-0 M urea in refolding buffer (50 mM Tris, 
5 mM EDTA, 150 mM NaCl, 1.25 mM GSH and 0.25 mM GSSG, pH 8). Protein 
was eluted from the column in a gradient from 50mM-500mM imidazole in PBS. 
In the second instance insoluble BLyS was resolubilised in 6M GdnHcl, 10 mM 
DTT, centrifuged at 12,000 xg for 20 minutes and then filtered through 0.45 µm and 
0.22 µm filters before loading on an IMAC HiTrap FF column charged with nickel 
sulphate. The refolding buffer was a gradient of 4-2M urea, 20 mM  β-
mercaptoethanol, 100 mM Tris, pH 8. Elution was performed with a gradient of 20-
500 mM imidazole in 50 mM Tris, 150 mM NaCl, pH 8. 
The purification itself was a two stage process which involved refolding the urea 
denatured protein and then eluting using a standard imidazole gradient as shown in 
Figure 8-6. The requirement for refolding the BLyS protein is documented in the 
literature with a number of refolding protocols being published[10, 11]. After trying 
both types of protocol as well as refolding by dilution[12] there was no significant 
difference between the success of each method as verified by gel filtration study. The 
volume of sample generated from refolding by dilution was however a disadvantage 
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to the technique as well as the inability to automate the process of refolding and 
purification like the on-column refolding protocol with the AKTA purifier. 
 
 
Figure 8-6. Purification results for on column refolding of BLyS from inclusion bodies. During 
the renaturation process some BLyS is lost from the column, however the final yield of refolded BLyS 
was 23 mg/ L culture. The first gradient shows the refolding step whilst the second is the imidazole 
elution gradient. 
 
During the elution it was noted that a second protein purified alongside BLyS with a 
molecular weight of approximately 40kDa. A similar band is also observed in other 
refolding studies where E.coli is used as the expression system. 
8.3.3 Characterisation of the BLyS 60-mer complex 
8.3.3.1 Analytical gel filtration 
500 µl BLyS sample was loaded onto a Superdex-75 10/300 column equilibrated 
with 50mM sodium phosphate, 150mM NaCl pH 8, and eluted at 0.5ml/ min. 
Gel filtration analysis was used on each type of refolding experiment to assess 
possible differences in folding state that could occur between the methods. A side by 




Figure 8-7. Comparison of refolding state of BLyS by gel filtration analysis. The on column 
refolding protocols produced almost identical elution profiles. From left to right: On column refolding 
using GSH GSSG, On column refolding using β-mercaptoethanol and 100 mM Tris. Finally refolding 
by dilution using HEPES buffer. 
 
Elution of BLyS began at 8 ml which in the Superdex 75 10/300 corresponds to the 
void volume of the column where macromolecules larger than 600 kDa are excluded 
from the matrix. As BLyS is known to form a 60-mer it seemed likely that this was 
the state of the protein during the gel filtration process, the molecular weight of the 
60-mer would be approximately 1.2 mDa. Alternatively it was also possible that the 
protein was being voided from the column as a result of aggregation. 
Whilst there are some smaller peaks in the dilution method profile these were very 
low concentration and were not detectable in coomassie stained gels. To check the 
purity of the BLyS peaks from gel filtration samples were run on SDS-PAGE gel and 
silver stained (Figure 8-8). The largest bands in the refolded protein lanes were a 
similar size to the soluble BLyS, the refolding by dilution sampled contained two 
contaminants which had not been visible through coomassie staining, one protein of 
50 kDa and the other approximately 60 kDa.  
After gel filtration there was little contamination in the column refolded BLyS 




Figure 8-8. Silver stain results of refolded BLyS in comparison to soluble BLyS. (a) Refolded by 
dilution. (b) On column refolding (c) BLyS protein in soluble fraction.  
 
8.3.3.2 Thermal denaturation 
6.5 µM BLyS protein was used in each sample well with 50mM sodium phosphate, 
150mM NaCl pH 8 buffer. Melting profiles were obtained in triplicate for samples 
which had been incubated with 10X Sypro orange dye for one hour at 4 °C and for 
samples which had been incubated with the dye for 90 seconds prior to loading into 
the thermocycler. The effect of pH was also measured as a variable in the range of 
6.4-7.4. 
In order to assess whether the protein was in the form of a 60-mer or in an 
aggregated state a thermal melt was performed. The melt results were not what 
would typically be expected (Figure 8-9). Only at pH 6.4 and pH 6.8 with 1 hour 
incubation is there a peak which may be attributed to a melting event at 60 °C. 
Initially it could be assumed that this is because the protein is aggregated, however if 
the structure of the 60-mer is examined more closely (Figure 8-10) it is 




Figure 8-9. Melting profile of refolded BLyS protein with varying pH. Two sets of data were 
recorded for each pH value. The first was from the protein sample being mixed with Sypro orange and 
then immediately loaded into the thermocycler, in the second Sypro was incubated with the protein for 
one hour prior to the start. 
 
 
Figure 8-10. Hydrophobic profile of BLyS 60-mer. Taking the PDB structure for the 60-mer 10TZ 
and colouring the hydrophobic residues orange, it is apparent that the virus like macromolecule 
presents significant hydrophobic surface area to solution. 
 
The BLyS 60-mer structure does not just present a number of hydrophobic surfaces 
on the outer structure, there are also 11 channels into the protein with a minimum 
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Both the large area of hydrophobic contacts on the outer surface as well as a similar 
surface area on the inner surface create an environment that would make the Sypro 
orange dye fluoresce. Therefore the results in Figure 6-6 could be explained not just 
by presence of aggregated protein but also by Sypro orange binding to the numerous 
hydrophobic sites present on the correctly folded 60-mer complex. The difference in 
behaviour observed as a consequence of increased incubation time may be explained 
by the preparation of the one hour incubations at 4 °C rather than room temperature, 
which would suggest that the BLyS 60-mer is unstable at room temperature. 
8.3.3.3 Intrinsic fluorescence spectroscopy 
Each BLyS monomer contains one tryptophan residue, the residue is solvent exposed 
but not within the target binding site. Changes in fluorescence observed in the 
presence of compounds cannot give a positive indication that the compound is 
binding in the active site, however it gives a general indication that there may be a 
conformational change occurring. 
8.3.3.4 Comparisons of emission spectra between refolded and 
denatured BLyS 
Fluorescence from PBS buffer was measured and then subtracted fom the spectra for 
2.6 µM BLyS in PBS buffer. Similarly 8M urea in PBS was subtracted from the 2.6 
µM BLyS in 8M urea sample. 
To gain a better understanding of the difference between a denatured (and therefore 
incorrectly folded) BLyS sample and the sample from refolding experiments the 




The fluorescence profile for the refolded BLyS was consistent with a maxima of 
approximately 1.4 million RFU at 336.5 nm. The denatured BLyS fluorescence was 
quite different. The maxima position had not only been red shifted from 336.5 nm to 
350 nm but there was also a 14% decrease in fluorescence overall. Emission at 
longer wavelength is characteristic of the tryptophan residue becoming more solvent 
exposed[13] which would agree with the protein becoming more disordered as a result 
of the chaotropic agent. From this result a clear difference between the refolded and 
unfolded states can be seen. 
 
Figure 8-11. Fluorescence profiles of urea denatured and refolded BLyS. (a) Results obtained 
from this study. (b) Results obtained by Cao et al.   
 
Fluorescence results from this study do not wholly correlate with those obtained 
from Cao et al[10]. Whilst unfolding the protein causes a red shift in both cases, Cao 
et al observed an increase in fluorescence which is in contrast to that reported here. 
Despite the authors of the other study using a protein concentration which was twice 
that reported here, the UV trace observed was of low intensity and the curve 
uncharacteristic of a typical tryptophan fluorescence measurement. While the use of 
an excitation wavelength of 295 nm was used in this study to minimise fluorescence 
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effects from the tyrosine and phenylalanine residues the recorded fluorescence from 
tryptophan should have still overwhelmed any signal from these residues at the 280 
nm excitation wavelength used by Cao et al. Closer inspection of the spectra (Figure 
8-10 b) does show that there is no discernable peak at 303 nm which would correlate 
with tyrosine emission and the starting wavelength of measurement is higher than the 
emission peak of phenylalanine at 282 nm. Given the low intensity of the signal there 
is the possibility that a low signal to noise ratio is playing a factor. 
8.3.3.5 Transmission electron microscopy (TEM) analysis 
In order to assess the protein concentration which would give best resolution of 
BLyS multimeric state with the least aggregation protein concentrations of 216 µg / 
ml, 635 µg/ ml, 1.350 mg/ ml and 15 mg/ml were used. Protein samples were applied 
to copper grids which were previously glow discharged and carbon coated. All 
samples were visualised using negative staining with 2 % uranyl acetate on a Phillips 
F20 Biotwin transmission electron microscope. 
As the BLyS 60-mer is such a large macromolecule it can be directly visualised by 
electron microscopy. By preparing a selection of BLyS concentrations for TEM the 
concentration which contained a representative population of the protein state could 
be found. The 216 µg / ml and 635 µg/ ml samples (Figure 8-12 a and b) were too 
low concentration to accurately assess if the protein had significant aggregation 
therefore concentrations at 1.350 mg/ ml and 15 mg/ ml were also used (Figure 8-12 
c and d). These higher concentrations allow some aggregation to be seen as darker 
grey regions on the images, however even at 15 mg/ml concentrations the aggregated 




Figure 8-12. Transmission electron microscope images of BLyS concentration range. (a) BLyS 
concentration 216 µg / ml. (b) BLyS concentration  635 µg/ ml. (c) BLyS concentration 1.35 mg/ ml. 
(d) BLyS concentration 15 mg/ml. Scale bar shown is 100 nm. 
 
When  a high resolution image of the BLyS sample is compared to that from the 
literature there is a good correlation between the observed shapes from this study and 
the published structure which measured approximately 20nm in diameter[14].  
8.3.3.6 Dynamic light scattering 
BLyS protein was buffer exchanged into PBS (0.14 M NaCI, 0.01 M PO4 Buffer, 
0.003 M KCI) and concentrated to 0.3mg/ ml. The sample was then clarified by 
centrifugation at 13,000 RPM in a chilled benchtop centrifuge. Measurements were 





Two peaks were visible from the DLS results (Figure 8-13) which have an apparent 
molecular weight of approximately 1.2 mDa and 73 mDa respectively according to 
the Mark-Houwink distribution equation. The higher molecular weight peak is likely 
some of the aggregated protein, as seen in the TEM results, which has reformed after 
gel filtration. Analysis of the sample by volume shows that the aggregated protein 
makes up very little of the sample as it appears as a single peak with an approximate 
diameter close to 20 nm which is in agreement with the measured diameter of the 
crystal structure of the BLyS 60-mer complex. 
 








8.4 Virtual screening of the BLyS structure with LIDAEUS 
8.4.1 Defining the site points for BLyS 
Using the crystal structure of the BLyS/BAFF-R complex (PDB codes 1OTZ and 
1POT) the site points for LIDAEUS docking were created as described in Chapter 2 
(Figure 8-14). A particular point of interest is the pocket which is located at the 
position where Leu28 interacts with Arg231. The depth of the binding pocket is a 
key concern when undertaking small molecule screening and drug design as the 
shallowness of the pocket determines how “druggable” the site is[15].  
 
Figure 8-14. Defining site points on the BLyS/BAFF-R interface. The BAFF-R fragment (sequence 
FDLLVR) used to define the site points which will guide LIDAEUS docking is shown in line format 
coloured purple. The pocket in the surface at the Leu28 position is a particularly attractive target for 
small molecule interaction. Green spheres represent hydrophobic sites, blue represents hydrogen bond 
donors and red represents hydrogen bond acceptors. 
 
8.4.2 Analysis of the Leu28 binding pocket reveals a suitable target for 
docking 
A number of programs have been developed to evaluate the depth of a protein 
surface pocket for suitability in small molecule ligand binding[16-18]. These programs 
236 
 
allow preliminary assessment of a protein’s drugability as a function of the 
characteristics of the pockets found on the protein surface (depth, solvent 
accessibility, etc). The surface of BLyS was evaluated for binding pockets using the 
PocketDepth program which found seven possible pocket regions (Figure 8-15) 
including the Leu28 binding region highlighted previously which shall be referred to 
as pocket 5. 
Whilst the six other locations would not be suitable targets for disruption of the 
BLyS/BAFF interaction because they are located too far away from the binding site, 
there is a possibility that they could be targeted for disruption of the BLyS 60-mer 
which could be a useful way of interrupting the association of the BLyS multimer 
with TACI. 
 
Figure 8-15. Binding pocket predictions from PocketDepth analysis on BLyS. Seven locations 





8.4.3 LIDAEUS docking of the EDULISS database to the BLyS protein 
The LIDAEUS run against the entire EDULISS database was performed using >4m 
small molecule compounds as described in Chapter 2. The top 200 compounds were 
kept and assessed by eye how well they fit into the Leu28 binding pocket. The most 
interesting compounds from this are shown in Table 8-1. The compounds selected by 
LIDAEUS were then scored using Autodock. The Autodock results were slightly 
different from those obtained from LIDAEUS, often the highest scoring pose was 
slightly different from that suggested by LIDAEUS (although still located within the 
target pocket). 






Autodock score Compound ID 
 
-53.9 -4.6 25SPH1-178-375 
 




-48.9 -4.5 25SPH1-115-197 
 
-47.5 -4.4 35SPH1-122-641 
 
-46.6 -4.9 25SPH1-007-145 
 
-46.4 -5.4 26SPH1-677-512 
 
-44.8 -4.6 25SPH1-061-217 
 




-42.6 -4.3 35SPH1-032-786 
 
-41.8 -5.0 25SPH1-072-060 
  
Of the 200 compounds retained from the LIDAEUS docking 25SPH1-115-197 
(Cyclobutaneoctol) appeared 18 times. The small ring structure is an ideal shape for 
binding into the target pocket, however it is also a compound commonly used as a 
pesticide and therefore its use as a drug is limited. Looking at compounds 25SPH1-
178-375, 26SPH1-825-056 and 26SPH1-825-056 in more detail the hydrogen bond 
networks can be observed (Figure 8-16 to 8-18).
 
Figure 8-16. Predicted binding mode between 25SPH1-178-375 and BLyS shows a number of 





Figure 8-17. Predicted binding mode between 26SPH1-825-056 and BLyS shows a number of 
hydrogen bonding opportunities both deep inside the pocket as well as the upper lip. 
 
 
Figure 8-18. Predicted binding mode between 35SPH1-122-641 and the BLyS protein. 8 
Hydrogen bonds are possible between the compound and the protein. 
 
The LIDAEUS docking results indicate that a ring structure is an important part of 
anchoring the small molecule into the pocket. The ring alone is able to access the 
pocket fairly well, however it is also likely to be able to enter one of the other 6 
pockets on the BLyS surface. To test this, structures for 35SPH1-122-641 and 
25SPH1-072-060 were docked into the pockets from Figure 8-15 and were found to 
have similar affinity scores for some of the other pockets on the protein. As such 
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compounds 25SPH1-178-375, 26SPH1-825-056 and 26SPH1-677-512 are more 
likely to be ligands with better specificity for the target binding site than the other 
compounds in Table 8-1  
 
8.5 Ligand selection for BLyS/BAFF-R disruption screening 
Only a small selection of the top 10 compounds from Table 8-1 were readily 
available for in vitro testing. All compounds for this study were purchased from 
Sigma-Aldrich and were available for immediate dispatch. The compounds available 
for in vitro screening are shown in Table 8-2 and accounted for a good spectrum of 
the top 100 results. The final compound in the table was included as a compound of 
interest from a similar study conducted by Wissam Mehio[19] which was not able to 
be tested previously but was a high scoring molecule in that docking study. 
Table 8-2. List of compounds selected for assay with BLyS protein. 
 








SPH1-171-521 R0250 16 
 
SPH1-100-780 A6259 43 
 
SPH1-100-826 A6645 59 
 
SPH1-168-399 138622 71 
 
SPH1-104-152 G4635 - 
 
Hexopyranose sugar moieties are not generally regarded as an optimal synthetic 
starting point in drug discovery, usually due to their high polarity and poor 
pharmokinetics. However there has been interest in their use as a scaffold[20] which 
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can provide a source of molecular diversity[21].  Glycomimetic drugs which have 
better bioavailability and improved plasma half life over traditional carbohydrates 
have been developed. These drugs are able to exploit the recognition of specific 
carbohydrate sequences on cell surfaces in their mechanism of action, this led to the 
development of the antiviral drug Tamiflu[22].  Compounds with a sugar-like moiety 
have found to disrupt protein-protein interactions in the SH3 domain of PSD95[23]. 
Recent advances in the synthesis of saccharides shows potential in the development 
of novel antiviral, antibacterial and anticancer therapeutics[24]. 
8.6 Measuring the effect of virtual screening compounds on 
BLyS fluorescence 
Fluorescence measurements were taken using a Fluoromax-3 specrofluorometer 
(Horiba Jobin Yvon) with a 5nm slit width. Total sample volume was 600 µl in a   1 
cm path length quartz cuvette at 10 °C. The excitation wavelength was 295 nm and 
the emission range was from 320-450 nm in 0.5 nm increments. Readings were taken 
in triplicate and then averaged. 
When measuring compound fluorescence the six compounds obtained from virtual 
screening were dissolved at a concentration of 20 mM in 100% DMSO, except for 
compound F-8502 which was not fully soluble in DMSO but soluble in 100% 
ddH2O. 
Fluorescence of all compounds at a concentration of 250 µM in PBS was measured 
by excitation at 295 and measuring emmision from 320-450nm to allow subtraction 
from the protein and compound mixture. A DMSO concentration of 1.25% was kept 
consistent accross all samples including the compound which was dissolved in water. 
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The effect on BLyS fluorescence by each compound was measured by mixing 2.6 
µM BLyS with 250 µM of the test compound, briefly mixing by pippetting and 
incubating on ice for 10 minutes before starting measurement. 
The fluorescence spectra obtained for the dissolved compounds (Figure 8-19) 
showed that all but two of the compounds had very little fluorescent activity over the 
Raman scatter from the buffer.  
 
Figure 8-19. All six compounds chosen for BLyS fluorescence study have very little fluorescent 
properties. The advantage of this is that a significant change in fluorescence can be directly attributed 
to a change in the environment of the tryptophan residues in BLyS. 
 
The compound effects on BLyS fluorescence were interesting as a number of 
different effects that were observed (Figure 8-20). Compound F8502 was the first to 
be tested and showed no change in fluorescence compared to the reference cell 
containing BLyS and 1.5% DMSO. This was also the case for compounds A6645 
and 138622. Compound R0250 caused a much more noticeable change in 
fluorescence where a 20% decrease in signal was observed. 































Figure 8-20. Effects of compounds from virtual screening on BLyS protein fluorescence. 
 
Although no change in fluorescence was observed for compounds F8502, A6645 and 
138622 this could be because of their highly hydrophilic nature which may cause 
competition with water for the binding site. 
Compounds A6259 and G4635 caused an increase in fluorescence. These compounds 
have the potential to bind covalently to BLyS via the aldehyde functional group 
(compound A6259) and via a Michael addition to the C=C bond in the heterocyclic 
ring (compound G4635), although neither reaction has been tested. A number of 
drugs have been developed which feature the aldehyde functional group in the 
primary structure or in metabolic intermediates; the HIV inhibitor Abacavir[25] and 
the anticancer drugs Cyclophosphamide[26], Ifosamide[27] and Misonidazole[28] all 
feature this moiety. Outwith the scope of drug development such compounds can 
also be useful biochemical tools. 
The other compounds appeared to have no activity with BLyS apart from compound 































fluorescence is usually observed when the tryptophan residue becomes less solvent 
exposed, as a result of conformational changes in the protein or by direct ligand 
association with the tryptophan itself. In BLyS the tryptophan residue is located near 
pocket 3 (Figure 8-14) which is on the opposite side of the protein to the target 
binding site in pocket 5 (Figure 8-14). Docking the R0250 molecule into pocket 5 
shows a low affinity of -3.5 kcal/ mol as the molecule is unable to enter the pocket 
itself.  Association with the tryptophan on the outer surface of the pocket is possible 
but the affinity is much weaker compared to the target binding site. 
8.7 Conclusions and future work 
The BLyS protein is an interesting target not only from a disease treatment 
standpoint, but also because of the novel multimerisation that it can undergo. After 
refolding and purification the BLyS multimer was characterised by electron 
microscopy to confirm the multimer topology. Thermal denaturation gave further 
insight into the large hydrophobic area which is presented in the 60-mer compex 
which was found to readily bind Sypro orange dye. Dynamic light scattering also 
showed that the population of the sample was largely in this multimer state. 
As a virtual screening target the BLyS monomer had a number of possible druggable 
pockets, however the pocket containing Leu28 was the focus of this study as it 
controls association with the BAFF receptor. A number of saccharide scaffolds were 
tested for binding activity and one of these caused a large decrease in fluorescence 
which could be attributed to ligand binding. Increases in fluorescence were also 
shown with two compounds which may form covalent bonds to BLyS.  
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The binding activity of these compounds could be further explored by using the CRD 
domain of the BAFF receptor, or a smaller peptide sequence that mimics the BAFF 
receptor CRD domain in a competition binding experiment. In addition the use of co-
crystallisation techniques between BLyS and these small molecule ligands could also 
show not only where on the BLyS surface these ligands can associate but also if they 
have the potential to disrupt the 60-mer complex and prevent its reformation. 
Such study would offer up further points of enquiry which could allow the 
BLyS/TACI and BLyS/BCMA pathways to be targeted and their mechanisms could 
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